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CHAPTER I 
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Group B Streptococcus 
Introduction 
Streptococcus agalactiae, more commonly known as Group B Streptococcus (Group B 
Strep, GBS), is a Gram-positive pathogen that divides along a single axis to cause growth in a 
chain-like fashion. (Figure 1.1).1 According to the Lancefield classification system, the presence 
of the group B carbohydrate (GBC) antigen in the cell wall identifies Streptococcus agalactiae as 
a Group B streptocococcus (Figure 1.2).2 
 
 
Figure 1. 1 Scanning electron micrograph image of GBS. Chain-like formations and division along a single axis 
are shown at 2,000x and 10,000x magnification (Image courtesy of Dr. Ryan Doster) 
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Figure 1. 2 Presence of Lancefield Group B Carbohydrate (GBC) in the Cell Wall and Structure of GBC. A) 
GBS is attached to the peptidoglycan of the cell wall via linkage to the N-acetyl muramic (NAM) moiety, a component 
of the peptidoglycan. B) The structure of the multiantennary GBC is shown linked to NAM. (Adapted from Caliot, 
E., Dramsi, S., Chapot-Chartier, M-P, Courtin P, Kulakauskas S, et al. (2012) Role of the Group B Antigen of 
Streptococcus agalactiae: A Peptidoglycan-Anchored Polysaccharide Involved in Cell Wall Biogenesis. PLoS Pathog 
8(6): e1002756. doi:10.1371/journal.ppat.1002756.) 
 
Group B Strep is typically associated with infection during the perinatal period and is a 
leading cause of neonatal infections.1, 3, 4 Before emerging as a prominent human pathogen, GBS 
was first identified as a cause of bovine mastitis in 1887.5 Mastitis in an infection of the mammary 
glands and can lead to a decrease in the quantity and quality of milk produced.5 Bovine GBS 
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infections usually respond to treatments of  penicillin-type antibiotics with cure rates ranging from 
75-95%, allowing for efficient control of bovine mastitis outbreaks.6-8  
It was not until 1935, almost 50 years after the first reported case of bovine infection, that 
human infection in the vaginal tracts of pregnant women was reported.1, 9 Soon after, GBS 
infection emerged as a cause of fatality in post-partum women.10 Still, few cases of infant-related 
diseases were reported until the early 1970s when GBS became the leading cause of neonatal sepsis 
and meningitis in the United States.10, 11 During this decade, the infant mortality rate due to GBS-
related diseases reached a high of 55%.11 Over the next few decades, strategies and guidelines for 
preventing, diagnosing, and treating GBS were developed by identifying and analyzing risk factors 
for both mother and neonate and using intrapartum antibiotic prophylaxis to prevent transmission. 
Intrapartum antibiotic prophylaxis is the administration of antibiotics during the labor and delivery 
period. This method of prevention is used to reduce the bacterial burden of maternal colonization, 
which in turn reduces the possibility of vertical transmission from mother to infant.12 
Several risk factors have been associated with maternal and neonatal GBS infections as 
well as transmission. Age, race, gender, pregnancy outcomes, and previous incidences of 
colonization or infection contribute to development of GBS disease.10, 11, 13 While few risk factors 
are prevalent enough to be used in prevention strategies, awareness of the conditions associated 
with GBS infections has proved insightful for understanding the perinatal pathophysiology of 
GBS.10  For instance, maternal colonization is a significant determination of vertical transmission 
and infection in the infant.13 This connection has led to administration of antibiotics to colonized 
mothers to prevent transmission.  
GBS colonizes between 10-40% of adults, but it is commonly asymptomatic in healthy 
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individuals.10, 14, 15 However, it can cause severe infections in immunocompromised individuals, 
especially infants who have an immature immune system. GBS colonizes the gastrointestinal and 
genitourinary tracts of adults but colonizes the gastrointestinal tract and throats of infants.13 
Colonization of genitourinary tracks does not occur until after puberty, and neonatal infections in 
throats arise after fetal aspiration or ingestion of GBS infected amniotic fluid and contraction 
during descent through the birth canal.16 
Infections caused by GBS during pregnancy can lead to several adverse outcomes 
including stillbirth, chorioamnionitis, and preterm birth.1 Choriamnionitis, an inflammation of 
fetal membranes due to a bacterial infection, can result from an ascending infection of maternal 
vaginal GBS colonization. Intrauterine infections can induce premature labor.  
Neonatal diseases caused by GBS occur either as early onset disease (EOD) or late onset 
disease (LOD), depending on the age at which an infant acquires the infection. While EOD 
typically presents within the first 24 hours after birth and can occur up to seven days old, LOD 
presents after the first 7 days of life.13 A 2017 meta-analysis reported global incidence risks to be 
0.41 for EOD and 0.26 for LOD per 1000 live births.17 EOD is associated with vertical 
transmission that originates from maternal colonization. Methods of vertical transmission include 
aspiration of contaminated fluids during birth or in utero via bacterial ascension into the amniotic 
sac through ruptured membranes or translocation through intact membranes.10, 11 EOD manifests 
mainly as sepsis and pneumonia, but can develop into meningitis.18-20 LOD can manifest in a 
similar manner to EOD, but predominantly occurs as meningitis.21 Unlike EOD, the transmission 
of LOD is less understood but is also associated with maternal colonization and prematurity.18, 22-
24 LOD is not always acquired vertically from the mother; instead, it can also be acquired through 
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horizontal transmission from maternal, hospital, and community sources.20  
 
Table 1. 1 Overview of Early and Late Onset Disease 
 Incidence Risk (per 100 live births) Infant Age Manifestations 
EOD 0.41 0 – 7 days Sepsis Pneumonia 
LOD 0.26 > 7 days Meningitis 
 
Bacterial Factors that Promote Infection 
  Genome sequencing of GBS has revealed the presence of at least 21 two-component 
systems (TCS).25-27 TCS are the most common signal transduction systems found in bacteria and 
are composed of a membrane-bound histidine kinase and a response regulator.18 For signal 
transduction to occur, the membrane-bound histidine kinase first recognizes an external stimulus 
and responds by phosphorylating the corresponding response regulator. The phosphorylation of 
this response regulator leads to a change in gene expression and subsequent adaptation to the 
bacteria’s environment.18 Signal transduction systems are responsible for regulating gene 
expression and other cellular responses. Roles of only five of these two-component systems 
(CovR/CovS, RgfC/FgrA, DltR/DltS, CiaR/CiaH, and FspR/FspS) have been elucidated.18, 27  
The CovR/CovS TCS regulates several virulence factors including production of pore-
forming toxins, escape of host recognition by expression of capsular polysaccharides (CPS) and 
C5a peptidase (ScpB), evasion of host-produced radical oxygen species (ROS), and increased 
binding to host cells with fibrinogen-binding protein A (FbsA).18, 28-32 The RgfC/FgrA TCS also 
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plays a role in the expression and regulation of FbsA.25, 27, 33, 34 Resistance to antimicrobial peptides 
(AMPs) through alanylation of lipotechoic acid is regulated by the DltR/DltS TCS.35, 36 The 
specific roles of CiaR/CiaH are less understood, but this TCS is known to aid in GBS intracellular 
survival and evasion of environmental stresses such as ROS and AMP.37, 38 FspR/FspS, a recently 
identified TCS, is necessary for vaginal persistence of the bacteria through regulation of genes 
involved in sugar transport.27 Many virulence factors of GBS are regulated by one or several of 
these two-component systems. 
The genome of GBS contains over 100 signaling systems and transcriptional regulators, 
which position GBS to colonize and survive in multiple environments.25, 34 In addition to the 
presence of genes encoding TCS, GBS encodes at least six other independent regulators of gene 
expression.18 These other systems are regulated by activities such as changes in concentration of 
biomolecules in the cytosol or fluctuation of other environmental factors.34, 39, 40 Increased studies 
of these systems will improve the understanding of GBS colonization and infection and provide 
targets for therapeutics to combat colonization and subsequent disease states. 
GBS has several importance virulence factors that contribute to its pathogenesis, which can 
be divided into three stages: 1) adherence to epithelial surfaces, 2) invasion and host damage, and 
3) survival in vivo. An overview of these virulence factors is presented in Table 1.2.  
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Table 1. 2 GBS Virulence Factors Invovled in Colonization and Infection 
Virulence Factor Mode of Action Host Target 
Fibrinogen-binding proteins Promote adherence (FbsA, FbsB, FbsC) Promote entry into host cells (FbsB) Fibrinogen 
Laminin-binding proteins Promote adherence (Lmb) Promote entry into host cells (Lmb) Laminin 
Serine rich repeat protein Promote adherence to epithelial cells (Srr-1) Enhance virulence (Srr-2) Fibrinogen 
Immunogenic bacterial 
adhesion (BibA) 
Promote adherence of GBS 
Binds complement regulatory protein C4bp C4-binding protein 
Pili Promote resistance to AMP Promote adherence to hose cells Collagen I 
Capsular polysaccharide 
Prevent recognition of GBS through molecular 
mimicry of host-cell surface glycoconjugates 
Masks pro-inflammatory cell wall components 
Siglecs 
α-C protein Facilitates GBS adherence to host epithelial cells 
Host cell surface 
glycosaminoglycan 
Pore-forming toxins 
β-H/C, CylE, CfB (CAMP 
factor) 
Promotes invasion of host cells and triggers 
host-cell lysis 
Impair cardiac and liver function 
Induces inflammatory responses and apoptosis 
Forms pores in host-cell membrane (CAMP) 
Binds to GPI anchored proteins (CAMP) 
Cell membranes 
Host phagocytes 
CAMP 
Serine protease (CspA) 
Cleaves fibrinogen and chemokines 
Impairs neutrophil recruitment and phagocytic 
killing of GBS 
Fibrinogen 
Peptidase (C5a) (ScpB) 
Prevents neutrophil recruitment due to 
cleavage of complement C5a 
Promotes adherence by binding to ECM 
fibronectin and epithelial cells 
Complement 
component C5a 
Fibrinonectin 
Superoxide dismutase (SodA) Detoxifies singlet oxygen and superoxide ROS generated by phagocytes 
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While GBS can adhere to a variety of human cells, the acidic pH of the vaginal mucosa is 
optimal for enhanced GBS attachment.26, 41 The CovR/CovS system responds to changes in pH 
and increases regulation of virulence factors in acidic environments.1 Adherence of GBS is also 
mediated by interactions between GBS surface proteins and host extracellular matrix (ECM) 
components, which allows subsequent invasion of the host cell (Figure 1.3).18 Similar to other 
related Gram-positive pathogens, both fibrinogen- and laminin-binding proteins are known to 
mediate adherence of GBS to the host.26 GBS binds to fibrinogen, a host glycoprotein produced in 
response to inflammation, by several fibrinogen-binding proteins (FbsA, FbsB, and FbsC).1, 18, 42 
Laminin-binding protein (Lmb) facilitates GBS binding to host-cell laminin, allowing for GBS 
attachment to the host basal membrane.18, 43 Adherence of GBS to host cells is also mediated by 
serine-rich repeat proteins (Srr), a family of glycoproteins that bind to host epithelial cells through 
interactions with host fibrinogen.1, 18, 44-46 GBS has four different forms of cell-surface 
immunogenic bacterial adhesins (BibA) that facilitate adherence of GBS to host cells.18, 47 BibA 
binds to C4-binding protein (C4-bp), a regulator of the classical complement pathway.18, 47 Another 
adhesin, PilA, is a GBS pili that mediates adherence by binding to the host cell.1, 18, 48 Pili are long 
appendages that protrude outside the capsule and cover the bacterial surface. Host sialic-acid-
recognizing immunoglobulin super family lectins (Siglecs) are also able to recognize and bind the 
sialic acid rich capsule of GBS.1, 49 Adherence and colonization of the vaginal mucosa furthers the 
risk of vertical transmission from mother to infant.  
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Figure 1. 3 Mechanisms of group B Streptococcus cellular adherence and invasion. Surface-expressed proteins 
FbsA/B, ScpB, Srr1, pili, BibA, LTA and ACP mediate group B Streptococcus (GBS) binding to host cells and ECM 
components, such as fibrinogen and fibronectin. Secreted β-haemolysin/cytolysin promotes GBS invasion, possibly 
by breaking down host barriers to reveal novel receptors on the basement membrane, such as laminin. GBS also use 
GAPDH to activate host plasminogen and degrade the ECM. Intracellular GBS invasion is enhanced by bacterial-
dependent cytoskeletal rearrangements triggered by host PI3K/AKT- and FAK-signalling pathways and the Rho 
family of GTPases. Alternatively, GBS can also use an unknown mechanism to cross host epithelial barrier by a 
paracellular route. Several GBS adhesins, including FbsB, ScpB, pili, LTA and ACP, also contribute to cellular 
invasion. Abbreviations: ACP, alpha C protein; BibA, GBS immunogenic bacterial adhesin; ECM, extracellular 
matrix; FAK, focal adhesion kinase; FbsA/B, fibrinogen-binding proteins A and B; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; GDP, guanosine diphosphate; GTP, guanosine triphosphate; Lmb, laminin-binding protein, 
LTA, lipoteichoic acid; PI3K, phosphoinositide 3-kinase; ScpB, C5a peptidase; Srr1, serine-rich repeat domain protein 
1. (Reproduced with permission from Maisey HC, Doran KS, Nizet V. Recent advances in understanding the 
molecular basis of group B Streptococcus virulence. Expert Reviews in Molecular Medicine. 2008;10:e27. 
doi:10.1017/S1462399408000811.) 
 
After adherence to host cells, GBS invasion and host damage can result from bacterial 
excretion of toxins and invasins (Figure 1.3). In addition to playing a role in GBS adhesion, FbsB 
and Lmb have been shown to promote GBS entry into epithelial cells.18, 49-51 Another protein that 
mediates GBS invasion of epithelial cells is alpha C protein (ACP), a surface-anchored protein 
that binds to host cell glycosaminoglycans.1, 18, 49, 52-54 Invasion of cells after damage results from 
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the action of pore-forming toxins. Two important pore-forming toxins of GBS are β-
hemolysin/cytolysin (β-H/C) and Christie Atkins Munch Peterson (CAMP) factor.18 β-H/C lyses 
epithelial and endothelial cells causing direct tissue injury and promoting intracellular invasion.18, 
26, 49 CAMP factor oligomerizes in the target membrane to form pores and provoke cell lysis.18, 26 
Interestingly, while CAMP factor aids in cell lysis, it has been shown to be unnecessary for 
systemic virulence of GBS, suggesting that CAMP factor is only essential when β-H/C activity is 
attenuated.18, 55 In addition to invasion through host damage, GBS has also been shown to 
participate in paracellular transport across membranes via transient modification of junctional 
complexes in the monolayer that are able to reassociate after bacterial translocation.49, 56 
In order for GBS to survive in vivo, bacteria must evade the host immune system while 
also maintaining access to nutrients necessary for survival and proliferation (Figure 1.4). Several 
of the virulence factors involved in GBS adherence and invasion contribute to bacterial survival 
in vivo. For example, GBS pili aid in adherence to host cells and play a role in mediating GBS 
resistance to AMPs.49, 57 Additionally, GBS evade AMPs by engaging the Dlt operon which leads 
to incorporation of excess D-alanine into the lipotechoic acid (LTA) component of the cell wall, 
decreasing the net negative charge on the surface of the bacteria (Figure 1.4).49 The innate immune 
system recruits phagocytes such as neutrophils and macrophages to the site of infection to clear 
bacterial pathogens. GBS CPS and serine proteases CspA and ScpB hinder pathogen recognition 
by the host and thereby prevent phagocytic uptake and clearance of GBS.18, 49, 58, 59 While CPS 
mimic host cells to prevent the recognition of GBS as a pathogen, serine proteases cleave peptides 
important in the signaling pathways of phagocytic recruitment and uptake of GBS. Evasion of 
oxidative stress from host-generated ROS by superoxide dismutase (SodA) also allows GBS to 
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persist in vivo (Figure 1.4).18 GBS utilizes sensor kinases (Stk1 and CovS) to determine the 
appropriate toxins and virulence factors to express in various host environments and defend against 
the host’s immune system.18, 32 
 
 
Figure 1. 4 Mechanisms of group B Streptococcus immune evasion. Group B Streptococcus (GBS) express several 
surface-expressed or secreted factors to evade host immune defenses and promote survival. The Dlt operon is 
responsible for increasing incorporation of D-alanine residues in cell-wall teichoic acids, thereby reducing 
electronegativity and affinity for cationic antimicrobial peptides. PBP1a and the pilB subunit of GBS pili also 
contribute to antimicrobial peptide resistance. ScpB, the sialic acid capsule, BibA, β protein and CspA all inhibit host 
clearance of GBS by interfering with complement components C5a, C3 and C3bp. SodA properties of the orange 
carotenoid pigment shield GBS from killing by phagocyte-generated reactive oxygen species. Alternatively, β-
haemolysin/cytolysin can boost GBS survival by cytolytic or proapoptotic injury to host phagocytes. Abbreviations: 
BibA, GBS immunogenic bacterial adhesin; CspA, cell-surface protease A; PBP1a, penicillin-binding protein 1a; 
ScpB, C5a peptidase; SodA, superoxide dismutase. (Reproduced with permission from Maisey HC, Doran KS, Nizet 
V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Reviews in 
Molecular Medicine. 2008;10:e27. doi:10.1017/S1462399408000811.) 
 
Biofilm formation is an important aspect of GBS pathogenesis that provides increased 
resistance to antimicrobial agents as well as host defenses.60 GBS pili have been shown to be 
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important for the production of biofilm.60 In a study conducted in Poland by Kaczorek, over 70% 
of isolates (n = 27) had the ability to produce biofilm, and  gene sequencing of these isolates 
revealed the prevalence of virulence-related genes encoding for protease-resistance surface 
proteins (rib), proteins used for adherence (bca), and pore forming toxins (cylE and cfb).61  A study 
by Boonyayatra showed a correlation between strains that exhibited antimicrobial resistance and 
produced biofilm.62 Payot and Dramsi have demonstrated the importance of GBS capsule 
polysaccharide biosynthesis in mediating biofilm formation.63, 64 Specifically, mutants missing 
either the cpsE gene, which is responsible for capsule formation, or the four neuBCDA genes, 
which are responsible for synthesis and modification of sialic acid residues, decreased the capacity 
of GBS to form biofilm in vitro.64 Due to the relationship between GBS biofilm production and 
virulence, developing treatments or preventions that specifically target biofilms could lead to an 
avenue of viable therapeutics. 
The capsular polysaccharide (CPS), part of the GBS capsule, is the most extensively 
studied GBS virulence factor.18 GBS CPS mimic host glycans, which allows for bacterial evasion 
of host innate immune responses.65 Due to this mimicry, the host immune response is less able to 
recognize GBS as a pathogen. GBS strains can be divided into serotypes based on CPS structure 
and polymerization. However, GBS CPS biosynthesis is similar across various strains, with the 
regulation, chain length, sialic acid synthesis, and oligosaccharide polymerization determined by 
sixteen genes of the cps loci.65  
There are ten capsular serotypes of GBS that have been identified to date: Ia, Ib, II, III, IV, 
V, VI, VII, VIII, and IX. The CPS of all serotypes share several constituent monosaccharides, but 
each is distinct in the polysaccharide repeating unit and antigen response.66 Conservation of an α-
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D-Neu5Ac(2→3)-β-D-Gal motif is found across all serotypes, suggesting that this structural 
feature is important for virulence and immune invasion (Figure 1.5).65, 66 A rhamnose residue 
distinguishes Type VIII varies from other serotypes.67 The most recently identified GBS capsular 
based serotype is Type IX, which is most similar to Types V and VII. 68, 69 The repeat units and 
polymerization patterns of each known serotype are shown in Figure 1.6. 66, 70-72 67-69, 73-77  
 
Figure 1. 5 Structural motif common to all GBS CPS. 
 
Some GBS isolates do not belong to any of the ten unique capsular serotypes shown above. 
These strains are referred to as non-typeable because they do not react with any of the CPS antisera 
that are associated with capsular serotypes I-IX.78 Non-typeable strains typically have a modified 
capsule type or produce an undetectable level of capsule. Since non-typeable strains are 
indistinguishable by their CPS, genetic methods of identification have been developed. These 
approaches have shown that some non-typeable isolates share genomic DNA with serotypeable 
isolates.79 Additionally, surface protein expression has been used to distinguish between GBS 
isolates.78 Non-typeable GBS strains account for less than 3% of colonizing strains in the United 
States but can still cause invasive disease (ca. 1.5% of invasive strains).78-81 As CPS serve as a 
strategy used by GBS strains to evade the innate immune system, non-encapsulated strains must 
have developed alternative mechanisms for this evasion. Even though the prevalence of non-
typeable GBS is low, discovering and understanding the evasion and virulence factors of this 
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subtype remains important because the development of GBS vaccines are often based on CPS. 
Alternatively, prevention of GBS infections by non-typeable isolates includes the development of 
protein-based vaccines that consist of a combination of antigens.82 
 
Figure 1. 6 Capsular Polysaccharide Repeat Units for GBS Serotypes 
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Methods for Serotyping and Other Classifications 
GBS serotypes can be distinguished by several methods. The original method for 
serotyping was the immunoprecipitation test pioneered by Lancefield and is based on the formation 
of a precipitate after the cross-reaction of a protein antigen with its corresponding antibody.83-86 
The sensitivity of this method is dependent on the amount of antibody in the antiserum. In an effort 
to decrease the assay time of the immunoprecipitation test, immunofluorescence staining and 
counterimmunoelectrophoresis methods were developed for GBS.86-88 Antibody-labeled reagent 
cells in slide coagglutination tests have also been used to identify and distinguish the serotypes of 
GBS.86, 89, 90 To increase sensitivity and accessibility of materials needed for other serotyping 
methods, enzyme immunoassays have also been developed.91, 92 The most commonly used 
serotyping method for GBS is latex agglutination tests that are based on the detection of antibodies 
specific for GBS CPS present in human serum.93, 94  
Phenotypic assessment by CPS serotyping has been a long-standing method used in the 
description of GBS disease state and distribution. However, to better understand the expression of 
other virulence factors, especially those used by non-typeable strains, alternative methods have 
been developed to distinguish different strains. Early development of alternative typing methods 
included both genomic and molecular characterization methods.95-98 Serotyping based on surface 
proteins instead of capsular polysaccharides has also proven to be useful in distinguishing between 
various protein serotypes of GBS.78, 99, 100 Further, there are methods to analyze serovariant 
distribution, which is accounts for both the CPS serotype and expression of select surface 
proteins.101 More recently, methods that focus on genotyping instead of serotyping have been 
developed. These include pulse-field gel electrophoresis, restriction endonuclease analysis, PCR-
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based techniques, and sequence typing.102-106 Studies dividing serovariants based on genes 
encoding for surface proteins have revealed that protein antigen serotyping and protein gene 
profiling can lead to inconsistencies in genetic and serotypic results.99, 100 Similar studies to 
compare CPS serotyping and gene typing use sequences of the capsular polysaccharide synthesis 
(cps) gene clusters.105 Gene typing allows for differentiation between GBS strains by sequence 
type. Multilocous sequence typing (MLST) is an expansion of initial gene typing methods that 
were based on the sequences of cps gene clusters. This sequence typing method involves nearly 
500-base pair fragments of seven different housekeeping genes.106 An online MLST database was 
established that offers investigators worldwide the ability to compare data from other 
geographically distinct regions, potentially providing insight into the epidemiology of GBS.106, 107 
More than 700 sequence types have been identified, and the majority of human isolates belong to 
six ancestral genotypes and strains.19, 106, 108 MLST does not necessarily parallel capsular serotype, 
but subdivision of GBS strains by both serovariants and sequence types can increase the 
discriminatory power of typing systems to improve epidemiological and pathogenetic associations 
of GBS infections.10, 99, 106  
Prevalence 
A recent meta-analysis explored the prevalence of GBS colonization in both mothers and 
infants and the adverse outcomes associated with GBS.109-118 While there are ten GBS capsular 
serotypes, five serotypes (Ia, Ib, II, III, and V) account for over 95% of GBS infections in infants 
(Figure 1.7).114, 119 Serotype III is the most prevalent serotype in almost all countries and regions; 
however, serotype Ia is more prevalent than serotype III in South America.114 
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Figure 1. 7 Global distribution of GBS serotypes in invasive disease in young infants (N = 6500 isolates). 
Prevalence of GBS serotypes presented as percentage (number of cases). (Figure adapted from: Infant Group B 
Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses. Clin Infect Dis. 
2017;65(suppl_2):S160-S172. doi:10.1093/cid/cix656) 
 
Serotype distribution differs between EOD and LOD. Sereotype III is associated with 45% 
of EOD and 71% of LOD (Figure 1.8).114 The other prominent serotypes, Types Ia, Ib, and V were 
more prevalent in EOD (20%, 8%, and 10%, respectively) than in LOD (14%, 6%, and 4%) (Figure 
1.8).114 Distribution of serotypes in maternal colonization may be linked to those seen in infant 
GBS diseases because vertical transmission of GBS from mother to infant would give rise to 
similarities in maternal colonization and infant infection.113 Disease-causing serotypes are 
similarly distributed across different regions, and serotype distribution information can be used to 
inform the development of treatments and preventions because vaccines are often based on 
serotype. 
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Figure 1. 8 Distribution of GBS serotypes for A) early onset GBS diseas and B) late onset GBS disease. (Figure 
adapted from: Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and 
Meta-analyses. Clin Infect Dis. 2017;65(suppl_2):S160-S172. doi:10.1093/cid/cix656) 
 
Treatments and Prevention 
Because GBS is an important cause of perinatal morbidity and mortality, governing health 
bodies such as the Centers for Disease Control and Prevention (CDC), the American Academy of 
Pediatrics (AAP), the American College of Obstetricians and Gynecologists (ACOG), and the 
Royal College of Obstetricians and Gynecologists (RCOG) have issued statements suggesting 
strategies to prevent and treat GBS infection.14, 15, 21, 120, 121 These strategies include prevention of 
vertical transmission by administering intrapartum antibiotic prophylaxis (IAP) to pregnant 
women who are colonized with GBS, which can prevent many perinatal infections.121 Both risk-
based and screening-based approaches have been used to identify women who should receive 
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IAP.10 Common practice in industrialized countries includes prenatal screening to identify women 
who are colonized with GBS and should be given IAP during labor and delivery. The time-frame 
recommended for GBS screening is 35-37 weeks of gestation or 32-34 weeks for twins.122 
Identification of risk factors associated with GBS has also been used as a measure for determining 
the administration of IAP.121 
 Antibiotic prophylaxis given to mothers colonized with GBS has greatly reduced the 
incidence of EOD.23, 123 In fact, since national guidelines for prevention and treatment of GBS 
were first released in the 1990s, incidences of EOD in the US has decreased by 80% (1.7 cases to 
< 0.4 cases per 1,000 live births).15, 124 However, this approach is not always implemented in low 
and middle-income countries where perinatal health care fluctuates.125 Cases of EOD have 
decreased with the use of IAP because it decreases maternal colonization and subsequent vertical 
transmission. Yet, IAP has had no effect on LOD or the incidences of stillbirth and prematurity 
related to GBS colonization because LOD is not directly correlated with maternal colonization and 
stillbirth and prematurity often occur before maternal screening for GBS.18, 119 
The standard antibiotic given during prophylaxis is penicillin, with ampicillin commonly 
serving as an alternative (Table 1.3).14, 121 Cefazolin is given to patients who have an allergy to 
penicillin and a low risk for anaphylaxis, angioedema, respiratory distress, or urticaria.15 However, 
clindamycin is the antibiotic of choice for a patient with an allergy to penicillin and a high risk for 
anaphylaxis or respiratory stress,. Erythromycin could be used instead of clindamyin before 
revised guidelines were released in 2010 by the CDC and the National Center for Immunization 
and Respiratory Diseases.124 Erythromycin has since been removed due to an increased resistance 
(25-35%) seen in several GBS strains.15, 124, 126, 127 Because some strains of GBS have also 
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developed resistance to clindamycin (13-20%), it is recommended that GBS isolates be screened 
for resistance, and vancomycin is used as a last resort against resistant strains.15, 124 These 
antibiotics are administered intravenously and given in doses aimed at achieving adequate levels 
in the fetal circulation and amniotic fluid.124 Penicillin, ampicillin, and cefazolin are usually able 
to achieve high intra-amniotic concentrations. However, data suggests that clindamycin and 
vancomycin do not reach fetal tissues as readily.124, 128-135 Because these alternatives have 
limitations in their pharmacokinetic profiles, alternative therapies need to be developed for women 
who react negatively to penicillin, ampicillin, or cefazolin. Additionally, many of the antibiotics 
used to treat GBS are broad spectrum and can influence the development of the infant microbiome 
by eliminating commensal bacteria. Thus, it is important to find alternative strategies to treat GBS. 
The structures of the antibiotics used to treat GBS are shown in Figure 1. 9. 
Table 1. 3 Antibiotics Used to Treat GBS 
Antibiotic Administration Resistance 
Penicillin Drug of choice <2%a 
Ampicillin Alternative to penicillin - 
Cefazolin Alternative for penicillin allergy <1% 
Clindamycin High-risk of anaphylaxis 13-20% 
Erythromycin No longer used due to increased levels of resistance 25-35% 
Vancomycin Resistance to Clindamycin <1%b 
areports listing intermediate or reduced susceptibility, but not entire resistance138, 139 bonly individual cases of 
vancomycin-resistant strains have been reported140 
 
GBS resistance mechanisms to clindamycin and erythromycin are usually due to ribosomal 
modifications mediated by erm genes or upregulated efflux pumps encoded by mef genes.136  
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Resistance genes can be detected by PCR and studies have revealed that over 90% of resistant 
isolates (n = 88) carried erm genes and only 6% carried mef genes.137, 136 No studies have been 
done to analyze the mechanisms associated with reduced susceptibility to penicillin, cefazolin, or 
vancomycin, but it is likely from similar mechanisms of ribosomal modification or up regulation 
of efflux pumps. 
 
 
Figure 1. 9 Structures of Antibiotics Used to Treat Group B Strep 
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While antibiotics are given to treat GBS infections and to prevent transmission from mother 
to infant during labor and delivery, vaccination is another attractive preventative strategy. 
Although viral vaccines are more prevalent because bacterial infections can often be treated with 
antibiotics, several standard vaccines are available to prevent bacterial infections from pathogens 
such as tuberculosis, pertussis, and diphtheria.141 The development of a successful GBS vaccine 
would rely on the production of protective antibodies that a mother could pass to her unborn 
child.142 The transfer of antibodies from mother to fetus has been linked to infant protection against 
GBS infection.143 CPS have structures similar to polysaccharides found in the host, which leads to 
lack of immunogenicity because the host is unable to recognize GBS as a foreign entity. As CPS 
play an important role in GBS virulence and antibodies to CPS have a protective role, vaccines 
using CPS as antigens have been developed and have entered clinical trials.144-146 In the 1980s, the 
first GBS polysaccharide-vaccines were developed using type-specific polysaccharides for Type 
III CPS.147 These initial studies demonstrated the feasibility of further developing CPS-based 
vaccines to protect neonates from GBS by maternal immunization. Other advancements in CPS-
based vaccines included conjugation of proteins to increase immune response and utilization of a 
multivalent approach based on CPS of several serotypes.144 Because five serotypes account for the 
majority of GBS disease, conjugate vaccines that incorporate polysaccharides from these serotypes 
could prevent roughly 95% of GBS disease in infants.10, 119  
In addition to polysaccharide-based vaccines, protein-based vaccines have also gained 
considerable interest. New genomic information for both protein expression and CPS production 
has become available with the readily accessible analyses of complete genomes of varying GBS 
serotypes.82 While CPS-based vaccines only have the ability to confer protection against the 
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serotypes included in the vaccine, protein-based vaccines could provide broad protection across 
all serotypes because they are based on ubiquitous GBS proteins.148  
Several major pharmaceutical companies, including GlaxoSmithKline (GSK) and Pfizer, 
have developed CPS-based vaccines that have entered both phase I and II clinical trials (Table 
1.4).148 A protein-based vaccine developed by MinervaX has entered phase I clinical trials (Table 
1.4).148 As more vaccines are developed and make their way into clinical trials, it will be important 
to consider their use and efficacy in both high-income as well as low- and middle-income 
countries.148, 149  
 
Table 1. 4 Overview of Vaccines in Development or Clinical Trials for GBS 
 Clinical Trial Stage Type of Vaccine 
GSK Phase I and II Trivalent (Ia, Ib, III) CPS-CRM197 
GSK Preclinical Pentavalent (Ia, Ib, II, III, V) CPS-CRM197 
Pfizer Early phase Multi-valent CPS-CRM197 
MinervaX Phase Ia and Ib N-terminal domain fusion protein (Rib and AlpC) GBS-NN 
 
Summary 
Group B strep is an important pathogen during the neonatal and perinatal period, and 
mother and infant health are closely related during transmission. Even though there have been 
great advances in preventing the transmission of early onset disease, little is known about GBS 
conferral that causes late onset disease. GBS can asymptomatically colonize a healthy adult while 
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causing adverse pregnancy outcomes and invasive infection in infants. A better understanding of 
how this pathogen regulates virulence factors would aid in the development of treatment. 
Additionally, finding ways to utilize compounds produced by the host to develop protective and 
preventative strategies against GBS infections could be of great importance in overcoming the 
antimicrobial resistance of GBS. 
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Human Milk Oligosaccharides Categorized by Lewis Blood Groups  
Introduction 
Human milk is the ideal food source for infants. Several professional bodies including the 
World Health Organization,1 the American Academy of Pediatrics,2 and the U. S. Department of 
Health and Human Services3 recommend exclusive breastfeeding for the first 6 months of life, 
with continued integration of human milk into a mixed diet up through two years of age. The 
benefits associated with breastfeeding range from regulating gut microbiota to decreasing the 
occurrences of infections, asthma, obesity, and sudden infant death syndrome, compared to infant 
formula.3-6,7,8,9,10,11 The advantages of breast feeding create a desire to understand the uniqueness 
of human milk relative to bovine milk, which is the basis of infant formula.  
Human Milk Composition 
Human milk contains both nutritional and bioactive factors that contribute to brain 
development, the central nervous system, and the host digestive system, while also influencing 
cardiovascular and metabolic health and susceptibility to infection.12-19 In contrast to infant 
formula, whose content is relatively consistent, human milk has an ever-changing composition 
based on the individual, stage of lactation, and geographical location.5 The earliest milk produced 
by mothers, known as colostrum, contains elevated levels of immunological and nutritional 
components and growth factors.5, 20 Additionally, the concentration of human milk 
oligosaccharides (HMO) is highest in colostrum.21-25 As an infant matures, so does the milk, and 
it increases levels of lactose to support the energy requirements of the growing infant.5, 20  
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On average, human milk contains 41 g/L fats, 8 g/L proteins, 70 g/L lactose, and 5-20 g/L 
oligosaccharides (Table 2.1).5, 6, 26-29 One of the most striking differences between human and 
bovine milk types is the quantity and nature of their respective carbohydrate components. Human 
milk contains a higher percentage of fucosylated HMOs (50-80%), while bovine milk contains a 
larger portion of sialylated oligosaccharides (ca. 70%). HMOs are the third largest macromolecular 
component of human milk and will be the focus of this chapter. However, the other components 
of human milk also play an important role and will be discussed in brief below.  
 
Table 2. 1 Comparison of macronutrients in human and bovine milk 5, 6, 27-30 
 Humans (g/L) Bovine (g/L) 
Protein 8 32 
Fat 41 37 
Lactose 70 48 
Oligosaccharides 
     Percent Sialylated 
     Percent Fucosylated 
5-15 
   10-20% 
   50-80% 
0.05 
   70% 
   1% 
 
 
Nutritional Components 
The nutritional components of human milk remain relatively conserved and originate from 
enzymes in the mammary glands, circulating maternal fluids, or maternal diet.5 Proteins, fats, and 
carbohydrates are macronutrients that contribute to the energy derived from milk. There is a wide 
array proteins found in human milk, but some of the most abundant include casein, α-lactalbumin, 
lactoferrin, secretory immunoglobulin A (sIgA), lysozyme, and serum albumin.5, 31 Palmitic and 
oleic acids are two highly abundant fats in human milk, and lactose is the most abundant 
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carbohydrate.5 Micronutrients also contribute to the nutritional aspect of human milk and can vary 
largely based on maternal diet. Naturally low concentrations of Vitamins K and D can be 
augmented by maternal diet supplementation with a multi-vitamin or infant diet supplementation 
with Vitamin D.5 Other micronutrients include vitamins A, B1, B2, B6, B12, thiamin, riboflavin, 
choline, and iodine.5, 32 
Bioactive Components 
In addition to its nutritive value, human milk also contains bioactive components that play 
an important role in infant health and development. The immunological potential and composition 
of human milk depends on several factors. Nevertheless, a recent analysis of immune factors in 
human milk among healthy women of various ethnic, geographic, dietary, socioeconomic, and 
environmental circumstances revealed a core set of soluble immune factors present in all or most 
of the breast milk samples (n = 370).33 These core immune factors extend across several different 
classes and include IgA, IgG, IgM, epidermal growth factor (EGF), Transforming growth factor 
β2 (TGF-β2), interleukin 7 (IL-7), IL-8, chemokine growth-regulated oncogene-α (Groα), and 
macrophage inflammatory protein β (MIP1β).    
Several growth factors are found in human milk and have diverse effects on multiple 
biological systems. For instance, EGF can withstand the harsh environment of the digestive tract 
and stimulate the growth of cells that are important for intestinal maturation and repair.34-36 The 
growth and development of the enteric nervous system relies on brain-derived and glial cell-line 
derived neurotrophic factors.37-40 These neurotrophic factors can increase peristalsis and neuron 
survival and outgrowth. Tissue growth is stimulated in part by the insulin-like growth factor (IGF) 
superfamily.5 Vascular endothelial growth factor (VEGF) regulates angiogenesis, an important 
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part of the vascular system.5, 41 Erythropoietin (Epo) is one of the hormones found in human milk 
and contributes to the prevention of anemia through increasing red blood cells.42, 43 Epo has also 
been shown to be important in intestinal development and protection against necrotizing 
enterocolitis.44, 45 Several hormones linked to metabolic regulation are found in human milk: 
adiponectin, leptin, resistin, and grehlin.46-49 These influence infant metabolism, energy 
conversion, and appetite control. Other growth-regulating hormones, such as calcitonin and 
somatostatin, are also found in human milk, but their specific role has yet to be fully elucidated.5 
Just as calcitonin increases calcium concentration in the gut and kidney, it is likely that it has a 
similar effect in the mammary gland to increase calcium levels transferred to the neonate.50  
Human milk is rich with innate immune factors that provide protection against infection 
and inflammation in infants (Table 2.2). For example, a collection of living cells such as 
macrophages, T cells, stems cells, and lymphocytes are found in human milk. These cells play an 
active role in conferring protection and initiating the programming for the neonate’s immune 
system.5, 51 Nearly 80% of these cells are macrophages and participate in phagocytosis of various 
pathogens or differentiate into dendritic cells that facilitate communication between the innate and 
adaptive immune systems.5, 52 Human milk stem cells help establish a microchimeric state in the 
infant and likely participate in tissue and immune cell regeneration.51, 53, 54 
Human milk also contains several cytokines and chemokines, important classes of immune 
factors, that participate in cell signaling and communication between cells (Table 2.2). Many 
cytokines act in concert with other immune regulators to produce a domino effect that contributes 
to the overarching development and responses of the immune system.56 Cytokines found in human 
milk can be categorized into two broad groups: those that reduce inflammation or those that 
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enhance inflammation and defend against infection.5 TGF-β2 is the most abundant cytokine in 
human milk and is one of three isoforms of the multifunctional TGF-β family.5, 57, 58 Considering 
endogenous TGF-β synthesis is lacking during neonatal development, TGF-β2 is an important 
immunomodulatory factor of breast milk because it induces oral tolerance in infants that leads to 
prevention of food allergies and to regulation of immune responses in the intestinal tract.33, 59-61 
Some of the regulatory cytokine found in human milk include granulocyte-colony stimulating 
factor (G-CSF), IL-10, and IL-7. These cytokines are responsible for aspects of intestinal 
development including cell proliferation and differentiation at the intestinal surface.62, 63 Specific 
roles of many pro-inflammatory cytokines in human milk—tumor necrosis factor α (TNF-α), IL-
6, IL-8, and interteron γ (IFNγ)—have yet to be identified. However, IL-8 is involved in the 
chemotaxis of leukocytes from maternal cells to human milk.64 The chemokine Groα, also known 
as C-X-C motif ligand 1 (CXCL1), plays an important role in neuroprotection and angeogenesis.65, 
66 Still, other chemokines such as MIP1β, also known as C-C motif ligand 4 (CCL4), MIP1α, and 
RANTES (regulated on activation, normal T cell expressed and secreted) play a role in suppressing 
HIV.67 
As infants develop their immune system, several immunoglobulins, a type of glycoprotein 
found in human milk, provide protection against pathogen invasion. sIgA, the most predominant 
immunoglobulin, influences the potential development of allergic diseases and the immune 
response to dietary antigens.68, 69 IgA, IgM, and IgG contribute to protection against pathogen 
colonization and invasion.33, 70-72 In addition to their effect on other pathogens, immunoglobulin 
antibodies have been shown to protect the neonate from GBS infection by interfering with 
carbohydrate-mediated attachment to epithelial cells or serving as antibodies of GBS CPS.20, 73-77 
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Table 2. 2 Immune Cells found in Human Milk55 
Cell Type Illustration Function 
Stem Cell 
 
Tissue and immune cell regeneration 
Neutrophils 
 
 
Phagocytosis 
Enzyme release 
Macrophages 
 
Phagocytosis 
Inflammation 
Phenotypic plasticity 
Cytokine and chemokine Secretion 
Dendritic Cells 
 
Phagocytosis 
Produce cytokines 
Display antigens to T-cells 
Eosinophils 
 
Allergy response 
Cytotoxicity 
Produce growth factors and cytokines 
T-cell 
 
Recognize antigens 
Stimulate immune cells 
Cytotoxicity 
Antibodies 
 
Recognize and bind antigens for 
clearance of invaders 
Cytokine and chemokines 
 
Cell signaling and communication 
 
 
Other glycoproteins in human milk also contribute to the function of an infant’s innate 
immune system. Lactoferrin is an iron-binding glycoprotein that has antimicrobial activity against 
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several viral, fungal, and bacterial pathogens.78-80 Lactoferrin also plays a role in host defense by 
binding to bacterial membranes, inhibiting TNF- α and IL-1β, and stimulating the activity and 
development of lymphocytes.51, 81 Lactadhedrin is a glycoprotein that confers protection against 
rotaviral infections and aids in recovery from intestinal inflammations.5, 82 Lactadhedrin also 
triggers signaling cascades involved in phagocytosis by acting as a bridge for macrophage 
recognition of lactadhedrin bound to the phosphatidylserine on apoptotic cells.83, 84 Other 
glycoproteins that protect against pathogen invasion by acting as decoy receptors include Mucin 1 
(MUC1), MUC4, and several gangliosides (GM1, GM3, and GD3).51, 85  
In addition to nutritional and immunological components, human milk also contains a 
multitude of bacterial species. Both culture-dependent and genomic-based approaches have been 
used to characterize the milk microbiome. Some of the bacterial species present in human milk 
include Staphyloccocus, Streptoccocus, Propionibacterium, Pseudomonas, and Lactobacillus.51, 
86-89 There are approximately 400 species of bacteria in human milk at any given time.88, 90 Many 
of these bacteria are commensal or symbiotic and provide infants with the infrastructure to develop 
a healthy gut micriobiome.91-93 Human milk is among the earliest vehicles for intestinal bacterial 
colonization but can also be a source of pathogenic bacteria that leads to newborn diseases.14, 73, 94-
96 Similar to many of the immune factors found in human milk, the concentration and types of 
bacteria are dependent on several factors such as geographical region, gestational age, genetics, 
mode of delivery, and maternal nutrition.97, 98  
Carbohydrate Components 
Human milk contains a substantial carbohydrate portion, of which lactose is the main 
carbohydrate constituent. Lactose serves as an energy source after digestion into its 
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monosaccharide components (glucose and galactose). Most cells utilize glucose for energy, and 
galactose can also be used for energy after it is converted to glucose in the liver.99  
In addition to lactose, human milk contains an abundant and structurally diverse set of 
carbohydrates known as human milk oligosaccharides (HMOs). In contrast to lactose, the 
oligosaccharides present in human milk are not digestible by infants.25, 100, 101 Instead, HMOs  
travel to the infant gut where they serve as prebiotics and help regulate the development of the 
infant gut microbiome by stimulating the growth of beneficial microoranisms such as 
bifidobacteria.100-103 In turn, the composition of the microbiome can influence an infant’s health.104 
Certain infant gut-associated bifidobacteria have genes and enzymes dedicated to HMO utilization, 
allowing them to thrive on HMOs as a carbon source.105 HMOs can also serve as antiadhesive 
antimicrobial agents and lower the risk of infections by functioning as decoy receptors for various 
pathogens.102, 106-110 Before host invasion, many pathogens first adhere to epithelial surfaces 
through lectin-glycan interactions. Some HMOs resemble the glycans on the surface of epithelial 
cells, and pathogens will bind to these HMOs rather than the host cells. Additionally, sialylated 
HMOs are thought to be important in brain development as sialic acid is an essential component 
of brain gangliosides and neural cell adhesion molecules.102, 111, 112  
While the functions of many individual HMOs remain unclear, a few structure-activity 
relationships have been described. For instance, 2’-fucosyllactose (2’-FL), one of the most 
prevalent HMOs, exhibits anti-inflammatory activity by modulating signaling cascades that result 
from E. coli infections.113 Specifically, 2’-FL inhibits membrane-bound CD14 expression, an 
important component of a complex that activates signaling pathways for the production of 
inflammatory mediators such as IL-8.113 Another HMO, disialyllacto-N-tetraose (DSLNT) has an 
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inhibitory effect on necrotizing entercolitis (NEC) in a neonatal rat model.114 While the exact 
mechanism of NEC prevention is unknown, it is likely to occur through signaling cascades 
mediated by the binding of DSLNT to siglec receptors, disrupting the interaction between siglecs 
and toll-like receptors to activate an immune response.114-116 
Discovery of HMOs 
A distinction in the composition of human and bovine milk was first noted in 1888. At this 
time, Eschbach observed that human milk contained a “more heterogeneous form of lactose” while 
bovine milk contained a “more homogenous form of lactose.”117 Researchers concluded that 
lactose was identical in both milks, but noted an additional carbohydrate fraction that had not yet 
been specified. This fraction remained unnamed until nearly 40 years later when it was termed 
“gynolactose” by two French chemists, Michel Polonowski and Albert Lespagnol.102, 117-119 They 
rudimentarily described gynolactose as containing nitrogen, hexosamines, and other 
carbohydrates. Soon after, Polonowski and Montreuil used 2-dimensional paper chromatography 
to identify 2’-FL and 3-fucosyllactose (3-FL) in the previously uncharacterized human milk 
fraction.117, 120 The initial identification of these components prompted the desire to characterize 
“gynolactose” more fully by assigning structural aspects to its components. Research by both 
Montreuil and Kuhn led to a clear description of several HMOs, including the previously described 
2’-FL and 3-FL as well as difucosyllactose (DF-L), lacto-N-tetraose (LNT), lacto-N-fucopentaose 
I (LNF-I), LNF-II, and lacto-N-difucohexaose I (LNDF-I) among others.117, 121-130 Some of the 
oligosaccharides in human milk showed similar activities to blood group determinants because of 
their structural resemblance (Figure 2.1). Specifically, 2’-FL and LNF-I simulated the activity of 
H determinant, LNDF-I the activity of Leb determinant, and LNF-II the activity of Lea 
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determinant.128, 131-134 The correlation between HMOs and blood groups led to a surge in the 
elucidation of new HMO structures that continues today.131, 135-142  
 
 
 
Figure 2. 1 Comparison of Blood Group Antigens and HMOs. The blood group H-antigen and Lewis structures 
found in glycan-containing molecules compared to HMOs that have similar or identical carbohydrate structures. 
Abbreviations: 2′-FL, 2′-fucosyllactose; LNF-I, lacto-N-fucopentaose I; LNDF-I, Lacto-N-difucohexaose I. 
 
Escherich, an Austrian pediatrician and microbiologist, in the late 19th century made a 
connection between intestinal bacteria and physiology of an infant’s digestion. This initial 
observation led to the appreciation of the differences in microbiota of breast-fed infants compared 
to those who were bottle-fed and furthered the notion that human milk has unique components that 
contribute to infant health and development. The chemical nature of these components remained 
unknown until a connection was made between the work on “gynolactose” and the growth-
promoting factor for bacteria, establishing oligosaccharides as a “bifidus factor.” Since then, 
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structural elucidation and functional studies of HMOs have continued to reveal a much greater 
influence of HMOs on infant health beyond serving as a “bifidus factor.”  
 
 
Figure 2. 2 Timeline of HMO research in the 20th century. It was pioneered by pediatricians and microbiologists 
who studied the benefits of human milk for the breast-fed infant and by chemists who worked to identify the unique 
carbohydrate portion of human milk. This led to the characterization of the “gynolactose” portion of human milk and 
subsequent identification of over 100 unique HMO structures along with functional studies of HMOs.26 
 
HMO Structure 
HMO composition and concentration vary among women and over the course of lactation, 
but five monosaccharides are incorporated into HMO structures: glucose (Glc), galactose (Gal), 
N-acetylglucosamine (GlcNAc), fucose (Fuc), and N-acetylneuraminic acid (Neu5Ac, also known 
by its common name, sialic acid, Sia) (Table 2.3). 26, 102, 143 There are estimates that over 200 
unique structures exist.  
HMOs contain lactose (Galβ1-4Glc) at the reducing end and can be elongated with lacto-
N-biose (Galβ1-3GlcNAc) to form type 1 chains or N-acetyllactosamine (Galβ1-4GlcNAc) to 
form type 2 chains (Figure 2.3A). HMOs range from 3 to 32 monosaccharide units.145, 146 Acidic 
HMOs have core structures that are decorated with sialic acid residues in an α-2,3 or α-2,6 linkage 
1880s-1900s
• Different carbohydrates in human and 
bovine milk.
• Microoganisms are important for 
health
• Breast-fed and bottle-fed infants have 
different fecal composition
1930s
• characterization of "gynolactose" of 
human milk
1950s-1980s
• Identification and functional studies of 
HMOs
• Connection between HMO epitopes 
and those of blood and tumor cells
• HMOs are prebiotics and have anti-
adhesive and anti-inflammartory 
properties
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to terminal galactose or in an α-2,6 linkage to GlcNAc. Fucose residues decorate core structures 
in α-1,2, α-1,3, or α-1,4 linkages in neutral HMOs. Sialylated HMOs have a lower abundance (10-
20%) relative to fucosylated HMOs (50-80%).6, 27, 28, 102, 131, 141, 142, 147-151 This is in contrast to the 
relative abundances of sialylated and fucosylated oligosaccharides in bovine milk, which is ca. 
70% and 1% respectively.102, 152, 153 The abundance of fucosylated HMOs in human milk is suited 
for the protective role many of these oligosaccharides play. 
 
Table 2. 3 Major Monosaccharide Building Blocks of HMOs144 
Monosaccharide Abbreviation Symbol Structure Linkage 
Glucose Glc 
  
None (at the 
reducing end) 
Galactose Gal 
  
β 
N-Acetylglucosamine GlcNAc 
  
β 
Fucose Fuc 
 
 
α 
N-Acetylneuraminic acid 
(sialic acid) 
Neu5Ac 
(Sia)   
α 
HO O
HO
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OH
HO
HO
O
OH
O
OHHO
HO O
HO
NHAc
O
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O
O
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O
HO OH
OH HO2C
O
HO
AcHN
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Figure 2. 3 Structure of Several HMOs. A) Basic structure of HMOs. HMOs have lactose at the reducing end and 
can be elongated by lacto-N-biose or N-acetyllactosamine and further decorated with fucose or sialic acid residues. 
B) Lactose can be fucosylated or sialylated by different linkages. C) Lactose can be elongated by lacto-N-biose (type 
I) or N-acetyllactosamine (type II). Elongated chains can be D) fucosylated or E) sialylated. Abbreviations: 2′-FL, 2′-
fucosyllactose; 3-FL, 3-fucosyllactose; 3′-SL, 3′-sialyllactose; 6′-SL, 6′-sialyllactose; LNT, lacto-N-tetraose; LNnT, 
lacto-N-neotetraose; LNH, lacto-N-hexaose; LNF-I, II, II, V, lacto-N-fucopentaose I, II, III, V; LST a, b, c, sialyl-
lacto-N-tetraoses a–c.26 
 
Pioneering work by Victor Ginsburg demonstrated that HMO structural features are 
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determined by gene-regulated expression of specific glycosyltransferases. The expression of these 
transferases, and consequently oligosaccharide structure and composition, are influenced by the 
mother’s Lewis blood group and secretor status.154, 155 Lewis blood groups, which are determined 
by the presence or absence of secretor and Lewis genes, dictate the expression of three different 
types of fucosyltransferases. Secretor mothers possess an active Se gene locus encoding for the 
fucosyltransferase II (FUT2). FUT2 transfers fucose in an α-1,2 linkage to a terminal galactose, 
resulting in milk that is rich in α-1,2 fucosylated HMOs. Nonsecretors lack an active Se locus and 
do not produce HMOs with this glycosidic linkage. Lewis positive mothers have an active Le gene 
locus encoding for the α-1,3 and α-1,4 fucosyltransferase FUT3 which installs fucose in an α-1,4 
linkage to N-acetylglucosamine. Several fucosyltransferases (FucT) are responsible for installing 
α-1,3 fucosyl linkages to either N-acteylglucosamine or glucose. Because Lewis negative mothers 
do not have an active Le locus, their milk lacks α-1,4 fucosylated HMOs. 
The distribution of Lewis blood groups across a given population varies based on 
geographical and ethnic factors. Recorded distributions for American populations are shown in 
Table 2.4. The largest percentage of the population (55-72%) are individuals belonging to the 
Lewis (a-b+) blood group, which express α-1,2FucT, α-1,3FucT, and α-1,4FucT. Lewis (a+b-) 
individuals account for 20-23% of the population and express α-1,3 FucT and α-1,4 FucT. Lewis 
(a-b-) express α-1,2 FucT and α-1,3FucT and account for 5-10% of the population. Lewis (a-b-
c+d-) is a very rare Lewis blood group, where an individual does not express any 
fucosyltransferases, and makes up less than 1% of the population.156  
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Table 2. 4 Lewis blood group determinants. The expressed enzymes and genotypes corresponding to each Lewis 
blood group are listed along with their prevalence as a percentage of the general population.133, 134 
Lewis Blood Group Expressed Enzymes 
Genotype 
Percent of Population 
Secretor Lewis 
Lewis (a-b+) 
α1-2 FucT 
α1-3 FucT 
α1-4 FucT 
Se/- Le/- 55-72 
Lewis (a+b-) α1-3 FucT α1-4 FucT se/se Le/- 20-23 
Lewis (a-b-) α1-2 FucT α1-3 FucT Se/- le/le 5-22 
Lewis (a-b-c+d-) - se/se le/le ≤1 
 
 
Biosynthesis of HMOs 
The biosynthesis of HMOs begins with the functionalization of a lactose core. Lactose 
synthesis is well studied and known to occur in the Golgi of the mammary glands by the action of 
the lactose synthase complex that consists of two enzymes: α-lactalbumin and β1-4 
galactosyltransferase (β1-4GalT1) (Figure 2.4).102, 157 In the absence of α-lactalbumin, β1-4GalT1 
transfers UDP-Gal to GlcNAc.102 However, as part of the lactose synthase complex, β1-4GalT1 
transfers UDP-Gal to glucose to yield lactose.158, 159  
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Figure 2. 4 Biosynthesis of neutral complex human milk oligosaccharides (HMO). The assumed biosynthetic 
pathway starts from the activated monosaccharides and includes the most important enzymes only [N-
acetylglucosaminyltransferases (GlcNAcT)]: iβ3GlcNAcT attaches N-acetylglucosamine (GlcNAc) in the β1–3 
position to terminal galactose (Gal), Iβ6GlcNAcT attaches GlcNAc in β1–6 position to terminal Gal. 
Galactosyltransferases (GalT): β3GalT attaches Gal in the β1–3 position to GlcNAc and β4GalT attaches Gal in the 
β1–4 position to GlcNAc. Fucosyltransferases (FucT): α2FucT attaches fucose (Fuc) in the α1–2 position to terminal 
Gal, secretor (Se) enzyme, α3FucT attaches Fuc in the α1–3 position to GlcNAc, α3/4FucT attaches Fuc in the α1–
3/4 position to GlcNAc and in the α1–3 position to Glc of the lactose core, Lewis (Le) enzyme. The no entry signs 
mean that no further elongation takes place. Fucosylation is indicated exemplarily for terminal type 1 and type 2 
chains. Glycan structures are depicted according to the recommendations of the Consortium of Functional Glycomics 
using the GlycoWorkbench software tool.  (Reproduced with permission from: Human Milk Oligosaccharides and 
Lewis Blood Group: Individual High-Throughput Sample Profiling to Enhance Conclusions from Functional Studies. 
Adv Nutr. 2012; 3 (3):440S-449S. doi:10.3945/an.111.001446. Adv Nutr | © 2012 American Society for Nutrition) 
 
Elongation of the lactose core is less understood because many of the specific 
glycosyltransferases required for the biosynthesis of HMOs have not been identified.144 Still, 
significant progress has been made in understanding the fucosylation patterns and associated 
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fucosyltransferases that are dependent upon blood group characteristics.102 It is likely that HMOs 
are elongated by extension of the lactose core via addition of monosaccharides by alternating 
actions of requisite glycosyltransferases (Figure 2.4).102, 160 For example, elongation to form the 
tetrasaccharide LNT would first require the action of an N-acteylglucosaminyltransferase 
(β3GalNAcT) to install GlcNAc on lactose, followed by a galactosyltransferase to install Gal on 
GlcNAc (Figure 2.4). Functionalization of the lactose core or elongated chains by other 
monosaccharides is accomplished by the action of a glycosyltransferase specific for each 
monosaccharide and each type of linkage. To date, several glycosyltransferases have been purified 
from human milk: β1-4GalT1, α1-3FucT, α-1,4FucT, and α-1,3/4FucT.161-166  
Identification and Characterization of HMOs 
The complex and diverse branching of HMO structures and the lack of amplification 
techniques has made the identification and characterization of HMOs a challenging undertaking.167 
Initial characterizations of HMOs was carried out using classical analytical methods.117 However, 
advanced techniques, including spectroscopic, chromatographic, and electromigration methods, 
have led to improved characterizations of mixtures for individual identification and quantification 
of HMOs.117, 167 Separation techniques coupled with mass spectrometric analysis are extensively 
used for both the qualitative and quantitative characterization of HMOs.167 
Liquid chromatography is the most common methods for HMO separation and 
characterization, and includes reversed-phase (RPC), high-pH anion-exchange (HPAEC), porous 
graphite carbon (PGC), normal-phase (NPC), and hydrophilic interaction (HILIC) 
chromatography.167 RPC can be used to study neutral oligosaccharides but requires pre-column 
derivatization to increase separation by this high-performance liquid chromatography (HPLC) 
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technique.168-170 HPAEC has been used to analyze both acidic and neutral HMOs.171, 172 While 
HPAEC does not require any derivatization, acidic and neutral HMOs must be separated prior to 
analysis. PGC has been used for the characterization of isomeric species after reduction to the 
respective alditols.167, 173 This method has also been used for the analysis of both neutral and acidic 
HMOs.174, 175 In NPC and HILIC techniques, a polar stationary phase and an apolar mobile phase 
lead to the separation of HMOs and allow for simultaneous determination of both neutral and 
acidic portions.24, 167, 176, 177 Fluorescent derivatization has been used to improve the sensitivity of 
these methods.176, 178, 179 
Gas chromatography (GC) is less widely employed to separate and identify HMOs.167 
Nevertheless, after acidic hydrolysis of HMOs, GC has been employed in some of the earliest 
studies to identify the monosaccharide constituents of HMOs.135, 136 More recent uses of GC for 
the identification of HMOs take advantage of the improved volatility of trimethylsilyl oxime 
derivatives of oligosaccharides.180 
Other techniques to analyze HMO samples include electromigration methods. Capillary 
zone electrophoresis (CZE) and micellar electrokinetic chromatography (MEKC) are employed 
for the separation of charged species, making these methods especially useful for studying 
sialylated HMOs.149, 167, 181, 182 These methods can also be used to study neutral HMOs after initial 
derivatization to generate an anionic species.183, 184  
In addition to identifying individual HMOs in a complex mixture, some of these techniques 
can also be used to characterize human milk samples based on the presence or absence of specific 
oligosaccharides. As mentioned previously, the secretor and Lewis status of the mother is directly 
linked to the types and quantities of HMOs present in milk.26, 106, 132, 185 Since fucosylated glycans 
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are abundant in human milk and can be used to distinguish between Lewis blood groups, 
identification of fucosylation patterns have been used to characterize human milk samples 
according to the Lewis blood group of the donor.  Specifically, recent reports have demonstrated 
the use of mass spectrometry and NMR for this purpose.186-188 NMR analysis focuses on the change 
in chemical shift between α-1,2, α-1,3, and α-1,4 fucosylated oligosaccharides (Figure 2.5).189 
Kunz and coworkers developed a high throughput mass fingerprinting technique that uses matrix-
assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) and 
MALDI-TOF tandem mass spectrometry (MS/MS) to identify major fucose-containing 
oligosaccharides and their fucosyl linkage types and subsequently assign the corresponding Lewis 
blood group (Figure 2.6).186  
 
 
 
 
Figure 2. 5 Comparison of spectra of mothers producing different profiles of HMOs. Spectra from mothers in 
blue, orange and red are non-Secretors, as these spectra do not contain signals corresponding to 2′-FL between δ 1.22 
and 1.25, while the mothers in green and black are classified as Secretors. (Reproduced with permission from Andreas, 
N. J., Al-Khalidi, A., Jaiteh, M., Clarke, E., Hyde, M. J., Modi, N., Holmes, E., Kampmann, B. and Mehring Le Doare, 
K. (2016), Role of human milk oligosaccharides in Group B Streptococcus colonisation. Clin Trans Immunol, 5: n/a, 
e99. doi:10.1038/cti.2016.43)) 
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Results 
Assigning Lewis Blood Groups to Human Milk Samples 
Based on the premise that human milk contains a variety of anti-infective agents, we 
hypothesized these molecules, specifically HMOs, can modulate Group B strep physiology. In 
order to test this hypothesis, isolation and characterization of HMOs from human milk samples 
was necessary.  
HMOs isolated from the milk of 19 different donors were kept separate, and Kunz’s 
methodology was used to assign Lewis blood groups to each sample. These assignments were then 
used to evaluate the hypothesis that Lewis blood groups are correlated to anti-bacterial activity of 
HMOs on GBS (Chapter 3). 
MALDI-TOF and subsequent MS/MS fragmentations of parent peaks m/z 657 and 1022 
was performed. These two peaks represent difucosylated oligosaccharides whose fragmentation 
patterns are correlated with the fucosyl linkages used to assign Lewis blood groups. Fragmentation 
of m/z 657 that results in a fragment peak at m/z 511 is associated with Le(a-b+) and Le(a-b-) 
blood groups, which both express the enzyme to form α-1,2 fucosyl linkages (FUT2) (Figure 2.6). 
The absence of a fragmentation peak at m/z 511 corresponds to Le(a+b-), which only has α-1,3 
and α-1,4 fucosyl linkages. To distinguish between Le(a-b+) and Le(a-b-) blood groups, the 
relative abundance of the fragment ions of m/z 1022 can be used. Le(a-b+) has a lower m/z 730 
relative to m/z 876, whereas Le(a-b-) has a similar or higher abundance of m/z 730 compared to 
m/z 876.186 
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Figure 2. 6 Representative MALDI-TOF MS HMO profile and corresponding MALDI-TOF MS/MS of m/z 657 
and m/z 1022 for HMOs from an individual donor. Signals obtained at m/z 657 represent an isotopic signal of 
sialyllactose (m/z 656) or the summed signals of difucosyllactose (m/z 657) plus the isotopic signal of sialyllactose 
(m/z 656). Signals obtained at m/z 1022 represent a signal of difucosylated lactose. The fragmentation of these two 
m/z can be used to determine the corresponding Lewis blood of group of the donor. Fragment ions of interest are m/z 
511 (from m/z 657) and the ratios of m/z 730 and 876 (from m/z 1022). 
 
Analysis of MS/MS of m/z 657 revealed donors 0, 5, 7, 8, 14, 16, 19, 20, 24, 32, 34, 37, 
38, and 42 to have a fragmentation peak of m/z 511, which is associated with Le(a-b+) and Le(a-
b-). Donors 17, 18, 29, 31, and 43 were missing this characteristic fragment ion and designated as 
Le(a+b-) (Table 2.5). Distinguishing between Le(a-b+) and Le(a-b-) required analysis of MS/MS 
of m/z 1022. Donors 0, 5, 7, 8, 14, 19, 20, 24, 32, 34, 37, and 42 were identified as Le(a-b+), and 
donors 16 and 38 were identified as Le(a-b-) (Table 2.5). The distribution of Lewis blood groups 
for the mothers in this study tracks well with distributions reported previously for larger 
populations (Table 2.6).99, 143, 154 
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Table 2. 5 Human milk donor designation and assigned Lewis blood groups 
Donor Lewis Blood Group 
0 a-b+ 
5 a-b+ 
7 a-b+ 
8 a-b+ 
14 a-b+ 
16 a-b- 
17 a+b- 
18 a+b- 
19 a-b+ 
20 a-b+ 
24 a-b+ 
29 a+b- 
31 a+b- 
32 a-b+ 
34 a-b+ 
37 a-b+ 
38 a-b- 
42 a-b+ 
43 a+b- 
 
 
 
 
 
 
Table 2. 6 Comparison of assigned Lewis blood group distribution to expected distribution 
Lewis Blood 
Group 
Out of 19 
Donor 
Distribution of 
Donors 
Expected Distribution of 
Donors 
Lewis (a-b+) 12 63% 55-72% 
Lewis (a+b-) 5 26% 20-23% 
Lewis (a-b-) 2 11% 5-22% 
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Conclusion 
The oligosaccharides in human milk are distinct from that of other mammals and are one 
of many bioactive components found in human milk. While several studies have shown the ability 
of HMOs to confer health and developmental benefits to the infant during the postnatal period, 
many of them have reported activity without describing specific structure-activity relationships 
However, some of these studies revealed disruption of pathogen adhesion and infection caused by 
HMOs. We hypothesized that the HMO composition of milk samples could be characterized by 
mass spectrometry and this information used to draw correlations between any activity and HMO 
composition. Specifically, we were interested in the effects of HMOs on the growth and biofilm 
formation of GBS. While the Bode and Le Doare research groups have separately shown the ability 
of HMOs to modulate the colonization and growth of GBS, our goal was to further investigate the 
relationship between HMO composition associated with Lewis blood group status and the extent 
of activity against GBS.  
  
Methods 
Purification of HMOs 
Human milk was obtained from nineteen healthy, lactating women between 3-90 days 
postnatal and stored at -20°C. The de-identified milk was provided by Dr. J. H. Weitkamp from 
the Vanderbilt Department of Pediatrics under a collection protocol approved by the Vanderbilt 
University Institutional Review Board (IRB#100897).  Milk samples and the respective 
components from subsequent purification steps were kept separate. The lipid components were 
removed by skimming after centrifugation. Proteins were precipitated by addition of ethanol at 4 
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°C and subsequent centrifugation. The HMO-containing supernatant was concentrated in vacuo, 
purified by P-2 Gel (H2O eluent), and the oligosaccharides were dried by lyophilization. 
MS and MS/MS Analysis of HMO Samples 
Dried HMO samples were reconstituted in water to approximately 1 mg/mL.  The HMO 
solutions were deposited on a matrix-assisted laser desorption/ionization (MALDI) target plate as 
follows:  1 µL HMO solution was spotted followed by 0.2 µL 10 mM NaCl and 1 µL DHB matrix 
(60 mg/mL in 50% methanol).  The spots were allowed to air dry, then analyzed in positive ion 
mode on a 9.4 T Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry (MS) 
(Bruker Solarix).  Mass spectra were acquired from m/z 300-2500.  Sodium ion adducts of HMO’s 
were detected with a mass accuracy of >2 ppm. 
MS/MS analysis was performed for selected ions with a linear ion trap mass spectrometer 
equipped with a MALDI source (LTQ XL, Thermo Scientific).  Selected sodium ion adducts of 
interest were isolated with a 1 amu window and fragmented via CID using a collision energy of 
35 eV.    
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Appendix A1: 
 
Spectra Relevant to Chapter II 
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Figure A1. 1 Matrix-assisted laser desorption/ionization (MALDI) full size MS spectra for HMO mixtures 
isolated from Donors 0, 5, 7, 8, 14, 16, 17, 18, 19, and 20. Sample labels are listed to the left of each spectrum with 
a D# designation such that D0 corresponds to Donor 0, and so on. Samples were analyzed in positive ion mode on a 
9.4T Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) (Bruker Solarix). Mass spectra 
were acquired in positive ion mode from m/z 300-2500. Sodium ion adducts of HMOs were detected with a mass 
accuracy of >2 ppm. 
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Figure A1. 2 Matrix-assisted laser desorption/ionization (MALDI) full size MS spectra for HMO mixtures 
isolated from Donors 24, 29, 31, 32, 34, 37, 38, 42, and 43. Sample labels are listed to the left of each spectrum with 
a D# designation such that D24 corresponds to Donor 24, and so on. Samples were analyzed in positive ion mode on 
a 9.4T Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (MS) (Bruker Solarix). Mass spectra 
were acquired in positive ion mode from m/z 300-2500. Sodium ion adducts of HMOs were detected  
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Figure A1. 3 Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of selected m/z 657.2 ion for 
HMO mixtures isolated from Donors 0, 5, 7, 8, 14, 16, 17, 18, 19, and 20. Sample labels are listed to the left of 
each spectrum with a D# designation such that D0 corresponds to Donor 0, and so on. MS/MS analysis was performed 
with a linear ion trap mass spectrometer equipped with a MALDI source (LTQ XL, Thermo Scientific). Selected 
sodium adduct ions of interest were isolated with a 1 amu window and fragmented via CID using a collision energy 
of 35 eV. Ions circled in red are deterministic for Lewis blood group and secretor status assignment. 
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Figure A1. 4 Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of selected m/z 657.2 ion for 
HMO mixtures isolated from Donors 24, 29, 31, 32, 34, 37, 38, 42, and 43. Sample labels are listed to the left of 
each spectrum with a D# designation such that D24 corresponds to Donor 24, and so on. MS/MS analysis was 
performed with a linear ion trap mass spectrometer equipped with a MALDI source (LTQ XL, Thermo Scientific). 
Selected sodium adduct ions of interest were isolated with a 1 amu window and fragmented via CID using a collision 
energy of 35 eV. Ions circled in red are deterministic for Lewis blood group and secretor status assignment. 
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Figure A1. 5 Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of selected m/z 1022.2 ion 
for HMO mixtures isolated from Donors 0, 5, 7, 8, 14, 16, 17, 18, 19, and 20. Sample labels are listed to the left of 
each spectrum with a D# designation such that D0 corresponds to Donor 0, and so on. MS/MS analysis was performed 
with a linear ion trap mass spectrometer equipped with a MALDI source (LTQ XL, Thermo Scientific). Selected 
sodium adduct ions of interest were isolated with a 1 amu window and fragmented via CID using a collision energy 
of 35 eV. Ions circled in red are deterministic for Lewis blood group and secretor status assignment. 
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Figure A1. 6 Matrix-assisted laser desorption/ionization (MALDI) MS/MS spectra of selected m/z 1022.2 ion 
for HMO mixtures isolated from Donors 24, 29, 31, 32, 34, 37, 38, 42, and 43. Sample labels are listed to the left 
of each spectrum with a D# designation such that D24 corresponds to Donor 24, and so on. MS/MS analysis was 
performed with a linear ion trap mass spectrometer equipped with a MALDI source (LTQ XL, Thermo Scientific). 
Selected sodium adduct ions of interest were isolated with a 1 amu window and fragmented via CID using a collision 
energy of 35 eV. Ions circled in red are deterministic for Lewis blood group and secretor status assignment.  
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Human Milk Oligosaccharides Exhibit Antimicrobial and Anti-Biofilm Properties Against 
Group B Streptococcus  
Adapted with permission from: 
Ackerman, D. L.; Doster, R. S.; Weitkamp, J. H.; Aronoff, D. M.; Gaddy, J. A.; Townsend, S. 
D., Human Milk Oligosaccharides Exhibit Antimicrobial and Antibiofilm Properties against 
Group B Streptococcus, ACS Infect. Dis., 2017, 3 (8), pp 595–605 
DOI: 10.1021/acsinfecdis.7b00064. Copyright 2017 American Chemical Society. 
https://pubs.acs.org/doi/10.1021/acsinfecdis.7b00064 
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Townsend, S. D., Antimicrobial and Antibiofilm Activity of Human Milk Oligosaccharides 
against Streptococcus agalactiae, Staphylococcus aureus, and Acinetobacter baumannii, ACS 
Infect. Dis., 2018, 4 (3), pp 315–324 DOI: 10.1021/acsinfecdis.7b00183. Copyright 2017 
American Chemical Society. https://pubs.acs.org/doi/10.1021/acsinfecdis.7b00183 
 
Introduction 
HMOs are a class of complex carbohydrates unique to human milk, and their bioactivity is 
well established. Both neutral and sialylated HMOs have previously been shown to modulate 
pathogen infection and proliferation. For instance, LNT inhibits binding of the parasite Entamoeba 
histolytica to human epithelial cells through the binding of Gal of LNT by a Gal/GalNAc specific 
lectin that otherwise mediates trophozoite attachment and invasion of host cells.1 Pneumococci 
initiate infections by binding to ligands containing lacto-N-biose and N-acetyllactosamine.2 LNnT 
and LSTc represent characteristic lung cell ligands and can prevent Streptococcus pneumoniae 
infections by serving as decoy receptors.2 In E. coli infections, sialylated fractions of HMOs 
showed a notable capacity to prevent hemagglutination by binding colonization factor antigens.3 
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Sialylated HMOs also protect bladder cells from the cytotoxicity and inflammation caused by 
uropathogenic E. coli (UPEC) infections through disruption of UPEC intracellular signaling to 
prevent degradation of focal adhesion proteins which in turn activates signals leading to cell 
damage.4 Fucosylated derivatives serve as decoy receptors for the adhesins and enterotoxins 
responsible for binding to host cells, and neutral, fucosylated derivatives have been shown to affect 
several pathogens including E. coli, Campylobacter jejuni, and norovirus.5-12 13, 14     
Group B Streptococcus (GBS) is a leading cause of neonatal infections. Recently the Bode 
and Le Doare research groups have separately reported the ability of HMOs to inhibit the 
proliferation of GBS in vitro and in vivo.15-17  
A study conducted by Le Doare and coworkers analyzed the correlation between a mother’s 
Lewis phenotype or secretor status and GBS colonization and transmission to the infant.16 Proton 
nuclear magnetic resonance (1H-NMR) was used to characterize milk samples based on the type 
and quantity of fucosylated HMOs present and to assign Lewis and secretor status to each donor. 
Chi-square analysis of maternal Lewis antigen status and maternal or infant colonization at 
delivery suggested that Lewis-positive mothers and their infants have lower rates of GBS 
colonization. However, secretor status did not prove to be statistically correlated to the incidences 
of GBS colonization. Further, they showed that increased concentrations of specific HMOs (3’-FL 
and LNDF-I) in maternal milk were correlated with decreased bacterial burden during colonization 
in vivo. An in vitro study showed that the presence of larger, branched fucosylated HMOs, such as 
LNDF-I, were associated with a reduction in GBS growth. In summary, they reported that 
fucosylated HMOs can inhibit GBS growth and colonization in a dose-dependent manner both in 
vitro and in vivo.  
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Bode and coworkers conducted a study to investigate the spectrum of antimicrobial activity 
exhibited by HMOs.17 HMOs from several different donors were either pooled or pooled then 
separated into neutral and acidic fractions for analysis of activity. After growing several species 
of bacteria (Group B strep, S. pyogenes (Group A strep), E. coli, P. aeruginosa, and methicillin-
resistant Staphylococcus aureus) in the presence of pooled HMOs, they concluded that HMOs 
exhibit narrow spectrum antibacterial activity against GBS and did not affect the growth of the 
other species. Further investigation showed that the antibacterial activity of HMOs extends across 
several serotypes of GBS and is dose dependent. Neutral HMO fractions were responsible for the 
antimicrobial activity, with LNT and LNFP-I showing the most significant activity as individual 
compounds. To probe the mechanism of action, a library of mutants was tested for their sensitivity 
to HMO antimicrobial activity. Interestingly, only one glycosyltransferase mutant (gbs0738) was 
able to proliferate in the presence of HMOs. While the exact role of this glycosyltransferase is 
under investigation, other glycosyltransferase mutants remained sensitive to HMO antibacterial 
activity. 
On the basis of the established evidence that HMOs possess antimicrobial activity, we 
hypothesized milk oligosaccharides could modulate both the bacterial growth and biofilm 
production of GBS. Similar to other bacterial pathogens, GBS biofilm formation is an important 
virulence pathway known to provide increased resistance to antimicrobial agents as well as host 
defenses.18 Previous research has demonstrated the importance of GBS CPS biosynthesis in 
mediating biofilm formation, supporting our hypothesis that oligosaccharides could influence 
biofilm establishment.19, 20 Additionally, GBS CPS from type Ib and II are similar in structure to 
certain HMOs (Figure 3.1).21, 22 A study by Pritchard and co-workers showed mouse antibodies 
for GBS CPS bind to HMOs, further suggesting that their structural similarity enable HMOs to 
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mimic or influence CPS activity.21 
 
 
 
Figure 3. 1 S. agalactiae Capsular Polysaccharide Repeat Units Share Structural Elements of Human Milk 
Oligosaccharides. 
 
In this chapter, we detail two related studies that report the effect of oligosaccharide isolates 
from donor human milk samples on the growth, biofilm formation, and biofilm architecture of 
GBS. In an initial study, the antimicrobial properties as well as the effect on biofilm formation and 
biofilm architecture were evaluated for oligosaccharides from five donor human milk samples. 
Using one GBS strain, this study included an investigation into both the qualitative and quantitative 
effects on biofilm by examining the structures and components of the biofilms formed in the 
presence of these HMO isolates. A second study expanded on our initial findings to report a 
broader evaluation of the antimicrobial and anti-biofilm activity by including HMO isolates from 
fourteen additional donor milk samples as well as three GBS stains of unique serotypes. 
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Initial Study 
We sought to understand the impact of HMOs on the growth and viability of GBS. Since 
we were interested in the effects of HMOs on both growth and biofilm formation, assays were 
conducted in two growth conditions: Todd Hewitt Broth (THB) and THB supplemented with 1% 
glucose. Glucose supplementation is thought to increase biofilm formation through acidification 
of the media, resulting in the upregulation of biofilm formation.1823  
HMOs were isolated from five donors, and Lewis blood groups were assigned as described 
in Chapter 2 (Table 2.5, donors 16, 20, 38, 42, and 43). Each donor milk sample was received pre-
labeled with a donor number that was kept associated with each sample of isolated HMOs. 
Carbohydrate concentrations of roughly 5 mg/mL were used to represent a low physiological 
concentration of HMOs, which can range from 5-20 g/L.23, 24 During the carbohydrate isolation 
process, precautions were not taken to remove lactose, which is highly abundant in human milk, 
and a concentration of 5 g/L represents a combination of lactose and HMOs. GBS strain CNCTC 
10/84, which is categorized as serotype V, was used for this study. 
 
HMOs Modulate Growth and Viability of S. agalactiae 
First, GBS cells were grown in THB in the presence or absence of HMOs from each donor 
breast milk sample. Culture turbidity was measured spectrophotometrically at 600 nm (OD600, a 
common wavelength to measure bacterial culture turbidity)25 as a measurement of bacterial 
growth, and samples were serially diluted and plated on blood agar plates to confirm bacterial cell 
viability. HMOs from donor 43 demonstrated marked antimicrobial activity against GBS 
compared with media alone (Figure 3.2, Figure A2.1), resulting in approximately 90% growth 
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inhibition over 24 h. Additionally, HMOs from donor 38 significantly inhibited GBS growth for 
the first 8 h of culture (Figure 3.2, Figure A2.1), with percent inhibition holding near 50% between 
4− 6 h and dropping to 27% at 7 h. HMOs from donors 16, 20, and 42 showed no significant effect 
on GBS growth in THB. 
 
Figure 3. 2 Effect of HMOs isolated from individual milk samples on GBS CNCTC 10/84 proliferation in Todd 
Hewitt Broth. Enumeration of CFU was performed at 0, 2−12, 22, and 24 h. The mean CFU/mL was calculated for 
each time point and is indicated by the respective symbols. Data displayed represents the mean CFU/mL ± SEM of 3 
biological replicates, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by 2-way ANOVA with posthoc 
Dunnett’s mutiple comparison test, with all donor samples compared to the GBS growth in media alone. 
 
Next, GBS cells were grown in THB containing 1% glucose in the presence or absence of 
HMO samples. Growth was measured as described previously. Similar to growth in THB, HMOs 
from donor 43 demonstrated growth inhibition as high as 80% against GBS compared with the 
control (Figure 3.3, A2.2). However, growth increases after 22 h, suggesting that the HMOs from 
donor 43 may be acting as a bacteriostatic agent. HMOs from all other donors (16, 20, 38 and 42) 
showed no significant effect on GBS growth in THB supplemented with 1% glucose.  
The half maximal inhibitory concentrations (IC50) in THB were determined for HMOs 
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from donors 38 and 43, which inhibited growth. HMOs from donor 38 had an IC50 of 23.2 mg/mL, 
which is just above the range of typical physiological concentrations of HMOs in human milk (5-
20 mg/mL). Correlating to its greater antimicrobial activity, HMOs from donor 43 had an IC50 of 
2.44 mg/mL, which is below typical physiological concentrations. 
 
Figure 3. 3 Effect of HMOs isolated from individual milk samples on GBS CNCTC 10/84 proliferation in Todd 
Hewitt Broth supplemented with 1% glucose. Enumeration of CFU was performed at 0, 2−12, 22, and 24 h. The 
mean CFU/mL was calculated for each time point and is indicated by the respective symbols. Data displayed 
represents the mean CFU/mL ± SEM of 3 biological replicates, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 
0.0001 by 2-way ANOVA with posthoc Dunnett’s multiple comparison test, with all donor samples compared to the 
GBS growth in media alone. 
 
Evaluation of HMO Effect on GBS Biofilm Formation 
In order to evaluate biofilm formation, a plate-based biofilm assay was used that measures 
bacterial growth as well as biofilm production by crystal violet (CV) staining. After growth media 
is aspirated, CV is used to stain the entire biofilm including cells and extracellular polymeric 
matrix.26 After staining and rinsing, CV that remains is solubilized and the amount of CV is 
measured spectrophotometrically using OD560, a wavelength used for CV absorbance. Biofilm 
production is expressed as a ratio of the biofilm produced (OD560) to the number of bacterial cells 
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present (OD600, biomass). This allows for a quantitative measurement of the amount of biofilm 
produced relative to growth (biomass turbidiy measurement).  
GBS biofilm production was largely unaffected by the presence of HMOs in the growth 
media (Figure 3.4A). HMOs from donor 43 significantly increased the biofilm/biomass ratio of 
cells grown in THB by over 200% (p = 0.0008 by one-way ANOVA with posthoc Dunnett’s 
multiple comparison test) but had no effect on biofilm/biomass ratio when the media was 
supplemented with glucose. This result is likely due to the inhibition of cell growth (as shown in 
Figure 3.2), which is in contrast to the restored growth observed after 22 h in THB with 1% glucose 
(Figure 3.3). When the biomass is significantly decreased (as is the case for donor 43), the ratio of 
biofilm to biomass becomes significantly higher because biofilm production is measured as a ratio 
of biofilm to biomass.  
When GBS cells were grown in media supplemented with glucose, HMOs from donor 38 
diminished the biofilm/biomass ratio by 17% compared to the control grown in media alone (p = 
0.0018 by one-way ANOVA with posthoc Dunnett’s multiple comparison test) (Figure 3.4B). A 
comparison of the relative biofilm amounts produced in both THB and THB supplemented with 
1% glucose are shown in Appendix 2 (Figure A2.3).  
Microscopic Evaluation of Biofilms Grown in the Presence of HMOs 
In addition to biofilm quantification, we evaluated if incubation in the presence of HMOs 
could induce structural changes to GBS biofilms. Biofilms were grown in media supplemented 
with 1% glucose to enhance biofilm formation.   
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Figure 3. 4 HMOs at biologically relevant breast milk concentrations induce changes in biofilm formation of 
GBS cultures. The total biofilm to biomass ratio after 24 h of growth was compared for (A) THB medium alone. Data 
represented as the mean biofilm/biomass ratio ± SEM of 5 separate experiments, each with 3 technical replicates. *** 
represents p = 0.0008 by one-way ANOVA, F = 23.35 with posthoc Dunnet’s multiple comparison test comparing 
each HMO group against the control sample without HMOs. (B) THB medium supplemented with 1% glucose. Data 
are expressed as the percent mean biofilm/biomass ratio of control ± SEM of 5 separate experiments, each with 3 
technical replicates. ** represents p = 0.0018 by oneway ANOVA, F = 3.449 with posthoc Dunnet’s multiple 
comparison, compared to media alone. 
 
High resolution scanning electron microscopy (SEM) was used to analyze and evaluate 
changes in biofilm architecture and size. SEM can reach a much higher resolution and 
magnification than light microscopy and uses a beam of electrons repeatedly scanned across a 
sample’s surface to create an image and to gain information about the surface features. SEM 
analysis of GBS biofilms allows for comparison of the packing structure of the biofilms as well as 
formation of nutrient channels for samples grown in the presence and absence of HMOs. 
Compared to media alone, GBS cells incubated with HMOs from donor 43 demonstrated 
less diffuse biofilms and smaller biofilm mushroom structures (Figure 3.5). Additionally, GBS 
biofilms grown in the presence of HMOs from donors 16 and 38 had less prominent nutrient 
channels compared to GBS biofilms grown in the presence of HMOs from donors 20 and 42. This 
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observation aligns with the breast milk donor categorization of Lewis blood groups by MALDI 
profiling, suggesting that HMOs associated with certain Lewis blood groups may lead to 
alterations in GBS biofilm structure.  
 
 
 
Figure 3. 5 Scanning electron micrographs of biofilm formation after 24 h. GBS CNCTC 10/84 cells were grown 
in THB + 1% glucose supplemented with individual donor samples for 24 h at 37 °C. Images are shown at 250x 
magnification. 
  
We then examined these biofilms at higher magnification to visualize finer details in 
biofilm structure. While most donor samples had little effect on the cellular organization of the 
biofilm, SEM analysis at high magnification revealed that samples grown with HMOs from donor 
43 caused changes in GBS chaining morphology. GBS strain CNCTC 10/84 phenotypically forms 
long chains of bacteria within the biofilm structure. However, HMOs from donor 43 induced a 
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truncated chain phenotype compared to the control sample resulting in a denser packing 
morphology within the biofilm (Figure 3.6). 
 
 
 
 
Figure 3. 6 Scanning electron micrographs of biofilm formation after 24 h. GBS CNCTC 10/84 cells were grown 
in THB + 1% glucose supplemented with HMOs from individual donor samples for 24 h at 37 °C. Images are shown 
at 1000x magnification. 
 
Structural and compositional aspects of GBS 10/84 biofilms were analyzed using confocal 
laser scanning microscopy (CLSM). CLSM is a form of light microscopy that uses a narrow beam 
of light to change the depth of focus so that images can be taken in thin optical sections at different 
levels in a third dimension (z-plane). These images can be displayed to show the thickness in the 
z-dimension of an x-y snapshot (called a z-stack), or they can be stacked to generate a 3-D image. 
When CLSM is paired with the use of various cellular stains, different aspects of a specimen can 
be analyzed. For instance, live cells, dead cells, and carbohydrates can be uniquely stained and 
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imaged separately for individual analysis or overlay comparisons.  
Biofilms grown in the presence of HMOs from donor 38 showed a decrease in thickness 
of the biofilm relative to biofilms grown in media alone as seen by a comparison of the x- and y-
axis views of Figure 3.7. This is in agreement with the decrease in biofilm production seen in the 
plate-based assay (Figure 3.3B). Additionally, a comparison of the first and last z-stack images 
shows a greater carbohydrate (blue) content at the apical surface of the biofilm relative to the base, 
which is mostly composed of dead (red) and live (green) cells (Figure 3.8). 
 
 
 
Figure 3. 7 CLSM micrographs comparing biofilm formation of GBS CNCTC 10/84 grown in THB 
supplemented with 1% glucose or THB supplemented with 1% glucose and HMOs isolated from milk donors. 
Bacteria were grown under static conditions at 37 °C for 24 h on glass coverslips. Biofilms were stained immediately 
prior to analysis with SYTO 9 (green, live bacterial cells), propidium iodide (red, dead bacterial cells), and Calcofluor 
White (blue, carbohydrates) and imaged at 600Å~ magnification. Images shown represent a z-stack series of images 
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of the three stains where the larger panel is a “bird’s eye” view of the biofilms and the right and upper panels are side 
views of the x- and y-axis sections, respectively.  
 
 
 
Figure 3. 8 CLSM micrographs comparing apical and base sections of GBS CNCTC 10/84 biofilms grown in 
THB supplemented with 1% glucose or THB supplemented with 1% glucose and HMOs isolated from milk 
donors. Bacteria were grown under static conditions at 37 °C for 24 h on glass coverslips. Images shown represent 
the apical surface (left image) and base of the biofilm (right image) from a z-stack series. Biofilms were stained with 
SYTO 9 (green, live bacterial cells), propidium iodide (red, dead bacterial cells), and Calcofluor White (blue, 
carbohydrates) and imaged at 600Å~ magnification. 
 
Conclusions to initial study 
We have demonstrated that HMOs isolated from distinct donors exhibit antimicrobial 
properties against GBS. Moreover, we have shown that HMOs also disrupt the formation and 
structure of biofilms produced by this pathogen.  
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Given the discovery of the modulatory effects of HMOs against GBS, it is peculiar to note 
the diverse activity displayed by glycans from each donor (Table 3.1). HMOs from Donor 43 
significantly inhibited the growth of GBS in both THB (Figure 3.2) and THB supplemented with 
1% glucose (Figure 3.3) and changed the morphology of the biofilm (Figure 3.6). HMOs from 
donor 38 significantly inhibited GBS growth in THB for the first 8 h of a 24 h growth period 
(Figure 3.1) and significantly decreased in vitro biofilm production as measured by the 
biofilm/biomass ratio (Figure 3.4B). Additionally, HMOs from donors 38 and 43 affected the 
visual nutrient channel formation of GBS biofilms as shown by SEM (Figure 3.5). HMOs from 
donors 16, 20, and 42 showed no significant antibacterial or anti-biofilm effects. 
 
Table 3. 1 Summarization of the effect of HMOs on GBS 
Donor Lewis Blood Group 
Growth Change from Control (%)a Biofilm Change from Control (%) 
THB THB+1%Glc THB THB+1%Glc 
16 a-b- -7 ± 7 +1 ± 5 -18 ± 9 -6 ± 7 
20 a-b+ +4 ± 7 -5 ± 5 -3 ± 10 +4 ± 5 
38 a-b- -14 ± 5 0 ± 8 +6 ± 11 -17 ± 3 
42 a-b+ -6 ± 9 -10 ± 6 -29 ± 4 +13 ± 10 
43 a+b- -80 ± 11 -30 ± 4 +212 ± 44 -1 ± 6 
aGrowth change from control for t = 24 h (THB) and t = 22 h (THB+1%Glc) of growth during growth curve assays 
using OD600 values. 
 
This study of the antimicrobial and anti-biofilm properties of HMOs from various Lewis 
blood groups suggested that milk of mothers might differentially influence infant health in 
relationship to GBS. This conclusion follows from the study by Le Doare and coworkers that 
showed a correlation between Lewis status of the mother and incidence of GBS infections in both 
the mother and infant.16 Other studies have shown compounds associated with secretor milks, 
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specifically α-1,2-fucosylated HMOs, reduce incidence of diarrhea caused by infections with E. 
Coli and C. Jejuni.7, 8, 13, 27, 28 We hypothesized that there could be a relationship between the Lewis 
blood group of the mother and the antimicrobial or anti-biofilm activity of the HMOs in her milk. 
Testing this hypothesis was the goal of the expanded study described below. Additionally, 
increasing the number of individual donor milk samples would provide information about the 
extent of variability in effects of HMOs on GBS pathogenesis. 
Expanded Study 
 After confirming the antibacterial activity and establishing anti-biofilm activity of HMOs 
against GBS, we sought to expand the number of HMO samples studied in order to investigate a 
potential relationship between Lewis blood group and biological activity. Prior to bacterial assays, 
Lewis blood groups for the fourteen additional donors were assigned using the high throughput 
mass fingerprinting technique developed by Kunz and co-workers (Table 2.4, donors 0, 5, 7, 8, 14, 
17, 18, 19, 24, 29, 31, 32, 34, and 37).29  
Next, we tested the hypothesis that HMOs act as antimicrobial and anti-biofilm agents 
across several strains of GBS. Thus, three strains of S. agalactiae of varying serotypes were used: 
CNCTC 10/84, GB590, and GB2. CNCTC 10/84 is a Type V strain, whereas GB590 is a Type III, 
and GB2 is a Type Ia strain. These three serotypes account for over 85% of invasive infant GBS 
disease cases worldwide (Figure 1.7).30 Antimicrobial and anti-biofilm activities were evaluated 
at 24 h in both THB and THB supplemented with 1% glucose using carbohydrate concentrations 
of 5 mg/mL. As before, no precautions were taken to remove lactose, so carbohydrate 
concentrations included a mixture of lactose and HMOs. 
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HMOs Modulate Growth and Viability of S. agalactiae  
To determine the antimicrobial activity, we used the same plate-based assay described 
above, which allows for spectrophotometric quantification of both bacterial growth and biofilm 
production. We compared the biomass of bacteria grown in the presence of HMOs to that of 
bacteria grown in media alone for both growth conditions (THB and THB supplemented with 1% 
glucose). Several HMO samples were found to significantly inhibit bacterial growth for the three 
GBS strains in both growth conditions (p ≤ 0.05 by one-way ANOVA with posthoc Dunnett’s 
multiple comparison test) (Table 3.2, Figure A2.4, A2.5, A2.6). The results are presented as the 
average percent deviation from the control ± standard error of the mean (SEM) of three 
independent experiments each with three technical replicates where negative numbers represent 
inhibition of bacterial growth and positive numbers represent an increase in bacterial growth. 
In THB, HMOs from donors 5, 8, and 29 inhibited the growth of GBS at 24 hours across 
all three strains tested (CNCTC 10/84, GB590, GB2). HMOs from donor 8 had the greatest impact 
on growth, exhibiting an 75-89% decrease relative to the control, but only exhibited growth 
inhibition in THB.  HMOs from donor 29 had the next greatest reduction of growth in THB, 
ranging from 15-42% relative to the control. HMOs from donor 5 were able to inhibit growth 
compared to the control by 22-31%. Additionally, for GBS strain CNCTC 10/84, HMOs from 
donors 18, 24, and 32 significantly inhibited the growth in THB, with reductions of 13, 11, and 
14%, respectively. 
While the ability to inhibit growth was diminished in THB supplemented with glucose, 
HMOs from donors 5, 29, 32, and 37 still exhibited significant growth inhibition relative to control 
in GBS strain CNCTC 10/84 (Table 3.2, Figure A2.7, A2.8, A2.9) with observed inhibitions of 
  112 
12, 17, 16, and 17%, respectively. The growth of the other two strains (GB590 and GB2) was 
either unaffected or increased in the presence of HMOs (Table 3.2, A2.10, A2.11, A2.12).  
Notably, HMOs from donor 8 reduced growth by an average of over 70% for all GBS 
strains when grown in glucose free media. In contrast, when GBS was grown in media 
supplemented with 1% glucose, donor 8 HMOs decreased growth by less than 10% for all strains. 
Overall, greater HMO antimicrobial activity was seen in THB than THB supplemented with 1% 
glucose. This is likely due to the ability of GBS to proliferate at an accelerated rate in glucose, 
allowing the bacteria to overcome the antimicrobial effects of the HMOs.31 
Evaluation of HMO Effect on GBS Biofilm Formation 
We assessed changes in biofilm productionby comparing biofilm/biomass ratios of bacteria 
grown in the presence of HMOs to those grown in media alone. HMOs from each donor sample 
significantly reduced biofilm formation in at least one GBS strain (Table 3.3). It is important to 
note that in order to determine significant reductions in biofilm production when GBS was grown 
in THB, the results from Donor 8 were omitted from analysis of all strains. Results from Donor 8 
were confirmed to be outliers by both ROUT (Q = 1%) and Grubbs (a = 0.05) outlier tests. It is 
likely the exceptionally high biofilm/biomass ratios seen for Donor 8 HMOs are attributable to the 
extreme reduction in bacterial growth when bacteria were grown in THB (Table 3.2, Figure A2.4, 
A2.5, A2.6). When in THB, HMOs from this donor caused at least a 75% reduction in biomass 
compared to the control across the three strains. With the less dramatic antimicrobial activity of 
HMOs from Donor 8 in THB supplemented with 1% glucose, the biofilm/biomass ratios return to 
more reasonable values in this growth medium. 
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Table 3. 2 Antimicrobial Activity of HMOs against Three Strains of Group B Streptococcusa 
  Biomass Change from Control (%) 
  CNCTC 10/84 GB590 GB2 
Donor Lewis Blood Group THB 
THB 
+1%Glc THB 
THB 
+1%Glc THB 
THB 
+1%Glc 
0 a-b+ -4 ± 2 +11 ± 2 +14 ± 3 +11 ± 3 +5 ± 2 +9 ± 2 
5 a-b+ -26 ± 1 -12 ± 2 -31 ± 6 -9 ± 2 -22 ± 1 -5 ± 1 
7 a-b+ -3 ± 1 +13 ± 4 +6 ± 3 +8 ± 2 -1 ± 2 -3 ± 2 
8 a-b+ -80 ± 6 -5 ± 2 -75 ± 9 -8 ± 5 -89 ± 4 -6 ± 2 
14 a-b+ +3 ± 1 +43 ± 1 +8 ± 4 +50 ± 2 +14 ± 2 +57 ± 1 
19 a-b+ -8 ± 2 +7 ± 3 +13 ± 1 +28 ± 2 +1 ± 2 +14 ± 3 
24 a-b+ -11 ± 3 +8 ± 1 +11 ± 3 +20 ± 2 +9 ± 3 -3 ± 1 
32 a-b+ -14 ± 1 -16 ± 3 +10 ± 2 +15 ± 3 +14 ± 2 +6 ± 2 
34 a-b+ +2 ± 1 -2 ± 3 +21 ± 3 +25 ± 4 +15 ± 2 +19 ± 5 
37 a-b+ -1 ± 2 -17 ± 3 +23 ± 3 +24 ± 3 0 ± 2 +19 ± 3 
17 a+b- -2 ± 1 +4 ± 4 +7 ± 2 +17 ± 3 +7 ± 2 +17 ± 4 
18 a+b- -13 ± 3 +11 ± 1 -11 ± 3 +14 ± 2 -1 ± 2 -6 ± 2 
29 a+b- -42 ± 1 -17 ± 2 -35 ± 11 -22 ± 6 -15 ± 1 -6 ± 1 
31 a+b- -6 ± 2 +18 ± 2 +3 ± 2 +33 ± 4 +7 ± 2 +24 ± 3 
aSignificant growth inhibition (p ≤ 0.05, one-way ANOVA) compared to control is boldfaced) 
 
For GBS strain CNCTC 10/84, HMOs from donors 0, 5, 14, 17, 19, 24, 29, 32, and 37 
significantly inhibited biofilm formation in THB, with inhibitions ranging from 53-80% (Table 
3.3, Figure A2.13). In THB supplemented with 1% glucose, HMOs from donors 7, 14, 18, 24, and 
31 showed significant anti-biofilm activity by reduction of biofilm production by 36-81% relative 
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to the control (Table 3.3, Figure A2.14). 
GB590 was less susceptible to inhibition of biofilm production caused by HMOs. In THB, 
no HMOs were able to reduce the biofilm production significantly (Table 3.3, Figure A2.15). 
Biofilm inhibition over 30% was seen for HMOs from three donors (0, 14, and 17), but these 
values were associated with large fluctuations in SEM such that none were statistically significant. 
This is likely due to the large fluctuations in biofilm measurements (OD560), which can be 
attributed to variability in biofilm attachment to the well plate. In THB supplemented with 1% 
glucose, HMOs from donors 14 and 31 were able to significantly decrease the amount of biofilm 
produced relative to bacterial growth by 58 and 54%, respectively (Table 3.3, Figure A2.16).  
HMOs from donors 0, 5, 14, 19, 24, 29, and 31 significantly decreased the biofilm 
formation of GB2 in both THB and THB supplemented with 1% glucose from 23-93% (Table 3.3, 
Figures A2.17 and A2.18). Of note, reduction in biofilm/biomass ratio of 83 and 93% was seen for 
HMOs from donor 14 in THB and THB supplemented with 1% glucose, respectively. Furthermore, 
in THB supplemented with 1% glucose, HMOs from donors 8, 17, and 34 also exhibited anti-
biofilm activity reducing biofilm/biomass values by 49, 19, and 13%, respectively.  
Conclusions to Expanded Study 
GBS strain CNCTC 10/84 was most susceptible to the antimicrobial activity of HMOs, 
showing significant reduction in growth for eight samples compared to only three samples 
exhibiting antimicrobial activity in GB590 and GB2. GBS strains are classified by their CPS and 
surface associated proteins. One particular subset of surface associated proteins, surface-anchored 
alpha-like proteins (Alps), are found in nearly all GBS strains (>98%).32 Interestingly, CNCTC 
10/84 is one of few GBS strains that are considered non-Alp strains because they do not possess 
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any Alp encoding genes.  
 
Table 3. 3 Anti-biofilm Activity of HMOs against Three Strains of Group B Streptococcusa,b 
  Biofilm/Biomass Change from Control (%) 
  CNCTC 10/84 GB590 GB2 
Donor Lewis Blood Group THB 
THB 
+1%Glc THB 
THB 
+1%Glc THB 
THB 
+1%Glc 
0 a-b+ -67 ± 11 b -32 ± 13 -40 ± 28 -26 ± 6 -28 ± 1b -45 ± 3 
5 a-b+ -80 ± 7 a -1 ± 8 -17 ± 35 -19 ± 8 -51 ± 6 b -45 ± 3 
7 a-b+ -33 ± 13 -36 ± 11 -23 ± 22 -24 ± 5 +10 ± 37 -6 ± 4 
8 a-b+ +346 ± 229 -5 ± 17 +178 ± 115 -21 ± 7 +273 ± 71 -49 ± 5 
14 a-b+ -63 ± 13 b -38 ± 11 -46 ± 18 -58 ± 5 -93 ± 4 b -83 ± 1 
19 a-b+ -71 ± 7 b -23 ± 16 -10 ± 54 -28 ± 5 -40 ± 10 b -51 ± 2 
24 a-b+ -70 ± 8 b -81 ± 3 0 ± 46 -42 ± 10 -70 ± 9 b -33 ± 4 
32 a-b+ -79 ± 6 b -21 ± 12 -13 ± 44 -20 ± 6 +31 ± 25 -6 ± 3 
34 a-b+ -37 ± 16 -20 ± 8 +11 ± 32 +5 ± 7 +8 ± 24 -13 ± 3 
37 a-b+ -53 ± 11 b +34 ± 14 +22 ± 35 -5 ± 3 +39 ± 28 -10 ± 3 
17 a+b- -65 ± 7 b -20 ± 8 -35 ± 17 -11 ± 3 +11 ± 24 -19 ± 3 
18 a+b- -38 ± 18 -40 ± 12 -18 ± 40 -18 ± 3 -53 ± 21 b +7 ± 5 
29 a+b- -60 ± 8 b -27 ± 12 -3 ± 52 +80 ± 31 -37 ± 12 b -23 ± 5 
31 a+b- -33 ± 15 -43 ± 9 -23 ± 25 -54 ± 5 -43 ± 10 b -69 ± 2 
aSignificant growth inhibition (p ≤ 0.05, one-way ANOVA) compared to control is boldfaced. bStatistically 
significant activity when results from Donor 8 were omitted; Donor 8 was determined to be an outlier by both 
ROUT and Grubbs tests. 
 
Alp proteins are useful for virulence because they function as adhesins to adhere to cell 
surfaces.33, 34 Perhaps the lack of Alp proteins in CNCTC 10/84 and its need to employ other modes 
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of virulence for its infectivity make this strain more susceptible to the antimicrobial activity of 
HMOs. It is of note that CNCTC 10/84 is known as a hypervirulent strain, and the increased 
antimicrobial effects of HMOs against CNCTC 10/84 are encouraging since this strain belongs to 
the third most common serotype associated with infant infections caused by GBS. 
All HMO samples were found to significantly reduce biofilm production in at least one 
GBS strain. In several cases, biofilm inhibition was over 70%, demonstrating the ability of HMOs 
to suppress this form of GB virulence. 
CNCTC 10/84 and GB2 appeared to be particularly susceptible to changes in biofilm as 
over ten HMO samples significantly reduced biofilm formation in both strains, compared to only 
two HMO samples for GB590. However, GB590 also seemed particularly susceptible, but due to 
large fluctuations in biofilm measurements attributable to weak or inconsistent attachment of 
biofilms to the well-plate surface, few decreases in biofilm formation of GB590 were deemed 
significant.   
We have demonstrated that HMOs from a broad range of donors can inhibit both the growth 
and biofilm formation of GBS. Our initial hypothesis when we began this study was that the Lewis 
blood groups would correlate with antimicrobial or anti-biofilm activity. However, assaying three 
GBS strains against 14 donor samples has not revealed a relationship between biological activity 
and Lewis blood group. Instead, both the data from this expanded study and the initial study 
suggest that HMOs from secretors and nonsecretors belonging to all Lewis blood groups generally 
demonstrate comparable levels of biological activity. While Lewis blood groups are associated 
with linkage-specific fucosyl transferases, the concentration of HMOs can change over the course 
of lactation.23, 35 A systemic review by Stahl and coworkers that analyzed the concentrations of 
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oligosaccharides in previously published studies noted that secretor status, and thus Lewis blood 
groups, could also influence HMO concentration.28 Their analysis concluded that nonsecretor 
mothers produced higher concentrations of HMOs than secretor mothers.28, 36-38 Specifically, the 
milks from nonsecretor mothers had higher concentrations of nonfucosylated and α-1,3- and α-
1,4-fucosylated HMOs, whereas secretor mothers had higher concentration of α-1,2-fucosylated 
HMOs. The variability over the course of lactation and inherent increases in certain HMOs could 
account for the broad antimicrobial and anti-biofilm activity against GBS of HMO samples from 
donors of all Lewis blood groups used in our study.  
As HMO concentration and expression can change over the course of lactation, it is 
possible that the extreme antimicrobial activity of the HMOs from donor 8, particularly when 
compared to that of the other donors tested, is due to when in the lactation period the sample was 
collected. HMO concentration is highest in colostrum and several reports have shown higher 
concentrations of α-1,2 fucosylated HMOs, such as 2′ -FL, in this early milk.24, 35, 39 It is possible 
that milk from donor 8 was collected at an earlier lactation stage than the other samples and thus 
has larger quantities of certain HMOs that are particularly protective against GBS. Due to de-
identification, it is difficult to confidently assign reasons for the marked effects of this sample. 
Summary and Conclusions 
Overall, we have shown that HMOs demonstrate the ability to modulate both the bacterial 
growth and biofilm production of several GBS strains. HMOs exhibited up to 89% growth 
inhibition and up to 93% inhibition of biofilm production (Table 3.4). This work also resulted in 
the first example of HMOs serving as anti-biofilm agents.  
  118 
Table 3. 4 Summary of Extent of Growth and Biofilm Inhibition against Three GBS strains 
S. agalactiae Strain 
(Serotype) 
CNCTC 10/84 
(V) 
GB590 
(III) 
GB2 
(Ia) 
Growth Inhibition Up to 89% Up to 75% Up to 89% 
Biofilm Inhibiton Up to 81% Up to 58% Up to 93% 
 
This data adds to previous studies supporting the importance and potential inhibitory effect 
of HMOs in defending against GBS colonization. HMOs serve as a protective measure available 
from the host to decrease risk of GBS transmission. Previously, human milk-based biologics have 
demonstrated modulatory effects on bacterial biofilm formation. For example, in enteric pathogens 
such as E. coli and Bacteroides, sIgA and Mucin increased biofilm formation.40 Both sIgA and 
Mucins bind and agglutinate these particular bacterial species, and agglutination is postulated as a 
prerequisite for biofilm formation. In another study with S. mutans, lactoferrin and IgA were 
shown to inhibit biofilm formation while lactose and casein enhance biofilm formation.41 The 
variability of the effects of human milk components on different bacterial species could be due to 
the individual metabolic capabilities of bacteria. Genome analysis of several streptococci species 
(S. pyogenes, S. pneumoniae, and S. agalactiae) has shown that while S. pyogenes and S. 
pneumoniae have systems to metabolize fucose, lactose, mannitol, and raffinose, some strains of 
S. agalactiae lack these metabolic systems.42 We speculate the anti-biofilm activity of HMOs 
could be related to metabolism and the presence of complex, long-chain human milk 
oligosaccharides, which the bacteria cannot use as direct nutrients but may recognize these 
oligosaccharides as surrogates for “wild-type” bacterial polysaccharides as they are structurally 
similar.20, 43-45 This mechanism could coerce the bacteria into decreasing production of other 
biofilm forming components. From the standpoint of bacterial pathogenesis, the ability to construct 
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and maintain a structured, multicellular bacterial community depends on the production of 
extracellular matrix components. Microbes produce complex biofilm matrices consisting of 
proteins, extracellular DNA, and polysaccharides. Polysaccharide overproduction can alter the 
morphology of a colony.20, 43, 46  
Furthermore, our work indicates HMOs can inhibit bacterial growth. These effects 
appeared to be largely dependent on the nutritional composition of the growth medium. While 
biofilm formation is less affected by the media content, growth inhibition is decreased when THB 
is supplemented with glucose. Carbohydrate catabolism has been implicated as a critical step in 
the pathogenesis of streptococcal disease as a number of mechanisms (e.g., initiation of virulence 
factors) are closely associated with the ability of streptococci to use glucose.47 GBS is known to 
utilize excess glucose to increase replication and lower the pH of growth media.18, 48 We 
hypothesize that, in the case of GBS, glucose supplementation increases bacterial proliferation 
thereby assisting the bacteria to avert effects of exposure to HMOs. As seen in the growth curves 
of GBS grown in THB supplemented with glucose and HMOs from donor 43, there is an intense 
period of growth repression (Figure 3.3, t = 0-22 h). This potentially reflects a period where GBS 
is slowly proliferating and working to achieve a new balance of metabolic reactions due to the 
additional carbohydrate sources (HMOs). The approach to achieving a new balance may involve 
both changes in concentrations of metabolic intermediates and in the relative amounts of various 
enzymes during adaptation to a new carbon source.49 Interestingly, genetic analyses in related 
streptococcal species, such as S. mutans, reveal that accumulation of galactose metabolism 
intermediates can inhibit bacterial growth.50 Thus, it remains possible that exposure of GBS to 
HMOs may serve to alter carbohydrate metabolism leading to accumulation of toxic intermediates 
which ultimately repress bacterial growth or biofilm formation. This hypothesis could be tested by 
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examining cell-free media extracts for the evidence of carbohydrate utilization. Specifically, 
measuring the pH of the media can indicate the presence of organic acids that are a by-product of 
carbohydrate fermentation. Additionally, metabolomics and genetic analysis through RNA 
sequencing could reveal what changes are associated with growth of GBS in the presence of 
HMOs. 
A recent study conducted by Bode and coworkers showed the narrow-spectrum 
antimicrobial activity of HMOs to inhibit GBS growth.17 A library of GBS mutants was generated 
to probe the mechanism of this action. Only one out of 1300 mutants was found that overcame the 
antimicrobial activity of HMOs. This mutant lacked gbs0738 gene, which was postulated to encode 
for a glycosyltransferase that catalyzes incorporation of HMOs into the cell wall, causing the 
antimicrobial activity. While the exact use of this gene was not elucidated in their study, further 
literature review revealed that gbs0738 gene has an identical sequence to gbs0408 gene.51, 52 A 
report by Glaser and coworkers identified gbs0408 to be part of TnGBS1 and to encode for a 
protein responsible for initiating replication of plasmids or other mobile genetic elements (MGE).53 
TnGBS is an integrative and conjugative element (ICE), which is part of a larger category of 
mobile genetic elements (MGE). While ICE are not a permanent part of the host genone, they may 
represent a significant portion.53, 54 For instance, in the bacterium Orientia tsutsugamushi, ICE 
account for over 30% of the genome and in one E. coli strain, 15% of the genome is composed of 
ICE.53, 55, 56 ICE are postulated to carry genes that provide advantages for host colonization such 
as specific metabolite functions, drug resistance, or virulence factors.53, 54 Replication of TnGBS 
is correlated with transfer efficiency between cells, and the ability to regulate the activity of 
gbs0408-encoded protein could affect the ability of this ICE to be transferred to progeny bacteria, 
causing them to lose some of the virulence associated with the TnGBS gene cluster.53, 57, 58 More 
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specifically for the context of the anti-biofilm activity of HMOs, the evidence that gbs0408 gene 
plays a role in HMO activity could be related to the transfer of this genetic element to progeny 
bacteria. Research programs led by Gilot and Jenkinson have suggested that TnGBS regulates gene 
expression, biofilm formation, host colonization, and immunomodulation, leading us to 
hypothesize that this MGE is influenced by the presence of HMOs and is unable to replicate, 
rendering the bacteria unable to proliferate or produce biofilm as efficiently.57, 59, 60  
These studies examined the effect of whole carbohydrate extracts on GBS. As we found 
no significant difference between Lewis blood group classification of the mother and HMOs on 
the growth or biofilm formation of GBS, we postulate that future studies toward the effects of 
individual HMOs on GBS may uncover unique pharmacophores responsible for HMO 
antimicrobial and anti-biofilm properties. 
Methods 
Bacterial Strains and Culture Conditions 
S. agalactiae strain CNCTC 10/84 (ATCC) was cultured on tryptic soy agar plates 
supplemented with 5% sheep blood (blood agar plates) at 37 °C in ambient air overnight. Bacteria 
were subcultured from blood agar plates into Todd-Hewitt broth (THB) and incubated under 
shaking conditions at 37 °C in ambient air overnight. The following day, bacterial density was 
measured spectrophotometrically using optical density measurements at 600 nm (OD600), and 
bacterial numbers were determined using the predetermined coefficient of 1 OD600 = 109 CFU/mL. 
Bacterial Growth and Viability Analyses  
S. agalactiae strain CNCTC 10/84 cells were cultured overnight in THB and then 
subcultured by inoculating 106 cells per 5 mL of THB or THB supplemented with 1% glucose. 
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Cultures were grown under shaking conditions in THB alone or supplemented with 5 mg/mL 
HMOs isolated from the various human milk samples (Donors 16, 20, 38, 42, and 43) or in THB 
supplemented with 1% glucose or THB supplemented with 1% glucose and 5 mg/mL HMOs 
isolated from the various human milk samples (Donors 16, 20, 38, 42, and 43) at 37 °C in ambient 
air. Bacterial growth was evaluated by spectrophotometric reading of OD600, and bacterial viability 
was evaluated by serial dilution and plating onto blood agar plates and quantifying viable colony 
forming units per mL of culture (CFU/mL). 
Bacterial Biofilm Assays  
S. agalactiae strain CNCTC 10/84 was grown overnight as described above prior to 
subculturing 106 bacterial cells into 200 µL of THB supplemented with 1% glucose (to promote 
biofilm formation) in 96-well tissue culture plates (Corning, Inc.). Bacterial cells were added to 
wells containing media alone or wells supplemented with 5 mg/mL HMOs isolated from the 
various human milk samples (Donors 16, 20, 38, 42, and 43). Cultures were incubated under static 
conditions at 37 ° C in ambient air for 24 h. Optical density (OD600) was measured for each sample 
as a measure of bacterial growth. The medium was aspirated, and each well was washed once with 
phosphate-buffered saline (PBS, pH 7.4) to remove nonadherent cells. Wells were then stained 
with a 10% crystal violet solution for 15 min. After staining, the wells were again washed with 
PBS and then allowed to dry at room temperature for 30 min. After drying, crystal violet staining 
was solubilized with a 4:1 ethanol/acetone solution. The absorbance (OD560) was measured for 
each sample as a measure of biofilm formation. The data shown represents 5 independent 
experiments, each with 3 technical replicates. 
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Field-Emission Gun Scanning Electron Microscopy 
Bacterial cells were analyzed by scanning electron microscopy. Bacteria were cultured in 
THB supplemented with 1% glucose in wells containing 12 mm glass coverslips coated with poly-
L lysine (Corning, Bedford MA) at 37 ° C for 24 h. At 24 h, supernatants were removed, and 
samples were fixed with 2.0% paraformaldehyde and 2.5% gluteraldehyde in 0.05 M sodium 
cacodylate buffer for 24 h. Secondary fixation with 0.1% osmium tetroxide was performed for 5 
min prior to sequential dehydration with increasing concentrations of ethanol. After ethanol 
dehydration, samples were dried at the critical point using a critical point dryer machine 
(Tousimis), mounted onto aluminum sample stubs, and sputter-coated with 80/20 gold−palladium. 
Afterward, samples were painted with a thin strip of colloidal silver (Electron Microscopy 
Sciences) at the edge to facilitate charge dissipation. Samples were imaged with an FEI Quanta 
250 field-emission gun scanning electron microscope. Images shown are representative of three 
separate experiments. 
Confocal Laser Scanning Microscopy Analyses  
 Bacterial cells were cultured as above in wells containing THB supplemented with 1% 
glucose and containing glass coverslips coated with poly-L-lysine. Cultures were grown under 
static conditions for 24 h at 37 ° C. At 24 h, coverslips were washed with PBS prior to staining 
with a LIVE/DEAD BacLight bacterial viability kit, which includes both SYTO 9 (green) and 
propidium iodide (red) (Life Technologies) to visualize bacterial cells and calcofluor white (blue) 
(Sigma-Aldrich) to visualize the carbohydrate capsule/matrix within the biofilm. Coverslips were 
stained for 15 min followed by 2 washes with PBS. Both SYTO 9 and propidium iodide stain 
nucleic acids, but propidium iodide is only able to penetrate damaged cell membranes and 
competes with SYTO 9 to stain within dead bacterial cells. When used concurrently, stained 
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bacteria with intact cell membranes will fluoresce green and those with damaged cells will 
fluoresce red. Calcofluor white binds to β-1,3 and β-1,4 polysaccharides such as chitin and 
cellulose and has been shown to stain the extrapolymeric substances in biofilms of Streptococcus  
species and other bacteria. Coverslips were then mounted on glass microscope slides using Aqua 
Poly/Mount (Polysciences, Inc.). Samples were imaged with a Zeiss LSM 710 Meta Inverted 
confocal laser-scanning microscope with Zen 2011 software. 
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Figure A2. 1 Effect of HMOs isolated from individual milk samples on growth rate/proliferation of GBS 
CNCTC 10/84 in Todd Hewitt Broth. OD600 readings were taken at 0, 2−12, 22, and 24 h. Mean OD600 for each 
HMO sample and time point is indicated by the respective symbols. Data displayed represents the mean OD ± SEM 
of 3 biological replicates, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by 2-way ANOVA with posthoc 
Dunnett’s multiple comparison test, with all donor samples compared to the GBS growth in media alone. 
 
 
Figure A2. 2 Effect of HMOs isolated from individual milk samples on growth rate/proliferation of GBS 
CNCTC 10/84 in Todd Hewitt Broth supplemented with 1% glucose. OD600 readings were taken at 0, 2−12, 22, 
24, and 26 h. Mean OD600 for each HMO sample and time point is indicated by the respective symbols. Data displayed 
represents the mean OD ± SEM of 3 biological replicates, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 
by 2-way ANOVA with posthoc Dunnett’s multiple comparison test, with all donor samples compared to the GBS 
growth in media alone. 
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Figure A2. 3 HMOs at biologically relevant breast milk concentrations induce changes in biofilm formation of 
GBS cultures. The total biofilm measured after 24 h of growth was compared for (A) THB medium alone. Data 
represented as the mean biofilm/biomass ratio ± SEM of 5 separate experiments, each with 3 technical replicates. 
There was no statistical significance for GBS grown in THB. (B) THB medium supplemented with 1% glucose. Data 
are expressed as the mean biofilm/biomass ratio ± SEM of 5 separate experiments, each with 3 technical replicates. * 
represents p < 0.05 by oneway ANOVA, F = 5.935 with posthoc Dunnet’s multiple comparison, compared to media 
alone. 
 
 
 
 
 
 
Figure A2.4 Biomass for S. agalactiae strain CNCTC 10/84 after 24 h of growth in THB media alone or in the 
presence of ca. 5 mg/mL HMOs from various donors. Data represented as the mean biomass (OD600) ± SEM of 3 
separate experiments, each with 3 technical replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by 
one-way ANOVA, F = 88.34 with posthoc Dunnett’s multiple comparison test comparing each HMO sample against 
the control sample without HMOs. 
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Figure A2.5 Biomass for S. agalactiae strain GB590 after 24 h of growth in THB media alone or in the presence 
of ca. 5 mg/mL HMOs from various donors. Data represented as the mean biomass (OD600) ± SEM of 3 separate 
experiments, each with 3 technical replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way 
ANOVA, F = 19.55 with posthoc Dunnett’s multiple comparison test comparing each HMO sample against the control 
sample without HMOs. 
 
 
 
 
 
Figure A2.6 Biomass for S. agalactiae strain GB2 after 24 h of growth in THB media alone or in the presence 
of ca. 5 mg/mL HMOs from various donors. Data represented as the mean biomass (OD600) ± SEM of 3 separate 
experiments, each with 3 technical replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way 
ANOVA, F = 132.3 with posthoc Dunnett’s multiple comparison test comparing each HMO sample against the control 
sample without HMOs. 
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Figure A2.7 Biomass for S. agalactiae strain CNCTC 10/84 after 24 h of growth in THB + 1% glucose media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data represented as the mean biomass 
(OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, 
and **** p < 0.0001 by one-way ANOVA, F = 43.21 with posthoc Dunnett’s multiple comparison test comparing 
each HMO sample against the control sample without HMOs. 
 
 
 
Figure A2.8 Biomass for S. agalactiae strain GB590 after 24 h of growth in THB + 1% glucose media alone or 
in the presence of ca. 5 mg/mL HMOs from various donors. Data represented as the mean biomass (OD600) ± 
SEM of 3 separate experiments, each with 3 technical replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 
0.0001 by one-way ANOVA, F = 10.53 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
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Figure A2.9 Biomass for S. agalactiae strain GB2 after 24 h of growth in THB + 1% glucose media alone or in 
the presence of ca. 5 mg/mL HMOs from various donors. Data represented as the mean biomass (OD600) ± SEM 
of 3 separate experiments, each with 3 technical replicates. * represents p < 0.05, ** p < 0.01, *** p < 0.001, and **** 
p < 0.0001 by one-way ANOVA, F = 58.52 with posthoc Dunnett’s multiple comparison test comparing each HMO 
sample against the control sample without HMOs. 
 
 
 
 
Figure A2.10 Biofilm to biomass ratio for S. agalactiae strain CNCTC 10/84 after 24 h of growth in THB media 
alone or in the presence of ca. 5 mg/mL HMOs from various donors excluding Donor 8. Data expressed as mean 
biofilm/biomass ratio measurements (OD560 /OD600) ± SEM of 3 separate experiments, each with 3 technical 
replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, F = 4.065 with posthoc 
Dunnett’s multiple comparison test comparing each HMO sample against the control sample without HMOs. Results 
from Donor 8 were determined to be outliers using ROUT (Q = 1) and Grubbs (alpha = 0.05) outlier tests. 
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Figure A2.11 Biofilm to biomass ratio of S. agalactiae strain CNCTC 10/84 after 24 h of growth in THB + 1% 
glucose media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as mean 
biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical 
replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, F = 7.579 with posthoc 
Dunnett’s multiple comparison test comparing each HMO sample against the control sample without HMOs. 
 
 
Figure A2.12 Biofilm to biomass ratio for S. agalactiae strain GB590 after 24 h of growth in THB media alone 
or in the presence of ca. 5 mg/mL HMOs from various donors excluding Donor 8. Data expressed as mean 
biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. 
No results were found to be significant by one-way ANOVA, F = 1.061 with posthoc Dunnett’s multiple comparison 
test comparing each HMO sample against the control sample without HMOs. Results from Donor 8 were determined 
to be outliers using ROUT (Q=1) and Grubbs (alpha=0.05) outlier tests. 
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Figure A2.13 Biofilm to biomass ratio of S. agalactiae strain GB590 after 24 H of growth in THB + 1% glucose 
media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as mean 
biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. 
* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, F = 6.423 with posthoc Dunnett’s 
multiple comparison test comparing each HMO sample against the control sample without HMOs. 
 
 
Figure A2.14 Biofilm to biomass ratio for S. agalactiae strain GB2 after 24 h of growth in THB media alone or 
in the presence of ca. 5 mg/mL HMOs from various donors excluding Donor 8. Data expressed as mean 
biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. 
* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, F = 9.692 with posthoc Dunnett’s 
multiple comparison test comparing each HMO sample against the control sample without HMOs. Results from Donor 
8 were determined to be outliers using ROUT (Q = 1) and Grubbs (alpha = 0.05) outlier tests. 
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Figure A2.15  Biofilm to biomass ratio of S. agalactiae strain GB2 after 24 h of growth in THB + 1% glucose 
media alone or in the presence of ca. 5 mg/mL HMOs from various donors. Data expressed as mean 
biofilm/biomass ratio measurements (OD560/OD600) ± SEM of 3 separate experiments, each with 3 technical replicates. 
* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, F = 8.55 with posthoc Dunnett’s 
multiple comparison test comparing each HMO sample against the control sample without HMOs. 
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Synthesis and Biological Evaluation of a Series of Human Milk Glycoconjugates as 
Antibacterial Agents against Group B Streptococcus  
Introduction 
Carbohydrates are ubiquitous and play important roles in biological systems, making them 
attractive subjects in chemical and biological research.1-3 Carbohydrates influence cellular 
processes by participating in molecular or cell-cell recognition and adhesion, cellular transport, 
and cell signaling functions.2, 4 They appear as monosaccharides, oligosaccharides, and 
polysaccharides, and as components of peptidoglycans, glycoproteins, nucleic acids, 
lipopolysaccharides, and glycolipids. 
In order to study the mechanisms and structure-activity relationships associated with 
carbohydrates, they must either be isolated from natural sources, which can be a very tedious 
process, or synthesized by chemical or enzymatic means.1, 3, 5 Chemical synthesis of carbohydrates 
faces two main challenges: controlling the regioselectivity of glycosylation and forming the 
desired anomeric stereochemistry.3, 4, 6 Regioselectivity is acheived by differentially protecting the 
identical functional groups, mainly hydroxyls, present in carbohydrates.3 Anomeric 
stereochemistry is largely controlled by the solvent and nature of the C2 protecting group.2, 3 
Glycosidic linkages are formed by the connection of a donor and an acceptor. A 
glycosylation begins with activation of the donor’s anomeric leaving group (LG) (Figure 4.1). 
Once the leaving group is activated, it can leave, and an oxocarbenium ion is formed as an 
intermediate and be stabilized as either a contact ion-pair (CIP) or a solvent-separated ion-pair 
(SSIP) depending on the polarity of the solvent.7, 8 SSIP are stabilized by more polar solvents. The 
  143 
intermediates can be attacked by a nucleophile (the acceptor) at either the top or bottom face 
resulting in a 1,2-cis, α-glycoside or a 1,2-trans, β-glycoside, respectively (Figure 4.1).  Moreover, 
the nature and configuration of the protecting groups at C2 also influence the outcome of a 
glycosylation reaction. For instance, 1,2-trans relationships are often favored when C2 is sterically 
encumbering or the protecting group has the ability to participate in stabilizing the oxocarbenium 
intermediate.9 This stabilization occurs by participation from an acyl group at C2 resulting in an 
acyloxonium intermediate (Figure 4.2).5 Conversely, a non-participating group at C2, such as an 
ether, can be used to favor 1,2-cis glycosides.9  
 
 
 
Figure 4. 1 A general glycosylation mechanism. New glycosidic bonds are highlighted in color. LG = leaving group. 
PG = protecting group.8 
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Figure 4. 2 Mechanism of 1,2-trans selective glycosylations due to participation of the C2 substitutent.5 
 
A variety of anomeric leaving groups have been developed for use in oligosaccharide 
synthesis.3, 5 The leaving groups employed in this study were chosen for their ease of synthetic 
access and precedence in literature for achieving the desired glycosidic linkages. They include 
trichloroacetimidates, thiols, fluorides, and phosphites (Figure 4.3).  
 
 
 
Figure 4. 3 Leaving groups used in this study2, 5 
 
Trichloroacetimidates were first employed as leaving groups by Schmidt and coworkers 
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Trichloroacetimidates can be activated with catalytic amounts of Lewis acids such as TMSOTf 
and BF3•Et2O and Brønsted acids such as TfOH (Figure 4.3).  
Thioglycosides are appealing donors because of their ability to be activated by a broad 
range of electrophiles, their stability to a considerable amount of intermediate functional group 
transformations, their easy accessibility, and their capacity to be converted to other leaving groups. 
Glycoyslations using thioglycosides were first reported in 1973 by Ferrier and coworkers.11 Metal 
salts, halonium reagents, organosulfur reagents, and single electron transfer reagents can all be 
used to activate thioglycosides (Figure 4.3).12  
Fluoride donors are advantageous over other halides due to their increased stability. Unlike 
chlorides and bromides, they can withstand purification such as column chromatrography.13 
Mukaiyama first developed the use of fluorides as glycosyl donors in 1981.14 Fluoride donors were 
initially activated with a fluorophilic SnCl2-AgClO4 activator, but can also be activated under other 
conditions including activators with either SnCl2 or AgClO4 (SnCl2-TrClO4 and SnCl2-AgOTf). 
Lewis acids (BF3•Et2O, TMSOTf, Yb(OTf)3, TiF4, and SnF4, among many others) and group IV 
metallocenes (Cp2ZrCl2-AgClO4, Cp2HfCl2-AgClO4, Cp2ZrCl2-AgBF4, and Cp2HfCl2-AgOTf) 
have also proven to be useful activators(Figure 4.3).14, 15 
Finally, phosphites were independently introduced for use as sialyl donors by Wong and 
Schmidt.14, 16, 17 Since then, they have found wide-spread use in sialylations as well as other 
glycosylations.18-20 Phosphite donors can be activated with Lewis and Brønsted acids such as 
BF3•Et2O, TMSOTf, and TfOH (Figure 4.3).5  
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Rationale for Synthesis 
As detailed in the previous chapters, the carbohydrates in human milk can inhibit the 
growth and biofilm formation of GBS. The present study tests the hypothesis that the smallest 
HMOs produced by the mammary gland possess antibacterial activity. This hypothesis was 
developed based on an initial investigation into the relationship of HMO size and antimicrobial or 
anti-biofilm properties.  
 
Figure 4. 4 Identification of HMO fractions that inhibit the growth of S. agalactiae strain CNCTC 10/84. The 
total biomass (growth) after 24 h of growth was compared for (A) THB medium alone. Data represented as the 
mean biofilm/biomass ratio ± SEM of 3 separate experiments, each with 3 technical replicates. * p < 0.05, ** p < 0.01, 
*** p < 0.001, and **** p < 0.0001 by one-way ANOVA, F = 18.53 with posthoc Dunnet’s multiple comparison test 
comparing each HMO group against the control sample without HMOs. (B) THB medium supplemented with 1% 
glucose. Data are expressed as the mean biofilm/biomass ratio ± SEM of 3 separate experiments, each with 3 technical 
replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by oneway ANOVA, F = 17.89 with posthoc 
Dunnet’s multiple comparison, compared to media alone. 
 
The native HMOs from donor 42 were fractionated using size exclusion chromatography 
and organized into five fractions based on LC/MS profiles (Figure A3.1). While HMOs from donor 
42 had no significant activity in the initial study, we reasoned fractionating and removing lactose 
could increase the activity by concentrating active compounds into a few fractions. Each fraction 
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of 5 mg/mL. The assay revealed that HMOs from Fraction 7 significantly inhibited growth in both 
THB and THB supplemented with 1% glucose by 20 and 23%, respectively (Figure 4.4). This is 
encouraging as HMOs from donor 42 had no antimicrobial activity when pooled together (Figure 
3.2 and 3.3). Interestingly, the fractions were devoid of anti-biofilm activity (Figure A3.2). 
Structurally, the HMOs in fraction 7 ranged from trisaccharides to pentasacharides (including 
HMOs such as 2’/3-FL, LNT, and LNFP-I). Fractions 5 and 6 contained oligosaccharides of 8 
units or more, and franctions 8 contained a mixture of disaccharides, trisaccharides, 
tetrasaccharides. Fractions 9-13 contained both disaccharides and trisaccharides. 
We further advanced this hypothesis on the consideration that every HMO is constructed 
through “polymerization” of a single lactose core (Figure 4.5).  At the simplest level, lactose 
undergoes enzymatic fucosylation or sialylation to generate human milk trisaccharides (See also 
Chapter 3, Biosynthesis of HMOs, Figure 2.13). These manipulations most commonly occur at the 
C2/2’, C3/3’, and C6’ positions. 
 
 
Figure 4. 5 Human Milk Trisaccharide and Oligosaccharide Synthesis 
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trisaccharides to measure their activity against GBS and to probe the structure-activity relationship 
of lactose derivatives that are functionalized primarily at C3’ (Figure 4.6). In addition to seven 
synthetic compounds, we included two related, commercially available HMOs in our study. Four 
of these trisaccharides have been synthesized previously, but none have been tested for their 
activity against GBS. 3’-Sialyllactose (2) has been previously synthesized chemoenzymatically21-
24 and synthetically en route to antigens GM3, Lewis X, and sialyl Lewis X.25, 26 3’-Fucosyllactose 
(1)27 and epi-isoglobotriaose (4)28, 29 have been previously prepared chemoenzymatically. Finally, 
lacto-N-triose (3) has been prepared synthetically in a single study.30   
 
 
 
Figure 4. 6 Milk trisaccharides and congeners prepared in this study 
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congeners could serve as a place for exploring the individual HMOs or pharmacophores 
responsible for the antimicrobial and anti-biofilm activity previously observed. Our strategy was 
to dissect each target compound into two components: 1) a monomeric glycosyl donor and 2) a 
lactose acceptor that can be prepared on multigram scale in a single pass (Scheme 4.1). 
 
Scheme 4. 1 Synthetic approach to human milk trisaccharides functionalized at the 3’ position of lactose. 
 
 
Synthesis of Human Milk Glycoconjugates 
The general structure of one subset of milk trisaccharides features glycosyl residues at C3’ 
of lactose (Figure 4.1).  Hence, an initial objective was to prepare a common lactose acceptor with 
an open site at C3’ that could be quickly accessed and used to synthesize seven natural and non-
natural derivatives. While the ability to glycosylate the C3’-equatorial hydroxyl group of galactose 
in the presence of an axial acceptor at C4’ is known and we explored this option first,31 we achieved 
improved glycosylation yields when using a C4’ protected acceptor. 
Synthesis of the Lactose Diol Acceptor 
An anomeric mixture of 8 was cleanly converted to its α-bromide using HBr/AcOH in 
CH2Cl2 in greater than 95% yield (Scheme 4.2A).  Next, a Koenigs-Knorr type reaction with benzyl 
alcohol gave 9 as a single β-anomer in yields ranging from 52-79%.31 Unfortunately, this reaction 
requires stoichiometric amounts of silver salt as a promoter, rendering the sequence unfeasible on 
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To circumvent this problem, we turned to Lewis-acid catalysis (Scheme 4.2B).  A 
BF3•OEt2 mediated reaction of 8 with benzyl alcohol gave b-O-benzyl lactoside 9 alongside 8α in 
60-63% based on the β-anomer.32, 33 Presumably, anomeric stability renders 8α unreactive. Global 
saponification followed by acetonide formation gives 10, which can be crystallized from the 
reaction mixture in moderate yield (32-53%).33, 34 This reaction also yields the kinetically favored 
4’,6’-acetonide, which can be recovered and resubjected to the reaction conditions to generate the 
desired 3’,4’-acetonide. Finally, perbenzylation and acetonide hydrolysis gave acceptor 11 in 60-
85% yield over two steps.33, 34  This acceptor can be prepared on multigram scale in a single pass.  
 
Scheme 4. 2 Synthesis of Lactose Diol Acceptor 
 
 
Synthesis of Monosaccharide Donors 
For derivatization of the lactose acceptor 11, several monosaccharide donors were 
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compose HMOs (Table 2.3). While HMOs do not naturally contain mannose residues, we reasoned 
that a mannose derivative might have activity due to its prevalence in other human-produced 
glycans. Additionally, for synthetic ease, we opted to form an α-linked mannoside rather than a β-
linked mannoside, which is the linkage naturally found in human glycans. A PEGylated derivative 
was chosen to test how a carbohydrate mimetic functions in comparison to other derivatives.35  
Fucosyl fluorides give high α-selectivity and were employed here.15 Trichloroacetimidates 
were chosen for glucosamine, galactose, and glucose donors due to their ease of access from the 
peracetylated derivatives of each monosaccharide.10 Sialyl phosphite donors have been widely 
used because of high α-selectivity and improved yields.19 The thiomannoside was chosen due to 
commercial availability of the requisite starting material.  
The synthesis of fucosyl fluoride donor 16 started with peracetylation of L-fucose 12 to 
give 13 in greater than 90% yield (Scheme 4.3).36 Lewis acid mediated phenyl thioglycoside 
formation provided thioglycoside 14 in 80-98% yields.36 Following sodium methoxide 
saponification of 14, perbenzylation under standard conditions using sodium hydride and benzyl 
bromide yields thioglycoside 15 in 88-95% yield over two steps.36 Finally, thioglycoside 15 is 
converted to fluoride 16 with good α-selectivity (10:1) and high yields (94-98%) using N-
bromosuccinimide (NBS) and diethylaminosulfur trifluoride (DAST).36 Both fucosyl 
thioglycoside 15 and fucsoyl fluoride 16 were explored to optimize of fucosylations. 
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Scheme 4. 3 Synthesis of Fucosyl Fluoride Donor 
 
 
 
 
The sialyl phosphite donor 21 can be accessed in 3 steps from N-acetylneuraminic acid 17 
(Scheme 4.4).37 Fisher esterification to form methyl ester 18 (85-90% yield) followed by 
acetylation and anomeric hydrolysis reveals N-acetylneuraminate 19 in 70-79% yields.37 Reaction 
of 19 with dibenzyl N,N-diisopropylphosphoramadite in the presence of tetrazole reveals sialyl 
phosphite donor 20 in 64-88% yields.37  
 
Scheme 4. 4 Synthesis of Sialyl Phosphite Donor 
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O SPh
OAc
OAc
OAc
O OH
OH
OH
OH
O OAc
OAc
OAc
OAc
Ac2O, DMAP
pyr
91-98%
PhSH, SnCl4
CH2Cl2
80-98%
(12) (14)(13)
O
OBn
OBn
OBn
SPh O
OBn
OBn
OBn
F
NBS, DAST
CH2Cl2, -50 to 0°C
94-98%
1. NaOCH3, CH3OH
2. BnBr, NaH
    DMF, 0°C to rt
    2 steps: 86-95% α:β 10:1(16)(15)
O
HO OH
OH OH
CO2H
HO
AcHN
O
HO OH
OH OH
CO2Me
HO
AcHN
Dowex 50WX8 1. AcCl, MeOH    0°C-rt
2. Ag2CO3, acetone
    2 steps: 70-79%
MeOH
85-90%
17 18
O
AcO OAc
OAc OP(OBn)2
CO2Me
AcO
AcHNO
AcO OAc
OAc OH
CO2Me
AcO
AcHN
(BnO)2PNiPr2
tetrazole, CH2Cl2
64-88%
2019
  153 
Scheme 4. 5 Synthesis of Sialyl Thiol Donor 
 
 
 
 
Starting with D-glucosamine hydrochloride 21, trichloroethyl carbamate (Troc) protection 
of the amine and peracetylation yields fully protected glucosamine 22 in good yields over 3 steps 
(84-94%) (Scheme 4.6).40 Selective cleavage of the anomeric acetate to arrive at intermediate 23 
in 71-94% yield was accomplished using dimethylaminopropylamine. Reaction with DBU and 
trichloroacetonitrile provided 69-87% yield of Schmidt imidate 24.40   
 
Scheme 4. 6 Synthesis of Glucosamine Imidate Donors 
 
 
 
 
 
Both galactose and glucose imidate donors were accessed by anomeric deacetylation of 
galactose pentaacetate 26 or glucose pentaacetate 29 in good yields using 
dimethylaminopropylamine followed by imididate formation to give galactose donor 28 and 
glucose donor 31 in 69-87% and 67-83% yields, respectively (Scheme 4.7).41  
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Scheme 4. 7 Synthesis of Galactose and Glucose Imidate Donors 
 
 
 
 
 
 
We also explored the use of an ethylthiogalactoside donor 32, which can be accessed in 
one step from galactose pentaacetate 26 with SnCl4 and ethane thiol as a mixture of α:b anomers 
(6:5) in 71-94% yield (Scheme 4.8).42  
Scheme 4. 8 Synthesis of Thioethyl Galactose Donor 
 
 
 
 
 
Perbenzylation of commercially available phenyl α-D-thiomannoside 33 gives the 
thiomannoside donor 34 in one step in greater than 90% yields (Scheme 4.9).43  
 
Scheme 4. 9 Synthesis of Thiophenyl Mannose Donor 
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be used in an SN2 reaction with an alkoxide deriviate of the lactose acceptor to form the PEGylated 
derivative in 74-95% yield (Scheme 4.10). 
 
Scheme 4. 10 Synthesis of Tosylated PEG Donor 
 
 
 
First Round of Glycosylations using Lactose Diol Acceptor  
With the lactose diol acceptor 11 and monosaccharide donors in hand, we were able to 
explore six glycosylations to arrive at the desired trisaccharides in 20-54% yields. We first 
explored fucosylation conditions, en route to the trisaccharide 3’-FL (1) (Table 4.1).  Our plan 
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initially difficult to activate.  While excellent selectivity was observed, yields were consistently 
low. Ultimately, we turned to thioglycoside 16 (Entry 6).45  Although selectivity suffered and was 
inconsistent (1.4-2.2:1 α:β), yields increased to 50-65% using the thioglycoside donor, and the 
resulting anomers were easily separable, giving 37 in reasonable isolated yield. 
 
 
 
 
 
O
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Table 4. 1 Fucosylation of Lactose Acceptor 11. 
 
Entry Donor (X) Activator Yield α:βe 
1a,c F BF2·OEt2 22% α only 
2a,d F SnCl2, AgClO4 16% α only 
3a,d F Cp2HfCl2, AgOTf 20-28% α only 
4b,d F Cp2ZrCl2, AgOTf 5% α only 
5b,d F Cp2ZrCl2 AgClO4 trace α only 
6a,d SPh NIS/AgOTf 50-65% 1.4:1 
asolvent = Et2O/CH2Cl2, bsolvent = THF, ctemp. = 0°C to r.t., dtemp. = -40oC to r.t., eα:β ratio determined by 1H 
NMR 
 
The sialylation of 11 is depicted in Table 4.2. There are a number of useful methods 
developed to achieve α-sialylation.46 We initially screened a sialyl chloride (Entry 1) as it could 
be prepared in a single step from commercially available material.  Although we observed 
exclusive α-selectivity, the yield was only 15%.  To improve on this result, we examined a sialyl 
thioglycoside (Entry 2).  While we observed complete α-selectivity, only a mild improvement in 
yield was achieved (27%). Eventually, we turned to Wong’s sialyl phosphite47 (Entry 3), which 
provided 38 with exclusive α-selectivity in 43-45% isolated yield. 
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Table 4. 2 Sialylation of Lactose Acceptor 11. 
 
Entry Donor (X) Activator Yield α:βe 
1a,c Cl Ag2CO3, I2 15% α only 
2b,d SEt NIS/TfOH 27% α only 
3b,d OP(OBn)2 TMSOTf 43-45% α only 
asolvent = CH2Cl2, bsolvent = CH3CH2CN, ctemp. = 0oC to r.t., dtemp. = -20oC. eα:β ratio determined by 1H NMR. 
 
En route to lacto-N-triose (3), we examined the glycosylation of a single glucosamine 
Schmidt imidate donor 25, (Table 4.3).  Although poor results were observed using BF3•OEt2 as a 
catalyst, TMSOTf provided a clean and moderate yielding glycosylation to give 39 in 35-52% 
yields.  
 
Table 4. 3 N-acetylglucosylation of Lactose Acceptor 11. 
 
Entry Activator Yield α:βc 
1a,b BF3·OEt2 22-25% β only 
2a,b TMSOTf 35-52% β only 
asolvent = CH2Cl2, btemp = -20oC to r.t. cα:β ratio determined by 1H NMR. 
 
The installation of a galactose residue was accomplished with thioglycoside and imidate 
galactosyl donors readily prepared from galactose. While the glycosylation with thioglycoside 32 
varied in yield (35-52%, Table 4.4, Entry 1), reaction of Schmidt imidate 28 occurred in consistent 
isolated 51-56% yields and excellent anomeric selectivity to give 40 as a single β-anomer. 
O
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Table 4. 4 Galactosylation of Lactose Acceptor 11. 
 
 
Entry Donor (X) Activator Yield α:βe 
1a,b SEt NIS, AgOTf, 35-52% β only 
2a,b O(C)NHCCl3 NIS/TfOH 51-56% β only 
asolvent = CH2Cl2, btemp = -20oC, cα:β ratio determined by 1H NMR 
 
The final glycosylation focused on the addition of a mannose residue. This proceeded in a 
routine manner using one donor and activation conditions but varying the solvent. Under all 
conditions, activation of thioglycoside 34 with NBS and AgOTf in the presence of acceptor 11 
provided trisaccharide 41 in a completely α-selective manner. When the glycosylation was carried 
out in diethyl ether, yields of up to 15% were seen (Table 4.5, Entry 1). We postulated this was 
due the low solubility of the acceptor in diethyl ether. Using a mixed solvent system of 1:1 diethyl 
ether and dichloromethane resulted in improved yields that ranged from 20-39% (Table 4.5, Entry 
2). However, yields further improved to 39-47% when dichloromethane was used as the sole 
solvent (Table 4.5, Entry 3).   
 
Table 4. 5 Mannosylation of Lactose Acceptor 11. 
 
Entry Solvent Yield α:βc 
1a,b Et2O 15% α only 
2a,b CH2Cl2/Et2O (1:1) 20-39% α only 
3a,b CH2Cl2 39-47% α only 
aactivator = NBS/AgOTf, btemp = -20oC, cα:β ratio determined by 1H NMR 
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In the final study, we recalled polyethylene glycol (PEG) is used to mimic carbohydrates 
in a number of drugs.35 Our plan was to add a PEG moiety of similar molecular weight to 
glycopyranoses. Additionally, we wanted to examine whether 3’, 4’-alkoxide salts would show 
similar regioselective nucleophilicity as their parent alcohols.  Initially, we explored the use of a 
commercially available PEG-Br. Interestingly, regioselective mono-alkylation of 11 with a type 
36 PEG-Br proved challenging. When using 1.1 eq. of PEG bromide, the reaction displayed no 
regioselectivity, resulting in production of both mono- 42 and di-PEGylated lactose 43, with yields 
ranging from 19-38% and 10-29%, respectively.  Not surprisingly, using excess electrophile gave 
only di-PEGylated lactose 43 with yields ranging from 30-66%.  Exchanging the bromide for a 
tosylate provided increased yields of 43.  We concluded that while glycosylation of galactosyl type 
3,4-diols can occur preferentially at the equatorial acceptor, Williamson ether type alkylation is 
inherently different.  Thus, it appears that a differentiation in nucleophilicity lies only at the alcohol 
state.  
Table 4. 6 PEGylation of Lactose Acceptor 11. 
 
Entry (X) Conditions Yield (42) Yield (43) 
1b Br NaH, DMF 19% 29% 
2b Br NaH, DMF 38% 10% 
3c Br NaH, TBAI, DMF - 30-66% 
4d OTs NaH, DMF - 64-82% 
asolvent = DMF, btemp. = 0oC to r.t., ctemp. = 80oC, dtemp. = r.t. 
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Modified Lactose Acceptor  
Gycosylations using the lactose diol acceptor 11 resulted in only moderate yields (up to 
56%). As such, we turned our attention to an alternative lactose acceptor with C4’ protected as an 
acetate to determine if yields of the previously described glycosylations could be increased.  
The synthesis of the alternative lactose acceptor simply required one modification of the 
previously described lactose diol acceptor 11. Staring with lactose diol 11, an intermediary ortho-
ester formation followed by selective opening reveals the 3’ lactose acceptor 44 in 85-90% yield.48, 
49 
 
Scheme 4. 11 Synthesis of Axially Acetylated Lactose Acceptor 
 
Second Round of Glycosylations using Axially Acetylated Lactose Acceptor 
As we approached the glycosylation reactions using the revised lactose acceptor 44, we 
opted to use the highest-yielding, most-consistent donors in the initial glycosylation studies with 
lactose diol 11. The one exception was the use of fucosyl fluoride instead of the thioglycoside, as 
it was discovered that an increase in the equivalents of activator (SnCl2-AgClO4) and change in 
the order of addition resulted in improved yields. Furthermore, we included the installation of a 
glucose residue to access an additional congener. 
We were pleased to see that the previously optimized glycosylation reactions provided the 
conditions necessary to produce each compound in high yields as a single anomer. Fucosylation 
using the fucosyl fluoride 16 was promoted by SnCl2 and AgClO4 to give the protected fucosyl 
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lactoside 45 in 79% yield with complete α-selectivity. In contrast to this system, sialylation of 44 
consistently produced a low yield of the sialylated lactose species.  Ultimately, while Wong’s 
phosphite proceeded in a modest 47% yield, only the α-anomer was detected (Table 4.7, Entry 2). 
Glycosylation with the Schmidt trichloroacetimidates of glucosamine 25, galactose 28, and 
glucose 31 provided the corresponding trisaccharides in excellent yields and anomeric control 
(Table 4.7, Entries 3, 4 and 5). The final glycosylation focused on a straightforward installation of 
a mannose residue. Activation of thiophenylmannoside donor 34 with NBS and AgOTf followed 
by glycosylation occurred in a consistent, high isolated yield (93%), with excellent anomeric 
selectivity to give the trisaccharide 50 (Table 4.7, Entry 6) as a single α-anomer. 
While the previous glycosylations used an excess of donor, an excess of acceptor 44 was 
used in order to achieve a regioselective mono-PEGylation in 56% yield under Williamson ether 
synthesis conditions (Table 4.7, Entry 7).  While we did observe de-acetylation under these 
conditions, no diPEGylation was observed. 
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Table 4. 7 Glycosylations of Lactose Acceptor 44 
 
Entry Donor (x) Glycosylation conditions Trisaccharide 
 
1 
 
SnCl2, AgClO4  
1:1Et2O/CH2Cl2, 23°C 
79%, α-only 
 
 
2 
 
TfOH 
CH3CH2CN 
-30 °C to rt 
47%, α-only  
3 
 
 
TfOH 
CH2Cl2 
-5 °C 
95%, β-only  
 
4 
 
TfOH 
CH2Cl2 
-5 °C 
92%, β-only  
 
5 
 
TfOH 
CH2Cl2 
-5 °C 
75%, β -only  
 
6 
 
NIS/AgOTf 
CH2Cl2, -5 °C 
93%, α-only 
 
 
7 
 
NaH, DMF, 0 oC to rt 
56% 
 
 
Deptrotection Strategies for Trisaccharides  
When designing the synthesis and selecting protecting groups, we also had in mind the 
global deprotection strategies required after successful glycosylations. Two main protecting 
groups were used: acetates and benzyl ethers. Saponification of the acetates with sodium 
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methoxide followed by hydrogenation of the benzyl ethers using Pearlman’s catalyst (Pd(OH)2) 
yielded the fully deprotected trisaccharides in good yields ranging from 45-93% (Table 4.8). 
However, the sialyl-containing trisaccharide 46 required a methyl ester for protection of the 
carboxylic acid, which can be cleaved during the saponification step, using sodium hydroxide in 
place of sodium methoxide (Table 4.8, Entry 2). The glucosamine-containing trisaccharide 47 
incorporated a Troc-protected amine, which required an initial step to remove the Troc group and 
form the acetimidate in situ using a zinc/lead couple followed by addition of acetic anhydride 
(Table 4.8, Entry 3). 
Table 4. 8 Deprotection Strategies for Trisaccharides 
Entry Trisaccharide Deptrotection Strategy Deprotected Glycoconjugate 
 
1 
 
1. NaOMe, MeOH 
2. Pd(OH)2, H2, MeOH 
    80% 
 
 
2 
 
1. NaOMe, MeOH 
2. Pd(OH)2, H2, MeOH,  
     then H2O, 78%  
3 
 
 
1. 10% Zn/Pb, Ac2O, THF 
2. NaOMe, MeOH 
3. Pd(OH)2, H2, MeOH 
    83%  
 
4 
 
1. NaOMe, MeOH 
2. Pd(OH)2, H2, MeOH 
    90%  
 
5 
 
1. NaOMe, MeOH 
2. Pd(OH)2, H2, MeOH 
    93% 
 
 
6 
 
1. NaOMe, MeOH 
2. Pd(OH)2, H2, MeOH 
    45% 
 
 
7 
 
Pd(OH)2, H2, MeOH, 79% 
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We have developed a scalable synthesis of a lactose acceptor that can be used in gram-
scale glycosylations to produce human milk trisaccharides and congeners. The general strategy of 
glycosylating C3-equatorial hydroxyl groups in the presence of an axial hydroxyl group at C4 can 
be successful, but we achieved better yields when C4 was protected. Additionally, this 
regioselectivity breaks down when the hydroxyl groups are converted to their corresponding 
alkoxide salts. However, previous research with stannylene acetals has shown that mono-
alkylation of diols is achievable.50 Specifically, numerous groups have shown high regioselectivity 
of the C3, C4-galactose type diols to give alkylation at C3, which is postulated to be due to the 
dimeric or polymeric intermediates of stannylene acetals that position one oxygen for 
nucleophilicity over the other because it is only coordinated to one tin (Figure 4.7). 51-54 
 
Figure 4. 7 Dimeric structure of stannylene acetals54 
 
Evaluation of Biological Activity of Trisaccharides and PEG-Congener 
We evaluated each compound (Figure 4.6) and two commercially available HMOs for 
antibacterial and anti-biofilm activity against three strains of GBS (GB590, GB2, CNCTC 10/84) 
representing the three serotypes (III, Ia, and V) responsible for greater than 85% of neonatal 
infection. 2’-FL and 6’-SL (Figure 4.8) were attained from commercial sources to serve as 
constitutional isomers for two of the trisaccharides synthesized above (3’-FL and 3’-SL). We 
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reasoned that testing these two constitutional isomers, which are also naturally found in human 
milk, would guide our understanding of the significance of the branching and substitution pattern 
of small HMOs. 
 
 
Figure 4. 8 Additional Trisaccharides 
 
The effect of each trisaccharide on the three GBS strains was evaluated at 24 h in THB and 
THB supplemented with 1% glucose using the previously described plate-based biofilm assay. All 
assays were performed using a glycoconjugate concentration of 5 mg/mL as this value 
approximates low physiological concentrations; HMOs are typically found in breast milk at 5–20 
mg/mL.55 
First, we determined antimicrobial by comparing the biomass of bacteria grown in the 
presence of glycoconjugates to a control (bacteria grown in unsupplemented media). Several 
compounds were found to significantly inhibit bacterial growth for GBS in at least one set of 
growth conditions (p ≤ 0.05 by one-way ANOVA with posthoc Dunnett’s multiple comparison 
test). The results are presented as the percent growth of the control ± SEM of four independent 
experiments each with three technical replicates. In these studies, 3’-FL (1) and 3’-GalLac (4) 
showed interesting activity.  3’-FL (1) inhibited the growth of CNCTC 10/84 (THB supplemented 
with 1% glucose) and GB590 (THB) by 16% and 17%, respectively (Figures 4.9 and 4.10). 3’-
GalLac (4) showed greater inhibitory activity across each strain with values ranging from 17% 
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against 10/84 (THB supplemented with 1% glucose), 41% against GB590 (THB), and values as 
high as 24% against GB2 (THB supplemented with 1% glucose) (Figures 4.9, 4.10, 4.11). As 
observed in our previous studies, these values varied based on growth conditions. 
 
 
Figure 4. 9 Antimicrobial assays of S. agalactiae strain CNCTC 10/84 at 24 h was compared for (A) THB media 
of (B) THB media supplemented with 1% glucose. * represents p < 0.05 by one-way ANOVA, F = (A) 8.291 and 
(B) 9.791 with posthoc Dunnet’s multiple comparison test comparing each sample against the control. 
 
 
Figure 4. 10 Antimicrobial assays of S. agalactiae strain GB590 at 24 h was compared for (A) THB media or 
(B) THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by 
one-way ANOVA, F = (A) 17.69 and (B) 32.48 with posthoc Dunnett’s multiple comparison test comparing each 
sample against the control. 
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Figure 4. 11 Antimicrobial assays of S. agalactiae strain GB2 at 24 h was compared for (A) THB media or (B) 
THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-
way ANOVA, F = (A) 56.29 and (B) 29.37 with posthoc Dunnett’s multiple comparison test comparing each sample 
against the control. 
 
To determine changes in biofilm production, we compared biofilm/biomass ratios of 
bacteria grown in the presence of HMOs to the control (media). This ratio accounts for 
antimicrobial activity and permits analysis of changes in biofilm production relative to the number 
of bacterial cells. The data represents the mean percent biofilm/biomass (OD560/OD600) of the 
control ± SEM of four separate experiments, each with three technical replicates. Using this 
standard, three compounds significantly reduced biofilm formation in at least one GBS strain. 
Interestingly, the fucosylated derivatives (2’-FL, 51 and 3’-FL, 1) exhibited the greatest biofilm 
inhibition. 2’-FL (51) decreased the amount of biofilm produced relative to growth for CNCTC 
10/84 grown in THB by 25% (Figure 4.12) and for GB590 grown in THB supplemented with 1% 
glucose by 19% (Figure 4.13). Additionally, 3’-FL (1) also showed inhibition of biofilm 
production for GB2 in THB supplemented with 1% glucose (Figure 4.14). Of particular interest, 
3’PEGLac (7) showed anti-biofilm activity across all strains ranging 14% to 27%, though none of 
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these values were deemed significant. This is likely due to variation in biofilm measurements after 
plate workup.  
 
Figure 4. 12 Biofilm/biomass ratios for CNCTC 10/84 at 24 h. was compared for (A) THB media or (B) THB 
media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way 
ANOVA, F = (A) 1.774 and (B) 10.1 with posthoc Dunnett’s multiple comparison test comparing each sample against 
the control. 
 
 
Figure 4. 13 Biofilm/biomass ratios for GB590 at 24 h. was compared for (A) THB media or (B) THB media 
supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, 
F = (A) 7.16 and (B) 10.13 with posthoc Dunnett’s multiple comparison test comparing each sample against the 
control. 
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Figure 4. 14 Biofilm/biomass ratios for GB2 at 24 h. was compared for (A) THB media or (B) THB media 
supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, 
F = (A) 16.69 and (B) 23.06 with posthoc Dunnett’s multiple comparison test comparing each sample against the 
control. 
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activity of these compounds.  
 
 
 
Figure 4. 15 Structures of Additional Carbohydrates Tested against GBS 
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the three GBS strains tested in either growth condition (THB or THB supplemented with 1% 
glucose). Instead, each of these carbohydrates significantly increased the growth in at least one 
strain in one or both growth condition (Figure 4.16, 4.16, and 4.18).  Growth increased up to 26% 
compared to the control sample grown in media alone. GBS has multiple genes for carbohydrate 
transport and metabolism that are differentially expressed according to growth conditions.57, 58 It 
is likely that these specific strains have a transcriptome with genes for metabolizing these or similar 
carbohydrates, and the increase in growth of GBS is due to metabolism of these compounds after 
the upregulation of these genes.  
 
 
Figure 4. 16 Antimicrobial assays of S. agalactiae strain CNCTC 10/84 at 24 h was compared for (A) THB 
media of (B) THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 
0.0001 by one-way ANOVA, F = (A) 28.88 and (B) 7.261 with posthoc Dunnet’s multiple comparison test comparing 
each sample against the control. 
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Figure 4. 17 Antimicrobial assays of S. agalactiae strain GB590 at 24 h was compared for (A) THB media of 
(B) THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by 
one-way ANOVA, F = (A) 9.95 and (B) 11.84 with posthoc Dunnet’s multiple comparison test comparing each sample 
against the control 
 
 
 
 
Figure 4. 18 Antimicrobial assays of S. agalactiae strain GB2 at 24 h was compared for (A) THB media of (B) 
THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-
way ANOVA, F = (A) 32.23 and (B) 9.674 with posthoc Dunnet’s multiple comparison test comparing each sample 
against the control. 
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Lactose and the monosaccharides had little impact on the biofilm as determined by the 
biofilm to biomass ratio. Only sialic acid significantly reduced the biofilm production in all three 
strains in at least one growth condition (Figure 4.19, 4.20, and 4.21) with percent reduction ranging 
from 15-30%. The ability of sialic acid to affect the production of biofilm could potentially be due 
to the presence of sialic acid in the capsule of GBS. In all GBS strains, sialic acid is a terminal 
residue in the capsular polysaccharide repeating unit and the capsule is associated with GBS 
virulence, such as biofilm formation. Perhaps there is a feedback loop that causes GBS to down 
regulate its biofilm production with excess sialic acid in the media. 
 
Figure 4. 19 Biofilm/biomass ratios for CNCTC 10/84 at 24 h. was compared for (A) THB media or (B) THB 
media supplemented with 1% glucose. * represents p < 0.05 by one-way ANOVA, F = (A) 2.551 and (B) 6.979 
with posthoc Dunnett’s multiple comparison test comparing each sample against the control. 
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Figure 4. 20 Biofilm/biomass ratios for GB590 at 24 h. was compared for (A) THB media or (B) THB media 
supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, 
F = (A) 13.43 and (B) 9.306 with posthoc Dunnett’s multiple comparison test comparing each sample against the 
control. 
 
 
 
Figure 4. 21 Biofilm/biomass ratios for GB2 at 24 h. was compared for (A) THB media or (B) THB media 
supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, 
F = (A) 28.85 and (B) 6.997 with posthoc Dunnett’s multiple comparison test comparing each sample against the 
control. 
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Several commercially available oligosaccharides were able to significantly inhibit the 
growth of GBS. The greatest growth inhibition across all strains was achieved with colominic acid, 
an oligosaccharide composed of sialic acid monomers. In the presence of colominic acid, the 
reduction of growth of GBS ranged from 9-40% (Figure 4.22, 4.23, and 4.24). Sialic acid is present 
in the capsule of all GBS strains in an α-2,3 linkage with galactose. Colominic acid has α-2,8 
linkages. The presence of sialic acid may trigger the bacterial use of this carbohydrate for capsule 
synthesis, but it cannot be utilized due to the linkages in the polymer. In strain CNCTC 10/84, 
xylans, laminarin, and dextran sulfate significantly inhibited the growth in both THB and THB 
supplemented with 1% glucose. Growth reduction of these oligosaccharides ranged from 8-35%. 
Maltodextrin was also able to inhibit the growth in strain CNCTC 10/84 in THB supplemented 
with 1% glucose by 35%.  
 
 
Figure 4. 22 Antimicrobial assays of S. agalactiae strain CNCTC 10/84 at 24 h was compared for (A) THB 
media of (B) THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 
0.0001 by one-way ANOVA, F = (A) 79.36 and (B) 38.26 with posthoc Dunnet’s multiple comparison test comparing 
each sample against the control. 
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Figure 4. 23 Antimicrobial assays of S. agalactiae strain GB590 at 24 h was compared for (A) THB media of 
(B) THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by 
one-way ANOVA, F = (A) 19.36 and (B) 18.31 with posthoc Dunnet’s multiple comparison test comparing each 
sample against the control. 
 
 
 
 
Figure 4. 24 Antimicrobial assays of S. agalactiae strain GB2 at 24 h was compared for (A) THB media of (B) 
THB media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-
way ANOVA, F = (A) 44.07 and (B) 16.71 with posthoc Dunnet’s multiple comparison test comparing each sample 
against the control. 
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While many of the oligosaccharides significantly increased the biofilm produced relative 
to the biomass, GOS and dextrin sulfate were able to significantly decrease the biofilm/biomass in 
separate strains in THB supplemented with 1% glucose. GOS exhibited 24% biofilm reduction in 
GB590, and dextrin sulfate showed a biofilm reduction of 23% compared to the control in GB2 
(Figures 4.25, 4.26, 4.27).  
 
 
Figure 4. 25 Biofilm/biomass ratios for CNCTC 10/84 at 24 h. was compared for (A) THB media or (B) THB 
media supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way 
ANOVA, F = (A) 20.57 and (B) 5.046 with posthoc Dunnett’s multiple comparison test comparing each sample 
against the control. 
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Figure 4. 26 Biofilm/biomass ratios for GB590 at 24 h. was compared for (A) THB media or (B) THB media 
supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, 
F = (A) 13.07 and (B) 7.462 with posthoc Dunnett’s multiple comparison test comparing each sample against the 
control. 
 
 
Figure 4. 27 Biofilm/biomass ratios for GB2 at 24 h was compared for (A) THB media or (B) THB media 
supplemented with 1% glucose. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, 
F = (A) 45.33 and (B) 17.49 with posthoc Dunnett’s multiple comparison test comparing each sample against the 
control. 
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Conclusions 
We synthesized a number of human milk trisaccharides and unnatural congeners in order 
to probe the activity of single entity compounds. Our synthetic strategy focused on functionalizing 
a lactose core at the C3’ position using a common lactose acceptor. We developed a robust 
synthesis of a C3’ lactose acceptor that was acetylated at C4’ and otherwise perbenzylated. 
Additionally, each glycosylation reaction was optimized on a gram scale to yield hundreds of 
milligrams of deprotected trisaccharides to be used for assays testing their biological activity. In 
doing this, we found that even though 3’,4’-lactose diols can exhibit selective nucleophilicity at 
the equatorial C3’ hydroxyl, yields can be improved when there is no competition with the axial 
C4’ hydroxyl.  
Our goal was to identify the minimum pharmacophore needed to observe antimicrobial and 
anti-biofilm activity.  We established that lactose and monosaccharide building blocks have no 
antibacterial activity and little to no anti-biofilm activity against GBS. However, activity begins to 
surface once an additional monomeric unit is added to the scaffold.  
The structure-activity relationship has revealed that both fucose and galactose residues are 
important for antibacterial activity. Fucosylated HMOs are of particular interest as they account 
for up to 80% of the oligosaccharides in human milk.55 Thus, it is notable that the fucosylated 
trisaccharides exhibit both antimicrobial and anti-biofilm activity in all strains in at least one 
growth condition. Galactose is also of importance as it is one of the three building blocks that 
forms the backbone of every HMO. However, GOS, a polymer of galactose residues with glucose 
at the reducing end, does not exhibit antimicrobial or anti-biofilm activity except under one growth 
condition for one strain (24% biofilm reduction in GB590 in THB supplemented with 1% glucose). 
  180 
It would be interesting to explore the effects of a fucose polymer, such as sulfated fucans, on the 
growth and biofilm of GBS to determine if the activity lies in the lactose core decorated with 
fucose or in an oligosaccharide containing a fucose residue or branch. Sulfated fucans contain 
negatively charged sulfate groups which could also influence their antimicrobial or anti-biofilm 
properties. In the same vein, it is interesting to note that the sialic acid trisaccharide derivatives 
had no effect on the growth of GBS, but colominic acid, a sialic acid polymer, was able to inhibit 
growth. This could be due to the ability of colominic acid to better mimic the sialic acid containing 
capsule of GBS, resulting in a feedback inhibition that inhibits bacterial growth. 
Many of the monosaccharides and commercially available oligosaccharides (sucrose, 
lactulose, lactitol, maltose, and cellobiose) increased the growth of GBS across all strains under at 
least one growth condition. This indicates that GBS has the ability to utilize smaller carbohydrates 
for growth and metabolic purposes. Genetic sequencing could reveal if GBS has enzymes specific 
for these types of saccharides or if the enzymes can act promiscuously to accommodate a wider 
range of carbon sources. 
In terms of anti-biofilm activity, it was of particular interest that the PEGylated derivative 
showcased notable inhibition of biofilm. Given the length of the PEG linker, this finding supports 
our previously established hypothesis that larger oligosaccharides are responsible for that mode of 
activity. Installing PEG branches of varying lengths as well as other poly-ether compounds would 
provide an interesting route to explore this hypothesis.  
While the results obtained in this study were modest in comparison to our previous studies, 
it is important to note that human milk itself contains a highly variable composition of HMOs. 
Thus, it is likely that these molecules work in synergy to provide the effects we have previously 
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observed. Further studies with combinations of individual HMOs could be conducted to probe the 
synergistic effects that result in increased antimicrobial and anti-biofilm activity.  
Experimental Methods 
Bacterial Strains and Culture Conditions  
All S. agalactiae strains (CNCTC 10/84, GB590, GB2) was cultured on tryptic soy agar 
plates supplemented with 5% sheep blood (blood agar plates) at 37 °C in ambient air overnight. 
Bacteria were subcultured from blood agar plates into Todd-Hewitt broth (THB) and incubated 
under shaking conditions at 37 °C in ambient air overnight. The following day, bacterial density 
was measured spectrophotometrically using optical density measurements at 600 nm (OD600), and 
bacterial numbers were determined using the predetermined coefficient of 1 OD600 = 109 CFU/mL. 
Bacterial Growth and Biofilm Assays 
S. agalactiae strains were grown overnight as described above prior to subculturing 106 
bacterial cells into 200 µL of THB or THB supplemented with 1% glucose in 96-well tissue culture 
plates (Corning, Inc.). Bacterial cells were added to wells containing media alone or wells 
supplemented with 5 mg/mL in individual carbohydrates. Cultures were incubated under static 
conditions at 37 ° C in ambient air for 24 h. Optical density (OD600) was measured for each sample 
as a quantification of bacterial growth. The medium was aspirated, and each well was washed once 
with phosphate-buffered saline (PBS, pH 7.4) to remove nonadherent cells. Wells were then 
stained with a 10% crystal violet solution for 15 min. After staining, wells were washed with PBS 
and then allowed to dry at room temperature for 30 min. After drying, crystal violet staining was 
solubilized with a 4:1 ethanol/acetone solution. The absorbance (OD560) was measured for each 
sample as a measure of biofilm formation. The data shown represents 3 independent experiments, 
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each with 3 technical replicates. Results were analyzed compared to controls in the absence of 
HMOs and expressed a percentage of biomass or biofilm/biomass of the control. Tables show 
percent change in biofilm/biomass ratio with negative numbers indicating a net decrease in biofilm 
production and positive numbers indicating a net increase in biofilm production. 
Trisaccharide Synthesis 
General Procedure. All non-aqueous reactions were carried out under an inert argon 
atmosphere with dry solvents under anhydrous conditions, unless otherwise stated. All air- or 
moisture-sensitive liquids were transferred via disposable or oven-dried stainless syringes. 
Reaction temperature were monitored and controlled via thermocouple thermometer and 
corresponding hot plate stirrer. Reactions were conducted at room temperature (approximately 23 
°C) unless otherwise noted. Flash column chromatography was performed as described by Still et. 
al. using silica gel (230-400 mesh). Analytical thin-layer chromatography (TLC) was performed 
on Sorbtech Silica XHL UV254, glass backed, 250 µm plates or Silicycle SiliaPlate aluminum 
backed, F-254, 200 µm plates and visualized using cerium ammonium molybdate stain and heat 
or p-anisaldehyde stain and heat.  Yields refer to chromatographically and spectroscopically (1H 
NMR) homogeneous material, unless otherwise stated.  
Materials. Dry acetonitrile (MeCN), dichloromethane (DCM), diethyl ether (Et2O), 
tetrahydrofuran (THF) and toluene (PhMe) were obtained by passing the previously degassed 
solvent through activated alumina columns and stored over 4Å or 3Å molecular sieves.  Dry 
triethylamine (Et3N) was obtained by distillation from CaH2, followed by storage over KOH 
pellets. N-iodosuccinimide and N-bromosuccinimide were recrystallized before use. All other 
reagents were purchased at the highest commercial quality and used without further purification, 
unless otherwise stated. 
  183 
Instrumentation: Infrared spectra were obtained as thing films on NaCl plates using a 
Thermo Scientific Nicolet FT-IR 100 series instrument and are reported in terms of frequency of 
absorbance (cm-1). 1H NMR spectra were obtained on a Bruker 400 or 600 MHz spectrometers 
and are reported as follows: chemical shifts (δ ppm), multiplicity (s = singlet, br = broad singlet, d 
= doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet 
of doublet of doublets, m = multiplet), coupling constants (Hz), integration, and assignment. 
Deuterated chloroform was calibrated to 7.26 ppm. Deuterated methanol was calibrated to 3.31 
ppm. Deuterated water was calibrated to 4.79 ppm. 13C NMR spectra were obtained on a Bruker 
100 or 150 MHz spectrometer with reporting relative to deuterated solvent signals. Deuterated 
chloroform was calibrated to 77.16 ppm. Deuterated methanol was calibrated to 49.0 ppm. 
Assignments were based on homonuclear correlation measurements and DEPT measurements. 
Low-resolution mass spectra (LCMS) were performed on a Surveyor MSQ spectrometer (Thermo 
Scientific). High-resolution mass spectra (HRMS) were recorded on a SYNAPT G2 or SYNAPT 
G2-S spectrometer (Waters) by electrospray ionization time-of-flight (ESI-TOF) reflectron 
experiments. Optical rotations were obtained using a JASCO P-2000 polarimeter. 
Compound Preparation 
 
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(((2R,3R,4S,5R,6R)-4,5-diacetoxy-2-
(acetoxymethyl)-6-(benzyloxy)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-
triyltriacetate (9). 32, 33 To a solution of lactose octaacetate (8 α,β) (1.0 eq., 6.6 g, 9.7 mmol, α:β 
17:83) and benzyl alcohol (1.8 eq., 2.3 mL, 22 mmol) in CH2Cl2 (35 mL) at 0 °C was added 
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BF3·Et2O (3.7 eq., 3.7 mL, 29 mmol). The reaction warmed to ambient temperature and stirred for 
14 h. The reaction was quenched with sat. aq. NaHCO3 and extracted with CH2Cl2 (2 x 20 mL). 
The combined organic extracts were washed with sat. aq. NaHCO3 (2 x 10 mL), water (1 x 10 
mL), and brine (1 x 10 mL). The organics were dried (MgSO4), filtered, and concentrated in vacuo. 
The crude residue was purified by flash column chromatography (hexanes→2:1 hexanes/EtOAc) 
to provide β-O-benzyl peracetylated lactose 9 (3.9 g, 66% relative to β anomer) as a white foam: 
mp: 66-69 °C; Rf 0.18 (1:1 hexanes/EtOAc); IR (thin film, cm-1): 2964, 1752; 1H NMR (400 MHz, 
CDCl3): δ 7.37-7.28 (m, 5H, Ar), 5.35 (dd, J=0.68, 3.28 Hz, 1H, H-4’), 5.16 (dd, J=9.20, 9.32 Hz, 
1H, H-3), 5.10 (dd, J=7.88, 10.40 Hz, 1H, H-2’), 4.97 (dd, J=7.84, 9.44 Hz, 1H, H-2), 4.96 (dd, 
J=3.37, 10.47 Hz, 1H, H-3’), 4.87 (d, J=12.28 Hz, 1H, PhCH), 4.60 (d, J=12.28 Hz, 1H, PhCH), 
4.54-4.50 (m, 1H, H-6b), 4.52 (d, J=7.88 Hz, 1H, H-1’), 4.49 (d, J=7.88 Hz, 1H, H-1), 4.15-4.05 
(m, 3H, H-6a’, H-6b’, H-6a), 3.87 (dt, J=1.04, 6.36 Hz, 1H, H-5’), 3.28 (dd, J=9.28, 9.64, 1H, H-
4), 3.58 (ddd, J=2.08, 4.96, 9.92 Hz, 1H, H-5), 2.15 (s, 3H, OAc), 2.14 (s, 3H, OAc), 2.06 (s, 3H, 
OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.01 (s, 3H, OAc), 1.97 (s, 3H, OAc); 13C NMR (100 
MHz, CDCl3): δ 170.3, 170.1, 170.0, 169.7, 169.5, 169.0, 136.6, 128.4, 128.0, 127.7, 111.0 (C-1), 
99.0 (C-1’), 76.2 (C-4), 72.7 (C-3), 72.6 (C-5), 71.6, 70.9, 70.7 (C-5’), 70.6 (PhCH), 69.0 (C-2’), 
66.5 (C-4’), 61.9 (C-6), 60.7 (C-6’), 20.8, 20.7, 20.6, 20.6, 20.4; LRMS calc. for C33H42O18Na 
[M+Na]+: 749.2, found 749.4. 
 
(2R,3R,4R,5S,6R)-2-(benzyloxy)-5-(((3aS,4R,6S,7R,7aR)-7-hydroxy-4-(hydroxymethyl)-2,2-
dimethyltetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-6-yl)oxy)-6-(hydroxymethyl)tetrahydro-
2H-pyran-3,4-diol (10). 33, 34 To a solution of 9 (1.0 eq., 4.0 g, 5.5 mmol) in MeOH (ca. 300 mL) 
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was added NaOMe (3.5 mL, 5.4 M). The reaction was stirred 2 h and Dowex 50Wx8 was added 
until the solution reached a neutral pH. The resulting suspension was filtered and concentrated in 
vacuo to yield a white solid. To a suspension of this white solid (2.4 g, crude) in acetone (ca. 200 
mL) was added 2,2-dimethoxy propane (12 eq., 8.0 mL, 65 mmol) and p-toluenesulfonic acid 
monohydrate (0.1 eq., 0.1 g, 06 mmol). The reaction mixture was stirred 60 h, at which point the 
solution became homogenous, and was concentrated in vacuo and recrystallized from hot ethanol 
(200 proof) to yield 3’,4’-acetonide 10 (1.2 g, 47%) as a white solid: mp: 161-164 °C; Rf 0.43 (9:1 
EtOAc/MeOH); IR (thin film, cm-1): 3391, 2923, 2914, 2872, 2866, 2360, 2329; 1H NMR (400 
MHz, MeOD): δ 7.25-7.42 (m, 5H, Ar), 4.92 (d, J=11.80, 1H, PhCH), 4.67 (d, J=11.85, 1H, 
PhCH), 4.39 (d, J=7.90, 1H, H-1), 4.37 (d, J=8.28, 1H, H-1’), 4.19 (dd, J=2.04, 5.48, 1H, H-4’), 
4.05 (dd, J=5.73, 7.26), 3.92-3.95 (m, 1H, H-5’), 3.92 (dd, J=2.29, 12.13, 1H, H-6a), 3.84 (dd, 
J=4.20, 12.10, 1H, H-6b), 3.75-3.79 (m, 2H, H-6’), 3.59 (dd, J=8.60, 9.30, 1H, H-4), 3.52 (dd, 
J=8.60, 9.04, 1H, H-3), 3.45 (dd, J=7.87, 7.73, 1H, H-2’), 3.40 (ddd, J=2.48, 4.12, 9.36, 1H, H-5), 
3.32 (m, 1H, H-2), 1.47 (s, 3H, CH3), 1.32 (s, 3H, CH3); 13C NMR (100 MHz, MeOD): δ 139.0, 
129.3, 129.2, 128.7, 111.1 (C(CH3)2), 104.2 (C-1), 103.1 (C-1’), 81.0 (C-3), 80.9 (C-3’), 76.5 (C-
4), 76.4 (C-5), 75.3 (C-5’), 75.1 (C-4’), 74.9 (C-2), 74.5 (C-2’), 71.8 (PhCH), 62.4 (C-6’), 61.9 
(C-6), 28.4 (CH3), 26.5 (CH3); LRMS calc. for C22H32O11Na [M+Na]+: 495.2, found 495.3.  
 
(2R,3R,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-
tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-
3,4-diol (11). 33, 34 To a solution of 10 (1.0 eq., 1.2 g, 2.6 mmol) in DMF (13 mL) at 0 °C was 
added benzyl bromide (9.1 eq., 2.8 mL, 24 mmol) followed by NaH (60% wt, 8.3 eq., 0.86 g, 22 
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mmol). The reaction stirred for 4 h and was poured into ice and extracted with EtOAc (3 x 50 mL). 
The combined organic extracts were washed with water (3 x 20 mL) and brine (1 x 20 mL), dried 
(MgSO4), filtered, and concentrated in vacuo to a yellow oil. The crude material was purified by 
flash column chromatography (hexanes→4:1 hexanes/EtOAc) to yield the perbenzylated 
acetonide as a clear oil (2.3 g, 96%). A solution of the perbenzylated acetonide (2.3 g, 2.492 mmol) 
in 80% aq. acetic acid (100 mL) stirred at 65 °C for 4 h. The reaction was quenched with sat. aq. 
NaHCO3 and extracted with CH2Cl2 (3 x 50 mL). The combined organic extracts were washed 
with sat. aq. NaHCO3 (2 x 20 mL) and brine (1 x 20 mL), dried (MgSO4), filtered, and concentrated 
in vacuo. The crude material was purified by flash column chromatography (4:1 hexanes/EtOAc) 
to yield lactose acceptor 11 (2.0 g, 91%) as a white solid: mp: 109-112 °C; Rf 0.27 (1:1 
hexanes/EtOAc); IR (thin film, cm-1): 3464, 3063, 3030, 2870; 1H NMR (400 MHz, CDCl3): δ 
7.21-7.38 (m, 30H, Ar), 4.98 (d, J=10.84, 1H, PhCH), 4.95 (d, J=11.76, 1H, PhCH), 4.91 (d, 
J=10.84, 1H, PhCH), 4.81 (d, 11.60, 1H, PhCH), 4.77 (d, 11.08, 1H, PhCH), 4.73 (d, J=10.80, 1H, 
PhCH), 4.67 (d, J=11.60, 1H, PhCH), 4.66 (d, J=12.08, 1H, PhCH), 4.62 (d, J=12.12, 1H, PhCH), 
4.50 (d, J=7.68, 1H, H-1), 4.47 (d, J=12.08, 1H, PhCH), 4.45 (d, J=11.76, 1H, PhCH), 4.44 (d, 
J=7.08, 1H, H-1’), 4.39 (d, J=12.00, 1H, PhCH), 4.02 (dd, J=9.16, 9.40, 1H, H-4), 3.95 (t, J=2.76, 
1H, H-4’), 3.83 (dd, J=4.08, 10.92, 1H, H-6), 3.57-3.64 (m, 2H, H-3, H-6), 3.48-3.52 (m, 2H, H-
2, H-6’), 3.38-3.45 (m, 3H, H-5, H-2’, H-3’), 3.36 (q, J=5.72, 1H, H-5’), 2.46 (d, J=3.6, 1H, OH), 
2.37 (d, J=4.64, 1H, OH); 13C NMR (100 MHz, CDCl3): δ 139.3, 138.7, 138.5, 138.4, 138.13, 
137.7, 128.7, 128.6, 128.5, 128.5, 128.41, 138.2, 128.2, 128.1, 128.1, 128.0, 127.9, 127.9, 127.8, 
127.7, 127.4, 102.72 (C-1’), 102.7 (C-1), 83.0 (C-3), 82.0 (C-2), 80.2 (C-2’), 76.7 (C-4), 75.4 
(PhCH), 75.3 (C-5), 75.1 (PhCH), 75.0 (PhCH), 73.7 (C-3’), 73.6 (PhCH), 73.4 (PhCH), 73.0 (C-
5’), 71.1 (PhCH), 68.9 (C-4’), 68.8 (C-6’), 68.4 (C-6); LRMS calc. for C54H58O11Na [M+Na]+: 
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905.4, found 905.5. 
 
(2R,3S,4R,5R,6S)-6-methyltetrahydro-2H-pyran-2,3,4,5-tetrayltetraacetate (13). 36 To a 
solution of L-fucose (0.71 g, 4.3 mmol) in CH2Cl2 (43 mL) was added pyridine (5.1 eq., 1.7 mL, 
22 mmol), acetic anhydride (4.9 eq., 2.0 mL, 21 mmol), and 4-dimethylaminopyridine (0.12 eq., 
0.060 g, 0.51 mmol). The reaction mixture stirred at ambient temperature for 4 h. The reaction was 
quenched with 1 M HCl and extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts 
were washed with 1 M HCl (1 x 15 mL), water (1 x 15 mL), and brine (1 x 15 mL), dried (MgSO4), 
filtered, and concentrated in vacuo to yield peracetyaled fucose 12 (1.2 g, 85%, 3:1 α:β ratio) as a 
clear oil: Rf 0.29 (2:1 hexanes:EtOAc); IR (thin film, cm-1): 2988, 1750, 1224; 1H NMR (400 MHz, 
CDCl3) (α anomer): δ 6.33 (d, J=2.80 Hz, 1H, H-1), 5.33-5.37 (m, 3H, H-3, H-4, H-2), 4.27 (q, 
J=6.48 Hz, 1H, H-5), 2.18 (s, 3H, OAc), 2.15 (s, 3H, OAc), 2.01 (s, 3H, OAc), 2.00 (s, 3H, OAc), 
1.16 (d, J=6.52 Hz, 3H, H-6); (β anomer): δ 5.69 (d, J=8.28 Hz, 1H, H-1), 5.30-5.34 (m, 1H, H-
2), 5.27 (dd, J=0.84, 3.40 Hz, 1H, H-4), 5.07 (dd, J=3.44, 10.40 Hz, 1H, H-3), 3.95 (dq, J=0.96, 
6.44 Hz, 1H, H-5), 2.18 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.03 (s, 3H, OAc), 1.99 (s, 3H, OAc), 
1.22 (d, J=6.44 Hz, 3H, H-6); 13C NMR (100 MHz, CDCl3) (α anomer): δ 170.7, 170.3, 170.1, 
169.3, 90.11 (C-1), 70.7 (C-3), 68.0 (C-4), 67.4 (C-5), 66.6 (C-2), 21.1 (OAc), 20.8 (OAc), 20.8 
(OAc), 20.7 (OAc), 16.1 (C-6); (β anomer): δ 170.7, 170.3, 170.1, 169.3, 92.3 (C-1), 71.4 (C-3), 
70.4 (C-5), 70.1 (C-4), 68.1 (C-2), 21.0 (OAc), 20.8 (OAc), 20.8 (OAc), 20.7 (OAc), 19.1 (C-6); 
LRMS calc. for C14H20O9Na [M+Na]+: 355.1, found 354.9. 
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(2S,3R,4R,5S,6R)-2-methyl-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyltri acetate (14). 36 
To a solution of 13 (1.0 eq., 1.2 g, 3.7 mmol) in CH2Cl2 (36 mL) at 0 °C was added thiophenol 
(2.0 eq., 0.75 mL, 7.4 mmol) and SnCl4 (2.0 eq., 0.86 mL, 7.4 mmol). The reaction warmed to 
ambient temperature and stirred for 20 h. The reaction was quenched with sat. aq. NaHCO3 and 
extracted with CH2Cl2 (2 x 30 mL). The combined organic extracts were washed with sat. aq. 
NaHCO3 (1 x 15 mL), water (1 x 15 mL), and brine (1 x 15 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The crude oil was purified by flash column chromatography (toluene→9:1 
toluene/EtOAc) to yield 14 (0.87 g, 62%, 1:15 α:β ratio) as a yellow oil: Rf (β anomer) 0.32 (2:1 
hexanes/EtOAc), (α anomer) 0.40 (2:1 hexanes/EtOAc); IR (thin film, cm-1): 1749, 1222; 1H NMR 
(400 MHz, CDCl3): δ 7.51-7.53 (m, 2H, Ar), 7.31-7.33 (m, 3H, Ar), 5.27 (dd, 1H, J=0.68, 3.32 
Hz, H-4), 5.23 (t, 1H, J=9.96 Hz, H-2), 5.06 (dd, 1H, J=3.36, 9.92 Hz, H-3), 4.71 (d, 1H, J=9.92, 
H-1), 3.84 (dq, 1H, J=0.76, 6.44, H-5), 2.15 (s, 3H, OAc), 2.09 (s, 3H, OAc), 1.98 (s, 3H, OAc), 
1.25 (d, 3H, J=6.44 Hz, H-6); 13C NMR (100 MHz, CDCl3): δ 170.6, 170.1, 169.4, 132.3 (Ph), 
128.8 (Ph), 127.9 (Ph), 86.5 (C-1), 73.1 (C-4), 72.4 (C-2), 70.3 (C-3), 67.3 (C-5), 20.8 (OAc), 20.6 
(OAc), 20.6 (OAc), 16.4 (C-6); LRMS calc. for C19H27O8S [M+CH3OH+H]+: 415.1, found 414.0. 
 
(2S,3R,4R,5S,6R)-3,4,5-tris(benzyloxy)-2-methyl-6-(phenylthio)tetrahydro-2H-pyran (15). 
36 To a solution of 14 (5.5 g, 14 mmol) in methanol (ca. 90 mL) was added NaOMe (3.0 mL). The 
reaction stirred for 3 h and Dowex 50Wx8 was added until the solution reached a neutral pH. The 
resulting suspension was filtered and concentrated in vacuo. To a solution of the crude intermediate 
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in DMF (50 mL) cooled to 0°C was added benzyl bromide (5.0 eq., 8.5 mL, 72 mmol) followed 
by Bu4NI (0.1 eq., 0.62 g, 1.4 mmol). After 10 min of stirring, NaH (60 wt%, 5.0 eq., 2.7 g, 72 
mmol) was added in one portion. The reaction was warmed to room temperature and stirred for 16 
h. The reaction was poured onto ice and extracted with CH2Cl2 (3 x 50 mL). The combined organic 
extracts were washed with water (1 x 25 mL) and brine (1 x 25 mL), dried (MgSO4), filtered, 
concentrated in vacuo. The resulting crude oil was purified by flash column chromatography 
(hexanes→4:1 hexanes/EtOAc) to yield 15 (5.7 g, 80%) as a white solid: mp: 103-105 °C; Rf 0.57 
(2:1 hexanes/EtOAc), IR (thin film, cm-1): 3062, 3030, 2867, 1124, 1090, 1067; 1H NMR (400 
MHz, CDCl3): δ 7.58-7.61 (m, 2H, Ph), 7.29-7.41 (m, 15, Bn), 7.20-7.22 (m, 3H, Ph), 5.02 (d, 1H, 
J=11.64 Hz, Bn), 4.80 (d, 1H, J=11.64 Hz, Bn), 4.72-4.75 (m, 3H, Bn), 4.68 (d, 1H, J=11.64, Bn) 
4.61 (d, 1H, J=9.68 Hz, H-1) 3.94 (t, 1H, J=9.4 Hz, H-2), 3.65 (d, 1H, J=2.36 Hz, H-4), 3.61 (dd, 
1H, J=3.16, 9.16 Hz, H-3), 3.54 (q, 1H, J=6.44 Hz, H-5), 1.28 (d, 3H, J=6.4 Hz, H-6); 13C NMR 
(100 MHz, CDCl3): δ 138.7, 138.3, 138.3, 134.3, 131.5, 128.7, 128.4, 128.3, 128.5, 128.1, 127.9, 
127.6, 127.6, 127.5, 127.4, 126.9, 87.5, 84.5, 77.1, 77.1, 75.5, 74.6, 74.5, 72.8, 17.24 (C-6); LRMS 
calc. for C33H34O4SNa [M+Na]+: 549.2, found 549.5. 
 
(2S,3S,4R,5R,6S)-3,4,5-tris(benzyloxy)-2-fluoro-6-methyltetrahydro-2H-pyran (16).36 To a 
solution of 15 (1.0 eq, 0.1017 g, 0.19 mmol) in CH2Cl2 (2.7 mL, 0.07 M) at -50 °C was added NBS 
(2.7 eq, 0.0915 g, 0.51 mmol) in one portion followed by dropwise addition of DAST (2.0 eq, 0.05 
mL, 0.38 mmol). The reaction was monitored by TLC and allowed to stir for 30 m and warm from 
-45 °C to -10 °C. The reaction was then cooled to -60 °C and quenched with MeOH (1.5 mL) and 
concentrated in vacuo. The resulting oil was dissolved in EtOAc and washed with sat. aq. 
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NaS2O3 (2 x 10 mL), H2O (2 x 10 mL), brine (1 x 10 mL), dried over MgSO4, concentrated in 
vacuo, and purified by flash column chromatography (5:1 hexanes/EtOAc) to yield lactose 
acceptor to yield α-fucosyl fluoride 16 (0.0611 g, 73%) and β-fucosyl fluoride (0.0170 g, 20%) as 
clear oils: Rf (α) 0.56 (4:1 hexanes/EtOAc), IR (thin film, cm-1): 3032, 2932, 1713, 1240; 1H NMR 
(400 MHz, CDCl3): δ 7.42-7.30 (m, 15H, Ph), 5.59 (dd, 1H, J=2.72, 54.1 Hz, H-1), 5.01 (d, 1H, 
J=11.4 Hz, PhCH), 4.87 (dd, 2H, J=2.4, 11.5 Hz, PhCH), 4.77 (dd, 2H, J=11.4, 11.5 Hz, PhCH), 
4.67 (d, 1H, J=11.5 Hz, PhCH), 4.11-4.04 (m, 2H, H-2, H-5), 3.96 (dd, 1H, J=2.64, 9.96 Hz, H-
3), 3.72 (d, 1H, J=1.68 Hz, H-4), 1.18 (d, 3H, J=6.48 Hz, H-6); 13C NMR (100 MHz, CDCl3): δ 
143.9, 138.4, 138.2, 138.0, 132.2, 129.0, 128.3, 127.8, 127.7, 127.6, 125.4, 106.3 (d, J=223 Hz, 
C-1), 78.7 (C-3), 77.2 (C-4), 75.6 (d, J=23.8 Hz, C-2), 74.9 (PhCH), 73.6 (PhCH), 73.2 (PhCH), 
69.1 (d, J=3.17 Hz, C-5), 16.5 (C-6). LRMS calc. for C30H36NO5Na [M+ACN+MeOH+Na]+: 
532.2, found 532.6. 
 
methyl(4S,5R,6R)-5-acetamido-2,4-dihydroxy-6-((1R,2R)-1,2,3-trihydroxypropyl) 
tetrahydro-2H-pyran-2-carboxylate (18).37 To a suspension of N-acetylneuraminic acid (1.0 eq, 
3.3841 g, 10.94 mmol) in methanol (100 mL) was added Dowex50WX8 resin and the resulting 
slurry stirred at room temperature for 16 h. The resin was removed by filtration and the resulting 
liquid concentrated in vacuo to yield 18 (3.1838 g, 90%) as a white solid: mp 165-167 °C; Rf: 0.43 
(4:1 EtOAc/MeOH), IR (thin film, cm-1): 3398, 2360, 2340, 1748, 1635; 1H NMR (400 MHz, 
MeOD): δ 8.14 (d, 1H, J=8.56 Hz, N-H), 4.05 (td, 1H, J=4.88, 9.76 Hz, H-4), 4.00 (dd, 1H, J=1.24, 
10.52 Hz, H-6), 3.84-3.77 (m, 2H, H-9, H-5), 3.78 (s, 3H, OCH3), 3.70 (ddd, 1H, J=2.80, 5.56, 
8.88 Hz, H-8), 3.62 (dd, 1H, J=5.64, 11.2 Hz, H-9), 3.48 (dd, 1H, J=1.12, 9.08 Hz, H-7), 2.22 (dd, 
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1H, J=4.92, 12.9 Hz, H-3eq), 2.02 (s, 3H, OAc), 1.89 (dd, 1H, J=11.4, 12.7 Hz, H-3ax); 13C NMR 
(100 MHz, CDCl3): δ 175.1 (C-1), 171.8 (Ac), 96.7 (C-2), 72.1 (C-6), 71.7 (C-8), 70.2 (C-7), 67.9 
(C-4), 64.9 (C-9), 54.3 (C-5), 53.12(OCH3), 40.7 (C-3), 22.6 (Ac); LRMS calc. for C12H22NO9 
[M+H]+: 324.1, found 324.3. 
 
(1S,2R)-1-((2R,3R,4S)-3-acetamido-4-acetoxy-6-hydroxy-6-(methoxycarbonyl)tetrahydro-
2H-pyran-2-yl)propane-1,2,3-triyl triacetate (19).37 To a solution of 18 (1.0 eq, 3.9720 g, 10.5 
mmol) in acetyl chloride (42 mL) at 0° C was added methanol (1.0 eq, 0.42 mL, 10.0 mmol) 
dropwise in a sealed reaction vessel, not allowing any gases formed to escape during the duration 
of the reaction. The reaction mixture was stirred at room temperature for 17 h. The mixture was 
diluted with ethyl acetate (50 mL) and washed with sat. NaHCO3 (3 x 100 mL), water (50 mL), 
and brine (50 mL), dried over MgSO4, filtered, and concentrated in vacuo. The resulting residue 
was dissolved in acetone (50 mL) and water (12.5 mL). Ag2CO3 (3.1 g) was added in one portion 
and the slurry was stirred in the dark for 36 h. The solid was filtered, concentrated to ca. 10 mL in 
vacuo, diluted with ethyl acetate and washed with water (50 mL) and brine (50 mL). The organic 
layer was dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was purified 
by flash column chromatography (1:1 EtOAc/hexanes→2:1 EtOAc/hexanes) to yield 19 (3.5308 
g, 68%) as a white solid: mp: 169-170 °C; Rf 0.28 (EtOAc); IR (thin film, cm-1): 3368, 2927, 1714, 
1368, 1030; 1H NMR (400 MHz, CDCl3): 5.62 (d, 1H, J=9.48 Hz, N-H), 5.34 (dd, 1H, J=1.44, 
5.68 Hz, H-7) 5.25 (ddd, 1H, J=2.44, 5.31, 7.64 Hz, H-8), 5.23-5.18 (m, 1H, H-4), 4.50-4.46 (m, 
2H, OH, H-9), 4.18-4.12 (m, 2H, H-6, H-5), 4.02 (dd, 1H, J=7.44, 12.3 Hz, H-9), 3.86 (s, 3H, 
OCH3), 2.26 (dt, 1H, J=1.68, 12.8 Hz, H-3eq), 2.18 (dd, 1H, J=5.32, 12.8 Hz, H-3ax), 2.14 (s, 3H, 
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Ac), 2.10 (s, 3H, Ac), 2.03 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.90 (s, 3H, Ac); 13C NMR (100 MHz, 
CDCl3): δ 171.1, 171.1, 171.0, 170.4, 170.3, 169.2, 95.0 (C-2), 71.3 (C-8), 71.2 (C-6), 69.4 (C-4), 
68.1 (C-7), 62.8 (C-9), 53.7 (OCH3), 49.7 (C-5), 36.2 (C-3), 23.3, 21.2, 21.0, 20.9. LRMS calc. 
for C20H30NO13 [M+H]+: 492.2, found 492.3. 
  
(1S,2R)-1-((2R,3R,4S)-3-acetamido-4-acetoxy-6-((bis(benzyloxy)phosphanyl)oxy)-6-
(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)pro pane-1,2,3-triyltriacetate (20).37 To a 
solution of 19 (1.0 eq., 86.1 mg, 0.102 mmol) in CH2Cl2 (2.0 mL) was added 1H-tetrazole (3% wt 
in CH3CN, 2.07 mL) and (BnO)2PNiPr2 (5.5 eq., 0.19 mL, 0.565 mmol) to yield a cloudy solution. 
The reaction was quenched with 1 M HCl (0.5 mL), and the aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were washed with water (1 x 2 mL) and brine 
(1 x 2 mL), dried (MgSO4), filtered, and concentrated in vacuo. The resulting residue was purified 
by flash column chromatography (1:1 hexanes/EtOAc) to yield 20 (122 mg, 94%) as a white foam: 
mp: 31-33 °C; Rf 0.45 (EtOAc); IR (thin film, cm-1): 3054, 2987, 1748, 1265; 1H NMR (400 MHz, 
CDCl3): δ 7.50-7.52 (m, 2H, Ar) 7.42-7.46 (m, 2H, Ar), 7.30-7.38 (m, 6H, Ar), 5.20 (dd, J=9.84, 
13.76, 1H, PhCH), 5.14-5.16 (m, 2H, H-8, H-7), 4.94-4.50 (m, 2H, PhCH), 4.85-4.92 (m, 2H, 
PhCH, H-4), 4.58 (dd, J=2.2, 12.66, 1H, H-9) 4.31 (d, J=10.4, 1H, NH), 4.10-4.15 (m, 1H, H-9), 
4.01 (q, J=10.52, 1H, H-5), 3.73 (s, 3H, OCH3), 2.41 (dd, J=4.96, 13.04, 1H, H-3eq), 2.00-2.12 (m, 
1H, H-3ax), 2.09 (s, 6H, OAc), 2.02 (s, 3H, OAc), 1.99 (s, 3H, OAc), 1.80 (s, 3H, OAc); 13C NMR 
(100 MHz, CDCl3): δ 170.7, 170.6, 170.5, 170.2, 167.0, 167.8, 138.8 (d, J=2.2), 138.1 (d, J=5.5), 
128.9, 128.6, 128.2, 128.0, 127.9, 127.8, 98.0 (d, J=7.3, C-2), 72.4, (C-6), 72.0 (C-8), 68.5 (C-4), 
62.8 (C-9), 53.3 (OCH3), 48.5 (C-5), 37.9 (C-3); LRMS calc. for C34H42NO15PNa [M+Na]+: 758.2, 
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found 758.3. 
 
(1S,2R)-1-((2R,3R,4S)-3-acetamido-4-acetoxy-6-(ethylthio)-6-(methoxycarbonyl)tetrahydro 
-2H-pyran-2-yl)propane-1,2,3-triyl triacetate (21).39 To a solution of 18 (1.0 eq, 1.3 g, 4.0 
mmol) in pyridine (20 mL) was added acetic anhydride (10 eq, 4.2 mL, 44 mmol) then DMAP (0.1 
eq, 51.1 mg, 0.418 mmol). The reaction mixture stirred under argon atmosphere at 0 °C and 
warming to room temperature overnight. The reaction was quenched with CuSO4 and extracted 
with CH2Cl2 (50 mL). The organic extracts were washed with water (3 x 20 mL), then CuSO4 (1 
x 20 mL), water (3 x 20 mL), brine (1 x 20 mL), dried over MgSO4, and concentrated to yield a 
peracetylated intermediate. To the crude intermediate in CH2Cl2 (6.5 mL) at 0 °C was added ethane 
thiol (0.175 mL, 2.4 mmol) then BF3•Et2O (0.33 mL, 2.7 mmol). The reaction mixture was allowed 
to warm to room temperature and stir for 17 h. The reaction was quenched with sat. aq. 
NaHCO3 and extracted with CH2Cl2. The organic extracts were washed with NaHCO3 (2 x 10 mL) 
and brine (1 x 10 mL), dried over MgSO4, and concentrated to a white foam. The foam was purified 
over flash column chromatography (4:1 hexanes:EtOAc→EtOAc) to yield 21 as a white foam 
(0.89 g, 42%): mp: 75-77 °C; Rf 0.57 (EtOAc); IR (thin film, cm-1): 2967, 1745, 1663, 1545, 1228; 
1H NMR (400 MHz, CDCl3): δ 5.51 (d, 1H, J=10.2 Hz, N-H), 5.42 (d, 1H, J=2.49 Hz, H-7), 5.32-
5.22 (m, 1H, H-4), 5.11 (dt, 1H, J=2.60, 8.00 Hz, H-8), 4.78 (dd, 1H, J=2.40, 12.4 Hz, H-9), 4.33 
(dd, 1H, J=2.36, 7.60 Hz, H-6), 4.14 (dd, 1H, J=8.08, 12.3 Hz, H-9), 4.07 (q, 1H, J=10.5 Hz, H-
5), 3.79 (s, 3H, OCH3), 2.63-2.46 (m, 3H, H-3eq, SCH2CH3), 2.15 (d, 1H, J=4.16 Hz, H-3ax), 2.11 
(s, 3H, Ac), 2.06 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.86 (s, 3H, Ac), 1.19 (t, 3H, J=7.52 Hz, SCH2CH3); 
13C NMR (100 MHz, CDCl3): δ 171.1, 171.0, 170.6, 170.3, 170.3, 168.5, 85.1, 72.7, 72.3, 69.4, 
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68.7, 62.6, 53.0, 49.6, 37.4, 23.2, 22.8, 21.1, 21.0, 20.9, 20.8, 14.2. 
  
(2S,3R,4R,5S,6R)-6-(acetoxymethyl)-3-(((2,2,2trichloroethoxy)carbonyl)amino)tetrahydro-
2H-pyran-2,4,5-triyltriacetate (23).40 To a solution of D-glucosamine hydrochloride (1.17 g, 
3.30 mmol) in pyridine (15 mL) was added acetic anhydride (13 eq., 4 mL, 42.3 mmol) and a 
catalytic amount of 4-dimethylaminopyridine. The reaction stirred for 17 h and was quenched with 
1 M HCl (15 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were 
washed with 1 M HCl (2 x 10 mL), sat. aq. NaHCO3 (1 x 10 mL), water (1 x 10 mL), and brine (1 
x mL), dried (MgSO4), filtered, and concentrated in vacuo to yield 23 (1.58 g, 92%) as a white 
foam: mp: 35-38 °C; Rf 0.21 (2:1 hexanes/EtOAc); IR (thin film, cm-1): 3328, 2960, 1753, 1225; 
1H NMR (400 MHz, CDCl3) (α anomer): δ 6.24 (d, J=3.65, 1H, H-1), 5.28 (dd, J=9.76, 10.50, 1H, 
H-3), 5.20 (dd, J=9.62, 9.89, 1H, H-4), 5.11 (d, J=9.42, H1, NH), 4.82 (d, J=12.13, 1H, Troc-CH), 
4.62 (d, J=12.05, Troc-CH), 4.28 (d, J=4.09, 12.51, 1H, H-6), 4.21 (d, J=3.71, 9.73, 1H, H-2), 4.06 
(d, J=2.14, 12.38, 1H, H-6), 4.01 (Troc-CH2), 2.21 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.05 (s, 3H, 
OAc), 2.04 (s, 3H, OAc), (β anomer): δ 5.74 (d, J=8.76, 1H, H-1); 13C NMR (100 MHz, CDCl3): 
δ 171.4, 170.8, 169.3, 168.7, 154.2, 95.4 (Troc-CCl3), 90.6 (C-1), 74.8 (Troc-CH2), 70.5 (C-3), 
69.9 (C-5), 67.6 (C-4), 61.6 (C-6), 53.4 (C-2), 21.1 (OAc), 20.8 (OAc), 20.8 (OAc), 20.7 (OAc); 
LRMS calc. for C19H25Cl3N2O11Na [M+ACN+Na]+: 585.0, found 585.1. 
  
(2R,3S,4R,5R)-2-(acetoxymethyl)-6-hydroxy-5-(((2,2,2-trichloroethoxy)carbonyl)amino) 
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tetrahydro-2H-pyran-3,4-diyldiacetate (24).40 To a solution of 23 (1.0 eq, 3.2 g, 6.1 mmol) in 
THF (30 mL, 0.2 M) was added dimethylaminopropylamine (5.0 eq., 3.8 mL g, 30 mmol). The 
reaction stirred at room temperature for 110 min and was quenched with 1 M HCl (50 mL). The 
reaction was diluted with CH2Cl2, washed with 1 M HCl (2 x 30 mL) and brine (30 mL), dried 
over MgSO4, filtered, concentrated in vacuo to yield 24 (2.8 g, 95%) as a white solid: mp: 175-
178 °C; Rf  (α anomer) 0.17 (2:1 hexanes/EtOAc); IR (thin film, cm-1): 3332, 1747, 1237; 1H NMR 
(400 MHz, CDCl3): δ 5.34-5.36 (m, 2H, H-3, H-1), 5.13 (t, J=9.56, 1H, H-5), 4.79 (d, J=12.00, 
1H, Troc-CH), 4.64 (d, J=12.04, 1H, Troc-CH), 4.21-4.29 (m, 2H, H-4, H-6), 4.12-4.17 (m, 1H, 
H-6), 4.06 (dt, J=3.60, 10.44, 1H, H-2), 3.13 (d, J=2.56, 1H, OH), 2.10 (s, 3H, OAc), 2.04 (s, 3H, 
OAc), 2.01 (s, 3H, OAc); 13C NMR (100 MHz, CDCl3): δ 171.12, 170.94, 169.59, 154.35, 95.47 
(Troc-CCl3), 92.00 (C-1), 74.76 (Troc-CH2), 70.79 (C-3), 68.37 (C-5), 67.99 (C-4), 62.14 (C-6), 
54.29 (C-2), 20.93 (OAc), 20.85 (OAc), 20.78 (OAc); LRMS calc. for C15H20Cl3NO10Na 
[M+Na]+: 502.01, found 501.15. 
  
(2R,3S,4R,5R,6R)-2-(acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)-5-(((2,2,2-
trichloroethoxy)carbonyl)amino)tetrahydro-2H-pyran-3,4-diyl diacetate (25).40 To a solution 
of 24 (1.0 eq, 3.2 g, 6.7 mmol) in CH2Cl2 (100 mL, 0.07 M) at 0 °C was added trichloroacetonitrile 
(10 eq., 6.7 mL, 67 mmol) and DBU (0.25 eq, 0.25 mL, 1.7 mmol). The reaction was stirred at 
room temperature for 3 h. The reaction was concentrated in vacuo, and purified by flash column 
chromatography (4:1 hexanes/EtOAc) to yield 25 (2.9 g, 70%) as a white foam: mp: 58-62 °C; Rf 
0.29 (2:1 hexanes/EtOAc); IR (thin film, cm-1): 3310, 1749, 1226; 1H NMR (400 MHz, CDCl3): δ 
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8.80 (s, 1H, N-H), 6.43 (d, J=3.56, 1H, H-1), 5.35 (dd, J=9.76, 10.56, 1H, H-3), 5.25 (dd, J=9.76, 
10.04, 1H, H-5), 5.17 (d, J=9.24, 1H, N-H), 4.74 (d, J=12.04, 1H, Troc), 4.70 (d, J=12.04, 1H, 
Troc), 4.26-4.32 (m, 2H, H-2, H-6), 4.10-4.16 (m, 2H, H-4, H-6), 2.08 (s, 3H, OAc), 2.06 (s, 6H, 
OAc); 13C NMR (100 MHz, CDCl3): δ 171.3, 170.7, 169.4, 160.6, 154.3, 95.4 (Troc-CCl3), 94.7 
(C-1), 90.6, 74.8 (Troc-CH2), 70.4 (C-3, C-4), 67.5 (C-5), 61.5 (C-6), 54.0 (C-2), 20.8 (OAc), 20.7 
(OAc); LRMS calc. for C17H20Cl6N2O10Na [M+Na]+: 644.9, found 645.2. 
  
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-hydroxytetrahydro-2H-pyran-3,4,5-triyl triacetate 
(27). To a solution of β-D-galactose pentaacetate (1.0 eq, 2.04 g, 5.23 mmol) in THF (26 mL, 0.2 
M) was added 3-(dimethylamino)-1-propylamine (5.0 eq, 3.26 mL). The reaction stirred for 90 
min. The reaction was quenched with 1 M HCl (50 mL) and diluted with CH2Cl2 (80 mL). The 
organic layer was washed with 1 M HCl (2 x 30 mL) and brine (1 x 30 mL), dried (MgSO4), and 
concentrated in vacuo to yield 27 (1.58 g, 87%, 5:2 β:α ratio) as an opaque gel: Rf: 0.22 (1:1 
hexanes/EtOAc); IR (thin film, cm-1): 3388, 3040, 2972, 2243, 1739; 1H NMR (400 MHz, CDCl3): 
β anomer: δ 5.53 (t, J=7.00 Hz, 1H, H-1), 5.48 (dd, J=1.16, 3.32 Hz, 1H, H-4), 5.41 (dd, J=3.28, 
10.81 Hz, 1H, H-3), 5.17 (ddd, J=1.04, 3.80, 11.08, 1H, H-2), 4.47 (dt, J=0.80, 6.60 Hz, 1H, H-5), 
4.16-4.05 (m, 2H, H-6), 2.91 (dd, J=1.12, 3.48 Hz, 1H, OH), 2.15 (s, 3H, OAc), 2.10 (s, 3H, OAc), 
2.06 (s, 3H, OAc), 1.99 (s, 3H, OAc); α anomer: δ 5.41 (m, 1H, H-3), 5.07 (m, 1H, H-2), 4.69 (m, 
1H, H-1), 4.16-4.05 (m, 3H, H-5, H-6), 3.96 (dt, J=1.08, 6.56 Hz, 1H, H-4), 3.50 (d, J=9.08 Hz, 
1H, OH), 2.16 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.00 (s, 3H, OAc); 13C NMR 
(100 MHz, CDCl3): β anomer: δ 170.7, 170.5, 170.4, 170.2, 90.9 (C-1), 68.4 (C-2), 68.3 (C-4), 
67.2 (C-3), 66.5 (C-5), 62.0 (C-6), 21.0 (OAc), 20.9 (OAc), 20.8 (OAc), 20.8 (OAc); α anomer: δ 
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96.2 (C-1), 71.3 (C-4), 71.1 (C-2), 70.4 (C-5), 67.3 (C-3), 61.6 (C-6); LRMS calc. for 
C16H23NO10Na [M+MeCN+Na]+: 412.1, found 412.2. 
  
(2R,3S,4S,5R,6R)-2-(acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (28). To a solution of 27 (1.0 eq, 1.58 g, 4.53 mmol) in CH2Cl2 (45 
mL, 0.1 M) was added trichloroacetonitrile (10 eq, 4.60 mL) and DBU (0.25 eq, 0.171 mL). The 
reaction stirred for 2 h and was concentrated in vacuo. The crude residue was purified by flash 
column chromatography (4:1 hexanes/EtOAc) to yield 28 (1.85 g, 83%) as a white solid: mp: 103-
105 °C; Rf: 0.41 (1:1 hexanes/EtOAc); IR (thin film, cm-1): 3303, 1743; 1H NMR (400 MHz, 
CDCl3): δ 8.66 (s, 1H, N-H), 6.60 (d, J=3.48 Hz, 1H, H-1), 5.56 (dd, J=1.08, 3.08 Hz, 1H, H-4), 
5.43 (dd, J=3.12, 10.84 Hz, 1H, H-3), 5.36 (dd, J=3.48, 10.84 Hz, 1H, H-2), 4.44 (t, J=6.52 Hz, 
1H, H-5), 4.17 (dd, J=6.64, 11.32 Hz, 1H, H-6), 4.08 (dd, J=6.68, 11.32 Hz, 1H, H-6), 2.17 (s, 3H, 
OAc), 2.03 (s, 3H, OAc), 2.02 (s, 3H, OAc), 2.01 (s, 3H, OAc) 13C NMR (100 MHz, CDCl3): δ 
170.5, 170.2, 170.2, 170.1, 161.1 (CCl3), 93.7 (C-1), 90.9 (C=NH), 69.1 (C-5), 67.7 (C-3), 67.5 
(C-4), 67.1 (C-2), 61.4 (C-6), 20.9 (OAc), 20.8 (OAc), 20.8, (OAc), 20.7 (OAc); LRMS calc. for 
C18H23Cl3N2O10Na [M+MeCN+Na]+: 555.0, found 555.2. 
 
(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-hydroxytetrahydro-2H-pyran-3,4,5-triyl triacetate 
(30). To a solution of β-D-glucose pentaacetate (1.0 eq, 2.17 g, 5.56 mmol) in THF (30 mL, 0.2 
M) was added 3-(dimethylamino)-1-propylamine (5.0 eq, 3.46 mL). The reaction stirred for 90 
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min. The reaction was quenched with 1 M HCl (50 mL) and diluted with CH2Cl2 (80 mL). The 
organic layer was washed with 1 M HCl (2 x 30 mL) and brine (1 x 30 mL), dried (MgSO4), and 
concentrated in vacuo to yield 30 (1.90 g, 98%, 5:2 β:α ratio) as an opaque gel: Rf: 0.23 (1:1 
hexanes/EtOAc); IR (thin film, cm-1): 3405, 1743, 1641; 1H NMR (400 MHz, CDCl3): β anomer: 
δ 5.53 (t, J=7.00 Hz, 1H, H-1), 5.48 (dd, J=1.16, 3.32 Hz, 1H, H-4), 5.41 (dd, J=3.28, 10.81 Hz, 
1H, H-3), 5.17 (ddd, J=1.04, 3.80, 11.08 Hz, 1H, H-2), 4.47 (dt, J=0.80, 6.60 Hz, 1H, H-5), 4.16-
4.05 (m, 2H, H-6), 2.91 (dd, J=1.12, 3.48 Hz, 1H, OH), 2.15 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.06 
(s, 3H, OAc), 1.99 (s, 3H, OAc); α anomer: δ 5.41 (m, 1H, H-3), 5.07 (m, 1H, H-2), 4.69 (m, 1H, 
H-1), 4.16-4.05 (m, 3H, H-5, H-6), 3.96 (dt, J=1.08, 6.56 Hz, 1H, H-4), 3.50 (d, J=9.08 Hz, 1H, 
OH), 2.16 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.00 (s, 3H, OAc); 13C NMR (100 
MHz, CDCl3): β anomer: δ 170.7, 170.5, 170.4, 170.2, 90.9 (C-1), 68.4 (C-2), 68.3 (C-4), 67.2 (C-
3), 66.5 (C-5), 62.0 (C-6), 21.0 (OAc), 20.9 (OAc), 20.8 (OAc), 20.8 (OAc); α anomer: δ 96.22 
(C-1), 71.3 (C-4), 71.1 (C-2), 70.4 (C-5), 67.3 (C-3), 61.6 (C-6); LRMS calc. for C14H24NO10 
[M+NH4]+: 366.1, found 366.3. 
  
(2R,3R,4S,5R,6R)-2-(acetoxymethyl)-6-(2,2,2-trichloro-1-iminoethoxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (31). To a solution of 30 (1.0 eq, 1.56 g, 4.52 mmol) in CH2Cl2 (45 
mL, 0.1 M) was added trichloroacetonitrile (10 eq, 4.6 mL, 45 mmol) and DBU (0.25 eq, 0.171 
mL, 1.13 mmol). The reaction stirred for 2 h and was concentrated in vacuo. The crude residue 
was purified by flash column chromatography (4:1 hexanes/EtOAc) to yield imidate 30 (1.84 g, 
83%) as a white solid: mp: 33-35 °C; Rf: 0.70 (1:1 hexanes/EtOAc) IR (thin film, cm-1): 3340, 
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1763, 1677; 1H NMR (400 MHz, CDCl3): δ 8.69 (s, 1H, N-H), 6.56 (d, J=3.68 Hz, 1H, H-1), 5.56 
(t, J= 9.84 Hz, 1H, H-4), 5.18 (dd, J=9.72, 10.0 Hz, 1H, H-3), 5.13 (dd, J=3.72, 10.2 Hz, 1H, H-
2), 4.27 (dd, J=4.12, 12.3 Hz, 1H, H-6), 4.21 (ddd, J=1.88, 4.08, 10.2 Hz, 1H, H-5), 4.13 (dd, 
J=2.00, 12.3 Hz, 1H, H-6), 2.07 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.01 (s, 3H, 
OAc) 13C NMR (100 MHz, CDCl3): δ 170.7, 170.1, 167.0, 169.6, 160.9 (CCl3), 93.0 (C-1), 90.8 
(C=NH), 70.1 (C-5), 70.0 (C-4, C-2), 67.9 (C-3), 61.5 (C-6), 20.8 (OAc), 20.7 (OAc), 20.6, (OAc); 
LRMS calc. for C16H24Cl3N2O10Na [M+NH4]+: 509.1, found 508.6. 
  
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(ethylthio)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
(32).42 To a solution of 26 (3.01 g, 7.72 mmol, 1 eq.) in CH2Cl2 (40 mL, 0.19 M) cooled to 0 °C 
was added ethanethiol (0.740 mL, 10 mmol, 1.3 eq) then BF3·Et2O (1.50 mL, 11.8 mmol, 1.5 eq.). 
The reaction warmed naturally and stirred for 17 h. The reaction was quenched with satturated 
NaHCO3, and the product extracted with CH2Cl2 (2 x 10 mL). The organic extracts were combined 
and washed with sat. aq. NaHCO3 (20 mL), water (20 mL), and brine (20 mL), dried over MgSO4, 
concentrated, and purified by flash column chromatography (4:1 hexanes/EtOAc) to yield 31 (2.96 
g, 98%, 6:5 α:β ratio) as a white solid: Rf:  0.21 (1:2 hexanes/EtOAc); IR (film): 3476, 2971, 2934, 
1751, 1371 cm-1; 1H NMR (400 MHz, CDCl3): δ 5.43 (dd, 1H, J=0.88, 3.36 Hz, H-4), 5.24 (t, 1H, 
J=9.99, H-2), 5.05 (dd, 1H, J=3.36, 10.0 Hz, H-3), 4.49 (d, 1H, J=9.96 Hz, H-1), 4.17 (dd, 1H, 
J=6.66, 11.3 Hz, H-6), 4.10 (dd, 1H, J=6.60, 11.3 Hz, H-6), 3.93 (dt, 1H, J=0.96, 6.60 Hz, H-5), 
2.79-2.65 (m, 2H, CH2CH3), 2.15 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.04 (s, 3H, Ac), 1.98 (s, 3H, Ac) 
1.28 (t, 3H, J=7.44 Hz, CH2CH3) ; 13C NMR (100 MHz, CDCl3): δ 170.5, 170.4, 170.2, 169.7, 
84.2 (C-1), 74.6 (C-5), 67.4 (C-2), 67.4 (C-4), 61.6 (C-6), 24.5 (CH2CH3), 21.0 (Ac), 20.8 (Ac), 
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20.7 (Ac), 15.0 (CH2CH3); LRMS calc. for C16H24O9SNa [M+Na]+: 415.1, found 415.1. 
  
(2R,3R,4S,5S,6R)-3,4,5-tris(benzyloxy)-2-((benzyloxy)methyl)-6-(phenylthio)tetrahydro-
2H-pyran (34). To a solution of 33 (0.137 g, 0.504 mmol) and benzyl bromide (5.5 eq., 0.330 mL, 
2.78 mmol) in DMF (5 mL) cooled to 0 °C was added NaH (60 wt%, 7.1 eq., 0.143 g, 3.59 mmol) 
in one portion. The reaction mixture was warmed to room temperature and stirred for 3 h. The 
reaction was quenched with water and extracted with EtOAc (3x). The combined organic extracts 
were washed with water (2x) and brine, dried over MgSO4, filtered, concentrated in vacuo, and 
purified by flash column chromatography (hexanes→4:1 hexanes/EtOAc) to yield 34 as a clear oil 
(0.300 g, 94%): Rf: 0.39 (4:1 hexanes/EtOAc); IR (film): 3062, 3030, 2899 cm-1; 1H NMR (400 
MHz, CDCl3): δ 7.19-7.46 (m, 30H, Ar), 5.61 (d, J=1.52, 1H, H-1), 4.91 (d, J=10.76, 1H, PhCH), 
4.73 (d, J=12.36, 1H, PhCH), 4.65 (d, J=11.92 1H, PhCH), 4.64 (d, J=12.40, 1H, PhCH), 4.63-
4.58 (m, 2H, PhCH), 4.54 (d, J=10.84, 1H, PhCH), 4.49 (d, J=11.96, 1H, PhCH), 4.27 (ddd, J=2.04, 
5.36, 10.2, 1H, H-5), 4.07 (t, J=9.44, 1H, H-4) 4.00 (dd, J=1.88, 3.00, 1H, H-2), 3.87 (dd, J=3.08, 
9.26, 1H, H-3), 3.84 (dd, J=5.50, 10.81, 1H, H-6), 3.75 (dd, J=1.84, 10.88, 1H, H-6); 13C NMR 
(100 MHz, CDCl3): δ 138.6, 138.3, 138.1, 131.8, 129.1, 128.6, 128.5, 128.5, 128.4, 128.1, 128.1, 
128.0, 127.9, 127.8, 127.8, 127.6, 127.5, 85.9 (C-1), 80.3 (C-3), 76.4 (C-2), 75.3 (PhCH), 75.2 (C-
4), 73.4 (PhCH), 72.9 (C-5), 72.3 (PhCH), 72.0 (PhCH), 69.4 (C-6); LRMS calc. for C40H44NO5S 
[M+NH4]+: 650.3, found 650.4. 
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2,5,8,11-tetraoxatridecan-13-yl 4-methylbenzenesulfonate (36). To a solution of 
tetraethyleneglycol monomethyl ether (0.376 g, 1.81 mmol) in CH2Cl2 (4.10 mL) was added TsCl 
(0.753 g, 3.95 mmol, 2.2 eq) and pyridine (0.220 mL). The reaction stirred at room temperature 
for 40 hours, was diluted with excess CH2Cl2 and quenched with 1 M NaOH, washed with sat'd. 
NaHCO3, water, and brine, dried over MgSO4, and concentrated to a clear oil. The oil was purified 
by flash column chromatography (1:1 EtOAc/hexanes to EtOAc) to yield 35 (0.621 g, 95%) as a 
clear liquid: Rf 0.55 (EtOAc); IR (thin film, cm-1): 3450, 2864, 1590, 1350; 1H NMR (400 MHz, 
CDCl3): δ 7.78 (d, 2H, J=8.32 Hz, Ar), 7.33 (d, 2H, J=8.08 Hz, Ar), 4.15 (dd, 2H, J=4.80, 5.80 
Hz), 3.67 (dd, 2H, J=3.92, 4.92 Hz), 3.63-3.60 (m, 6H), 3.57 (m, 4H), 3.54-3.52 (m, 2H), 3.36 (s, 
3H, OCH3), 2.43 (s, 3H, Ar-CH3); 13C NMR (100 MHz, CDCl3): δ 144.9, 133.1, 129.9, 128.1, 
72.0, 70.8, 70.7, 69.4, 68.8, 59.1 (OCH3), 21.7 (Ar-CH3); LRMS calc. for C16H26O7SNa [M+Na]+: 
385.2, found 385.1. 
 
(2R,3S,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-
tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-4-(((2S,3S,4R,5R,6S)-
3,4,5-tris(benzyloxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-ol 
(37). A solution 15 (1.2 eq, 74.5 mg, 0.141 mmol) and 11 (1.0 eq, 105 mg, 0.119 mmol) in 
Et2O/CH2Cl2 (5:1, 1.2 mL) was stirred over freshly activated 4Å MS for 1 h. The solution was 
cooled to -40 °C and NIS (2.4 eq, 0.0638 g, 0.284 mmol) and AgOTf (1.0 eq, 0.0336 g, 0.131 
mmol) were added. The reaction warmed to ambient temperature and stirred for 5 h. The reaction 
was quenched with triethylamine, filtered through a plug of Celite using additional CH2Cl2, 
O
HO
O
OBn
O
OBn
O
BnO
OBn
OBn
BnO
O
OBn
OBn
OBn 37
  202 
washed with sat. aq. Na2SO4 (2 x 10 mL) and brine (1 x 10 mL), dried (MgSO4), and concentrated 
in vacuo. The crude residue was purified by flash column chromatography (hexanes→40% 
EtOAc/hexanes) to yield 37α (63.6 mg, 41%) and 37β (32.0 mg, 21%) as white solids: mp (α): 45-
46 °C; Rf (α) 0.51 (2:1 hexanes:EtOAc); IR (thin film, cm-1, α): 3465, 3063, 3030, 2870; 1H NMR 
(600 MHz, CDCl3): (α) δ 5.25 (d, J=3.60, 1H, H-1’’), 4.96 (d, J=11.52, 1H, PhCH), 4.95 (d, 
J=10.86, 1H, PhCH), 4.92 (d, J=12.06, 1H, PhCH), 4.88 (d, J=10.86, 1H, PhCH), 4.83 (d, J=11.70, 
1H, PhCH), 4.82 (d, J=11.88, 1H, PhCH), 4.73 (d, J=11.76, 1H, PhCH), 4.72 (d, J=10.80, 1H, 
PhCH), 4.71 (d, J=10.92, 1H, PhCH), 4.70 (d, J=11.88, 1H, PhCH), 4.64 (d, J=11.52, 1H, PhCH), 
4.62 (d, J=12.06, 1H, PhCH), 4.57 (d, J=12.18, 1H, PhCH), 4.56 (d, J=12.00, 1H, PhCH), 4.44 (d, 
J=12.06, 1H, PhCH), 4.43 (d, J=7.62 1H, H-1), 4.41 (d, J=7.38, 1H, H-1’), 4.39 (d, J=11.88, 1H, 
PhCH), 4.34 (d, J=12.12, 1H, PhCH), 4.07 (q, J=6.36, 1H, H-5’’), 4.04 (dd, J=3.66, 10.2, 1H, H-
4’’),  3.97-4.00 (m, 2H, H-2’’, H-4), 3.92 (d, J=2.64, 1H, H-4’), 3.75 (dd, J=3.96, 10.92, 1H, H-
6), 3.70 (d, J=1.32, 1H, H-3’’), 3.63 (dd, J=6.96, 9.84, 1H, H-6’), 3.44-3.61 (m, 6H, H-2’, H-6, H-
3’, H-3, H-6’, H-2), 3.34 (t, J=6.12, 1H, H-5’), 3.22 (ddd, J=1.68, 3.78, 9.90, 1H, H-5), 2.41 (s, 
1H, O-H), 1.15 (d, J=6.48, 3H, H-6’’); 13C NMR (150 MHz, CDCl3): δ 139.3, 139.1, 138.9, 138.8, 
138.7, 138.6, 138.4, 138.3, 137.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2, 128.0, 
128.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.5, 127.4, 127.2, 127.1, 102.7 (C-1’), 102.6, (C-1), 
99.4 (C-1’’), 83.2 (C-3), 81.9 (C-2), 80.3 (C-3’), 79.3 (C-2’’), 79.2 (C-2’), 77.8 (C-3’’), 76.5 (C-
4), 75.9 (C-4’’), 75.5 (PhCH), 75.2 (PhCH), 75.1 (C-5), 75.1 (PhCH), 74.6 (PhCH), 73.5 (PhCH), 
73.1 (PhCH), 72.8 (H-5’), 71.1 (PhCH), 69.0 (C-4’), 68.6 (C-6’), 68.1 (C-6), 67.2 (C-5’’), 16.9 
(C-6’’); HRMS calc. For C81H86O15Na [M+Na]+: 1321.5864, found 1321.5773. 
  38
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(1S,2R)-1-((2R,3R,4S,6S)-3-acetamido-4-acetoxy-6-(((2S,3R,4S,5S,6R)-3-(benzyloxy)-6-
((benzyloxy)methyl)-5-hydroxy-2-(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-
((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-6-
(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate (38). A solution 
of 20 (1.0 eq., 50.8 mg, 0.069 mmol) and 11 (1.3 eq., 79.3 mg, 0.0900 mmol) in proprionitrile (2.0 
mL) was stirred over freshly activated 4Å MS for 30 min. The solution was cooled to -30 °C and 
trimethylsilyl trifluoromethanesulfonate (1 drop) was added. The reaction slowly warmed to 
ambient temperature and stirred for 24 h. The reaction was quenched with triethylamine, filtered 
through a plug of Celite using additional CH2Cl2, and concentrated in vacuo. The crude residue 
was purified by flash column chromatography (1:1 hexanes/EtOAC→ EtOAc) to yield 38 (42.1 
mg, 44.9%) as a white solid: mp: 57-60°C; Rf 0.35 (1:3 hexanes:EtOAc); IR (thin film, cm-1): 
3030, 2867, 1747; 1H NMR (400 MHz, CDCl3): δ 7.19-7.41 (m, 30H, Ar), 5.41 (ddd, J=2.56, 5.84, 
8.16, 1H, H-8’’), 5.31 (dd, J=2.08, 8.08, 1H, H-7’’), 5.08 (d, J-9.92, 1H, N-H), 4.98 (d, J=10.76, 
1H, PhCH), 4.94 (d, J=12.04, 1H, PhCH), 4.90 (d, J=10.92, 1H, PhCH), 4.83-4.90 (m, 1H, H-4’’), 
4.78 (d, J=11.76, 1H, PhCH), 4.74 (d, J=10.52, 1H, PhCH), 4.72 (d, J=10.88, 1H, PhCH), 4.68 (d, 
J=12.32, 1H, PhCH), 4.64 (d, J=12.36, 1H, PhCH), 4.58 (d, J=7.56, H-1’), 4.42-4.52 (m, 3H, 
PhCH), 4.47 (d, J=7.72, 1H, H-1), 4.34 (d, J=11.92, 1H, PhCH), 4.29 (dd, J=2.48, 12.40, 1H, H-
9’’), 3.94-4.13 (m, 5H, H-5’’, H-3’, H-6’’, H-4, H-9’’), 3.83 (t, J=3.40, 1H, H-4’), 3.76 (s, 3H, 
OCH3), 3.62-3.77 (m, 3H, H-6, H-6’), 3.45-3.58 (m, 5H, H-3, H-2’, H-5’, H-6’, H-2), 3.34-3.38 
(m, 1H, H-5), 2.68 (d, J=3.32, 1H, O-H), 2.51 (dd, J=4.72, 13.04, 1H, H-2’’), 2.00-2.08 (m, 1H, 
H-2’’), 2.09 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.99 (s, 3H, OAc), 1.90 (s, 3H, OAc), 1.88 (s, 3H, 
OAc); 13C NMR (100 MHz, CDCl3): δ 178.0, 170.7, 170.4, 170.2, 170.1, 168.5, 139.3, 139.1, 
138.8, 138.7, 138.6, 137.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.3, 128.0, 127.8, 127.7, 
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127.7, 127.6, 127.6, 127.5, 127.4, 127.3, 102.6 (C-1), 102.5 (C-1’), 98.5 (C-2’’), 83.1 (C-6’), 82.0 
(C-2), 78.6 (C-3), 76.6 (C-4), 76.5 (C-3’), 75.6 (PhCH), 75.3 (C-2), 75.2 (PhCH), 75.1 (PhCH), 
73.5 (PhCH), 73.2 (PhCH), 72.9 (H-6’), 72.6 (C-2’), 71.1 (PhCH), 69.2 (C-4’’), 68.9 (C-8’’), 68.6 
(C-6), 68.0 (C-4’), 67.3 (C-7’’), 62.5 (C-9’’) 62.4 (C-9’’), 53.2 (OCH3), 49.4 (C-5’’), 36.6 (C-2’’); 
HRMS calc. for C74H86NO23 [M+H]+: 1356.5591, found 1356.5457; HRMS calc. for 
C74H85NO23Na [M+Na]+: 1378.5410, found 1378.5374. 
  
(2R,3S,4R,5R,6S)-2-(acetoxymethyl)-6-(((2S,3R,4S,5S,6R)-3-(benzyloxy)-6-((benzyloxy) 
methyl)-5-hydroxy-2-(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl) 
tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-5-(((2,2,2-trichloroethoxy) 
carbonyl)amino)tetrahydro-2H-pyran-3,4-diyldiacetate (39). A solution of 25 (1.5 eq., 299 
mg, 0.479 mmol) and 11 (1.0 eq., 274 mg, 0.310 mmol) in CH2Cl2 (5.0 mL) was stirred over 
freshly activated 4 Å molecular sieves for 40 min. The solution was cooled to -5 °C and TMSOTf 
(1 drop) was added. The reaction stirred for 2 h, was quenched with triethylamine, filtered through 
a plug of Celite with additional CH2Cl2, washed with sat. aq. NaHCO3 (2 x 10 mL), water (2 x 10 
mL) and brine (1 x 10 mL), dried (MgSO4), filtered, and concentrated in vacuo.  The crude residue 
was purified by flash column chromatography (hexanes→1:2 hexanes/EtOAc) to yield 39 (192 
mg, 46%) as a white solid: mp: 137-139 °C; Rf 0.45 (1:1 hexanes/EtOAc); IR (thin film, cm-1): 
3058, 3031, 2869, 1751, 1231, 1072 ; 1H NMR (400 MHz, CDCl3): δ 7.21-7.41 (m, 30H, Ar), 5.00 
(t, J=9.64 Hz, 1H, H-4”), 4.98 (d, J=10.72 Hz, 1H, PhCH), 4.92 (d, J=11.88 Hz, 1H, PhCH), 4.90 
(d, J=10.72 Hz, 1H, PhCH), 4.89 (dd, J=9.32, 10.56 Hz, 1H, H-3”), 4.82 (d, J=12.08 Hz, 1H, 
PhCH), 4.77 (d, J=8.56 Hz, 1H, H-1”), 4.74 (d, J=10.60 Hz, 1H, PhCH), 4.73 (d, J=10.84 Hz, 1H, 
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PhCH), 4.65 (d, J=12.12 Hz, 1H, PhCH), 4.63 (d, J=11.84 Hz, 1H, PhCH), 4.61 (d, J=11.36 Hz, 
1H, PhCH), 4.54 (d, J=12.08 Hz, 1H, PhCH), 4.43-4.50 (m, 5H, PhCH, H-1, Troc-CH, H-1’), 4.37 
(d, J=11.96 Hz, 1H, PhCH), 4.23 (dd, J=5.04, 12.36 Hz, 1H, H-6”), 4.12 (dd, J=2.24, 12.24 Hz, 
1H, H-6”), 4.03 (t, J=9.32 Hz, 1H, H-4), 4.00 (brs, 1H, H-4’), 3.81 (dd, J=4.00, 10.96 Hz, 1H, H-
6), 3.69-3.74 (m, 2H, H-6, H-6’), 3.42-3.66 (m, 8H, H-2’, H-2”, H-5”, H-3’, H-3, H-6’, H-2, H-
5’), 3.31-3.34 (m, 1H, H-5), 2.51 (brs, 1H, OH), 2.04 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.98 (s, 3H, 
OAc); 13C NMR (100 MHz, CDCl3): δ 170.8, 170.7, 170.6, 169.5, 139.1, 138.7, 138.5, 138.4, 
137.6, 128.8, 128.5, 128.5, 128.4, 128.2, 127.0, 127.9, 127.8, 127.7, 127.7, 127.5, 127.4, 102.6 
(C-1’), 102.4 (C-1), 101.0 (C-1”), 95.6 (Troc-CCl3), 83.0 (C-3), 81.9 (C-2), 80.7 (C-3’), 80.1 (C-
2”), 75.7 (PhCH), 75.3 (C-5), 75.2 (PhCH), 75.0 (Troc-CH2), 73.7 (PhCH), 73.5 (PhCH), 73.0 (C-
5’), 72.0 (C-5”), 71.8 (C-3”), 71.1 (PhCH), 68.6 (C-4”), 68.4 (C-6’), 68.3 (C-6), 68.2 (C-4’), 62.1 
(C-6”), 56.3 (C-2”), 20.8 (OAc), 20.6 (OAc), 20.7 (OAc); HRMS calc. for C69H76Cl3NO20Na 
[M+Na]+: 1366.3924, found 1366.3805. 
  
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(((2S,3R,4S,5S,6R)-3-(benzyloxy)-6-((benzyloxy) 
methyl)-5-hydroxy-2-(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl) 
tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)tetrahydro-2H-pyran-3,4,5-
triyl triacetate (40). A solution of 32 (1.3 eq., 113 mg, 0.229 mmol) and 11 (1.0 eq., 160 mg, 
0.181 mmol) in CH2Cl2 (4 mL) was stirred over freshly activated 4Å MS for 1 h. The solution was 
cooled to -20°C and TMSOTf (1 drop) was added.  The reaction stirred for 2 h, was quenched with 
triethylamine, filtered through a plug of Celite with additional CH2Cl2, and concentrated in vacuo. 
The crude residue was purified by flash column chromatography (hexanes→3:2 hexanes/EtOAc) 
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to yield 39 (113 mg, 51%) as a white foam: mp: 56-58 °C; Rf 0.52 (1:1 EtOAc/hexanes); IR (thin 
film, cm-1): 3016, 2857, 1744; 1H NMR (400 MHz, CDCl3): δ 7.42-7.22 (m, 30H, Ph), 5.38 (dd, 
1H, J=0.76, 3.36 Hz, H-4”), 5.27 (dd, 1H, J=8.00, 10.44 Hz, H-2”), 5.00-4.96 (m, 2H, PhCH, H-
3”), 4.93 (d, 1H, J=12.08 Hz, PhCH), 4.89 (d, 1H, J=10.88 Hz, PhCH), 4.78 (d, 1H, J=8.04 Hz, H-
1”), 4.74-4.70 (m, 3H, PhCH), 4.64 (d, 1H, J=12.2 Hz, PhCH), 4.60 (d, 1H, J=11.28 Hz, PhCH), 
4.59 (d, 1H, J=12.2 Hz, PhCH), 4.48 (d, 1H, J=7.32 Hz, H-1’), 4.47 (d, 1H, J=11.56 Hz, PhCH), 
4.46 (d, 1H, J=7.4 Hz, H-1), 4.41 (d, 1H, J=12.2 Hz, PhCH), 4.36 (d, 1H, J=12.0 Hz, PhCH), 4.15-
4.10 (m, 2H, H-6”), 4.03-3.98 (m, 2H, H-4, H-4’), 3.90 (t, 1H, J=6.8 Hz, H-5”), 3.77 (dd, 1H, 
J=4.28, 11.08 Hz, H-6), 3.72 (dd, 1H, J=7.2, 9.64 Hz, H-6’), 3.68 (dd, 1H, J=1.48, 10.88 Hz, H-
6), 3.62-3.42 (m, 6H, H-2’, H-3’, H-3, H-6’, H-2, H-5’), 3.32-3.28 (m, 1H, H-5), 2.54 (s, 1H, OH), 
2.17 (s, 3H, Ac), 1.99 (s, 3H, Ac), 1.98 (s, 3H, Ac), 1.76 (s, 3H, Ac); 13C NMR (100 MHz, CDCl3): 
δ 170.6, 170.4, 170.2, 169.5, 139.2, 138.8, 138.6, 138.5, 138.4, 137.7, 128.5, 128.5, 128.4, 128.2, 
128.2, 128.0, 127.9, 127.8, 127.7, 127.7, 127.6, 127.5, 127.3, 102.7 (C-1), 102.3 (C-1’), 101.6 (C-
1”), 83.0 (C-3), 82.4 (C-3’), 82.0 (C-2), 79.2 (C-2’), 76.4 (C-4’), 75.6 (PhCH), 75.3 (C-5), 75.2 
(PhCH), 75.2 (PhCH), 73.7 (PhCH), 73.4 (PhCH), 72.9 (C-5’), 71.1 (C-5”), 71.0 (PhCH), 71.0 (C-
3”), 69.0 (C-2”), 68.5 (C-6’), 68.3 (C-6), 68.1 (C-4), 67.1 (C-4”), 61.5 (C-6”), 20.8 (Ac), 20.7 
(Ac), 20.6 (Ac); HRMS calc. for C68H76O20Na [M+Na]+: 1235.4828, found 1235.5840. 
 
 
(2R,3S,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-
tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-4-(((2R,3S,4S,5R,6R)-
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3,4,5-tris(benzyloxy)-6-((benzyloxy) methyl)tetrahydro-2H-pyran-2-yl)oxy) tetrahydro-2H-
pyran-3-ol (41). Mannosyl donor 34 and lactose acceptor 11 were dried on high vac for 12 h. A 
solution of 34 (162 mg, 0.184 mmol) and 11 (176 mg, 0.278 mmol) in Et2O:CH2Cl2 (1:1, 12 mL) 
was stirred over freshly activated 4Å mol sieves for 1 h. The solution was cooled to -50 °C and 
NIS (81.9 mg, 0.364 mmol) and AgOTf (37.2 mg, 0.145 mmol) was added and the reaction mixture 
warmed to room temperature and stirred for 12 h. The reaction was quenched with Et3N, filtered 
through a plug of Celite, washed with Na2S2O3, water, and brine, dried over MgSO4, concentrated 
in vacuo, and purified by medium pressure chromatography (CombiFlash EZ Prep, 12g Gold, 40 
m, hexanes→1:4 hexanes/EtOAc) to yield 41 as a clear oil (100 mg, 39%): Rf: 0.51 (3:2 
hexanes:EtOAc); IR (thin film, cm-1): 2914, 2873; 1H NMR (400 MHz, CDCl3): δ 7.02-7.39 (m, 
50H, Ar), 5.05 (d, J=1.48 Hz, 1H, H-1”), 4.98 (d, J=11.00 Hz, 1H, PhCH), 4.94 (d, J=11.00 Hz, 
1H, PhCH), 4.90 (d, J=11.00 Hz, 1H, PhCH), 4.89 (d, J=11.00 Hz, 1H, PhCH), 4.81 (d, J=11.00 
Hz, 1H, PhCH), 4.75 (d, J=11.00 Hz, 1H, PhCH), 4.72 (d, J=11.00 Hz, 1H, PhCH), 4.69 (d, 
J=11.00 Hz, 1H, PhCH), 4.65 (d, J=11.00 Hz, 1H, PhCH), 4.57-4.63 (m, 5H, PhCH), 4.51 (d, 
J=11.00 Hz, 1H, PhCH), 4.48 (d, J=7.76 Hz, 1H, H-1), 4.41-4.44 (m, 3H), 4.42 (d, J=7.04 Hz, 1H, 
H-1’), 4.35 (d, J=11.00 Hz, 1H, PhCH), 4.30 (d, J=11.00 Hz, 1H, PhCH), 3.98-4.05 (m, 4H, H-5”, 
H-4”, H-3, H-4’), 3.94 (dd, J=2.60, 9.76 Hz, 1H, H-3”), 3.83 (t, J=2.48 Hz, 1H, H-2”), 3.74 (dd, 
J=4.12, 10.84 Hz, 1H, H-6’), 3.57-3.69 (m, 5H, H-3’, H-6’, H-6”, H-6, H-6”), 3.55 (d, J=8.88 Hz, 
1H, H-4), 3.45-3.50 (m, 3H, H-6, H-2’, H-2), 3.30-3.35 (m, 1H, H-5’), 2.29 (d, J=3.56 Hz, 1H, 
OH); 13C NMR (100 MHz, CDCl3): δ 139.3, 139.0, 138.6, 138.5, 138.4, 138.1, 136.8, 128.6, 128.6, 
128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 102.7 (C-1, C-
1’’), 93.6 (C-1”), 83.1 (C-4), 81.9 (C-2), 79.8 (C-3”), 78.1 (C-2’), 76.5 (C-3), 75.8 (PhCH), 75.7 
(C-3’), 75.5 (PhCH), 75.3 (C-5’), 75.2 (C-2”), 75.2 (PhCH), 75.1 (PhCH), 75.1 (PhCH), 75.0 (C-
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4”), 73.6 (PhCH), 73.1 (PhCH), 73.1 (PhCH), 73.0 (PhCH), 72.5 (C-5), 72.2 (PhCH), 71.7 (C-5”), 
71.1 (PhCH), 69.1 (C-6”), 69.0 (C-6), 68.3 (C-6’), 64.9 (C-4”); HRMS calc. for C88H92O16Na 
[M+Na]+: 1427.6283, found 1427.6210 
  
(2R,3S,4S,5R,6S)-3,4-bis((2,5,8,11-tetraoxatridecan-13-yl)oxy)-5-(benzyloxy)-2-
((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl) 
tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran (43). To a solution of lactose acceptor 11 
(1.0 eq., 213 mg, 0.241 mmol) and 36 (2.6 eq, 225 mg, 0.620 mmol) in DMF (2.5 mL) at 0°C was 
added NaH (60%, 16 eq., 160 mg, 4.0 mmol). The reaction warmed to ambient temperature and 
stirred for 48 h. The reaction was quenched with water and extracted with EtOAc (3 x 15 mL). 
The organic extracts were combined and washed with water (2 x 10 mL) and brine (1 x 10 mL), 
dried (MgSO4), filtered, and concentrated in vacuo. The crude oil was purified by flash column 
chromatography (hexanes→EtOAc) to yield 43 (257 mg, 84%) as a clear residue: Rf 0.42 (EtOAc), 
IR (thin film, cm-1): 3031, 2873; 1H NMR (400 MHz, CDCl3): δ 7.23-7.41 (m, 30H, Ar), 5.00 (d, 
J=10.64, 1H, PhCH), 4.94 (d, J=12.04, 1H, PhCH), 4.90 (d, J=10.84, 1H, PhCH), 4.79 (d, J=11.24, 
1H, PhCH), 4.72 (d, J=11.88, 1H, PhCH), 4.71 (d, J=10.08, 1H, PhCH), 4.69 (d, J=11.24, 1H, 
PhCH), 4.65 (d, J=12.04, 1H, PhCH), 4.53 (d, J=12.16, 1H, PhCH), 4.71 (d, J=7.68, 1H, H-1), 
4.42 (d, J=11.72, 1H, PhCH), 4.41 (d, J=7.40, 1H, H-1’), 4.40 (d, J=12.28, 1H, PhCH), 4.36 (d, 
J=11.72, 1H, PhCH), 4.02-4.06 (m, 1H), 3.92 (dd, J=9.16, 9.40, 1H, H-4), 3.71-3.82 (m, 5H), 3.51-
3.68 (m, 32H), 3.46 (dd, J=7.72, 8.84, 1H, H-2), 3.38-3.42 (m, 1H, H-6’), 3.36 (s, 3H, OCH3), 3.35 
(s, 3H, OCH3), 3.34-3.38 (m, 1H, H-5), 3.31-3.34 (m, 1H, H-5’), 3.23 (dd, J=2.92, 9.68, 1H, H-
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3’); 13C NMR (100 MHz, CDCl3): δ 139.3, 139.1, 138.8, 138.6, 138.4, 137.7, 128.6, 128.5, 128.4, 
128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.3, 102.9 (C-1’), 102.6 (C-1), 
83.7 (C-3’), 83.1 (C-2), 82.0 (C-3), 79.9 (C-2’), 76.9 (C-4), 75.5, 75.3 (C-5), 75.2, 75.1, 74.5 (C-
4’), 73.5, 73.2, 73.1 (C-5’), 72.6, 72.0, 71.1, 71.0, 70.9, 70.8, 70.7, 70.6, 70.4, 68.5 (C-6), 68.2 (C-
6’), 59.2 (OCH3); HRMS calc. for C88H92O16Na [M+Na]+: 1285.6287, found 1285.6274. 
  
(2R,3R,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-4-hydroxy-6-(((2R,3R,4S,5R,6R)-
4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-
pyran-3-yl acetate (44). To a solution of 11 (1.0 eq, 3.38 g, 3.83 mmol) in MeCN (40 mL, 0.1 M) 
was added trimethylorthoacetate (3.0 eq, 1.56 mL, 11.5 mmol) and TsOH (cat). The reaction 
stirred at room temperature for 120 min then 80% TFA (4.0 eq, 1.50 mL, 15.3 mmol) was added 
and the reaction stirred for 15 min. The reaction was quenched with trimethylamine, concentrated, 
and purified by flash column chromatography (4:1 hexanes/EtOAc) to yield axially acetylated 
lactose acceptor 44 (3.30 g, 93%) as a white foam: mp:  33-35 °C; Rf 0.45 (1:1 hexanes/EtOAc); 
IR (thin film, cm-1): 3441, 2868, 1742, 1095, 1058; 1H NMR (400 MHz, CDCl3): δ 7.38-7.16 (m, 
30H, Ar), 5.33 (d, 1H, J=3.20 Hz, H-4’), 4.97 (d, J=10.6 Hz, 1H, PhCH), 4.95 (d, J=12.1 Hz, 1H, 
PhCH), 4.92 (d, J=10.9, 1H, PhCH), 4.80 (d, J=11.4 Hz, 1H, PhCH), 4.76 (d, J=9.08 Hz, 1H, 
PhCH), 4.66 (d, J=11.7 Hz, 1H, PhCH), 4.63 (d, J=12.3 Hz, 1H, PhCH), 4.49 (d, J=7.24 Hz, 1H, 
H-1), 4.47 (d, J=7.32 Hz, 1H, H-1’), 4.46 (d, J=11.7 Hz, 1H, PhCH), 4.45 (d, J=12.0 Hz, 1H, 
PhCH), 4.24 (d, J=12.0 Hz, 1H, PhCH), 4.03 (dd, J=9.16, 9.32 Hz, 1H, H-4), 3.82 (dd, J=4.04, 
11.0 Hz, 1H, H-6), 3.75 (dd, J=1.72, 101.0 Hz, 1H, H-6), 3.63 (dd, J=3.48, 9.56 Hz, 1H, H-3’), 
3.57 (dd, J=8.84, 9.08 Hz, 1H, H-3), 3.52-3.48 (m, 2H, H-5’, H-2), 3.42-3.36 (m, 2H, H-2’, H-5), 
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3.34 (d, J=6.64 Hz, 2H, H-6’), 2.03 (s, 3H, OAc); 13C NMR (100 MHz, CDCl3): δ 171.1, 139.1, 
138.7, 138.3, 138.0, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 
127.5, 102.6 (C-1), 102.3 (C-1’), 83.3 (C-3), 82.9 (C-2), 81.9 (C-2'), 80.2 (C-4), 75.5 (PhCH), 
75.3 (C-5), 75.2 (PhCH), 75.2 (PhCH), 73.5 (PhCH), 73.4 (PhCH), 72.6 (C-3'), 72.1 (C-5'), 71.1 
(PhCH), 69.7 (C-4'), 68.3 (C-6), 68.2 (C-6), 67.4 (C-6'), 20.9 (Ac); LRMS calc. for C56H64O12N 
[M+Na]+: 942.4, found 942.6. 
 
(2R,3S,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-
tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-4-(((2S,3S,4R,5R,6S)-
3,4,5-tris(benzyloxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl 
acetate (45). A solution 44 (2.2 eq, 1.10 g, 2.50 mmol), 16 (1.0 eq, 1.07 g, 1.16 mmol), SnCl2 
(10.2 eq., 2.2309 g, 11.77 mmol), AgClO4 (7.4 eq., 1.7772 g, 8.57 mmol), and 2,6-di-tert-
butylpyridine (10 eq., 3.0 mL, 10.0 mmol) in Et2O (0.1 M, 10 mL) was stirred over freshly 
activated 4Å MS for 72 h. The mixture was filtered through a plug of Celite using CH2Cl2 and 
concentrated in vacuo. The crude residue was purified by flash column chromatography 
(hexanes→30% EtOAc/hexanes) to yield 45 (1.23 g, 79%) as a white foam: mp: 35-37 °C; Rf 0.65 
(1:1 hexanes:EtOAc); IR (thin film, cm-1): 2912, 2852, 1740; 1H NMR (600 MHz, CDCl3): δ 5.25 
(d, J=3.60, 1H, H-1’’), 4.96 (d, J=11.52, 1H, PhCH), 4.95 (d, J=10.86, 1H, PhCH), 4.92 (d, 
J=12.06, 1H, PhCH), 4.88 (d, J=10.86, 1H, PhCH), 4.83 (d, J=11.70, 1H, PhCH), 4.82 (d, J=11.88, 
1H, PhCH), 4.73 (d, J=11.76, 1H, PhCH), 4.72 (d, J=10.80, 1H, PhCH), 4.71 (d, J=10.92, 1H, 
PhCH), 4.70 (d, J=11.88, 1H, PhCH), 4.64 (d, J=11.52, 1H, PhCH), 4.62 (d, J=12.06, 1H, PhCH), 
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4.57 (d, J=12.18, 1H, PhCH), 4.56 (d, J=12.00, 1H, PhCH), 4.44 (d, J=12.06, 1H, PhCH), 4.43 (d, 
J=7.62 1H, H-1), 4.41 (d, J=7.38, 1H, H-1’), 4.39 (d, J=11.88, 1H, PhCH), 4.34 (d, J=12.12, 1H, 
PhCH), 4.07 (q, J=6.36, 1H, H-5’’), 4.04 (dd, J=3.66, 10.2, 1H, H-4’’),  3.97-4.00 (m, 2H, H-2’’, 
H-4), 3.92 (d, J=2.64, 1H, H-4’), 3.75 (dd, J=3.96, 10.92, 1H, H-6), 3.70 (d, J=1.32, 1H, H-3’’), 
3.63 (dd, J=6.96, 9.84, 1H, H-6’), 3.44-3.61 (m, 6H, H-2’, H-6, H-3’, H-3, H-6’, H-2), 3.34 (t, 
J=6.12, 1H, H-5’), 3.22 (ddd, J=1.68, 3.78, 9.90, 1H, H-5), 2.41 (s, 1H, O-H), 1.15 (d, J=6.48, 3H, 
H-6’’); 13C NMR (150 MHz, CDCl3): δ 139.3, 139.1, 138.9, 138.8, 138.7, 138.6, 138.4, 138.3, 
137.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.55 127.4, 127.3, 
127.2, 127.1, 102.7 (C-1’), 102.6, (C-1), 99.4 (C-1’’), 83.2 (C-3), 81.9 (C-2), 80.3 (C-3’), 79.3 (C-
2’’), 79.2 (C-2’), 77.8 (C-3’’), 76.5 (C-4), 75.9 (C-4’’), 75.5 (PhCH), 75.1 (PhCH), 75.1 (C-5), 
75.0 (PhCH), 74.6 (PhCH), 73.6 (PhCH), 73.1 (PhCH), 72.8 (H-5’), 71.1 (PhCH), 69.0 (C-4’), 
68.6 (C-6’), 68.1 (C-6), 67.2 (C-5’’), 16.9 (C-6’’). LRMS calc. for C83H88O16K [M+K]+: 1379.6, 
found 1378.9. 
  
(1S,2R)-1-((2R,3R,4S,6S)-3-acetamido-4-acetoxy-6-(((2R,3S,4S,5R,6S)-3-acetoxy-5-
(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-
((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-6-
(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)propane-1,2,3-triyl triacetate (46). A solution 
of 20 (1.0 eq., 50.8 mg, 0.069 mmol) and 44 (1.3 eq., 79.3 mg, 0.090 mmol) in proprionitrile (2.0 
mL) was stirred over freshly activated 4Å MS for 30 min. The solution was cooled to -30 °C and 
trimethylsilyl trifluoromethanesulfonate (1 drop) was added. The reaction slowly warmed to 
ambient temperature and stirred for 24 h. The reaction was quenched with triethylamine, filtered 
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through a plug of Celite using additional CH2Cl2, and concentrated in vacuo. The crude residue 
was purified by flash column chromatography (1:1 hexanes/EtOAC→ EtOAc) to yield 46 (42.1 
mg, 44.9%) as a white solid: mp: 48-51 °C; Rf 0.41 (EtOAc); IR (thin film, cm-1): 3384, 2924, 
2853, 1746, 1227 ; 1H NMR (400 MHz, CDCl3): δ 7.41-7.16 (m, 30H, Ar), 5.62-5.58 (m, 1H, H-
8’’), 5.33 (dd, 3H, PhCH, H-4”), 4.89 (d, 1H, J=12.2 Hz, PhCH), 4.77 (d, 1H,  J=7.36 Hz, H-1’), 
4.75 (d, 1H, J=10.5 Hz, PhCH), 4.69 (d, 1H, J=10.9, PhCH), 4.64 (d, 1H, J=12.5 Hz, PhCH), 4.63 
(d, 1H, J=12.0 Hz, PhCH), 4.53 (d, 1H, J=12.3 Hz, PhCH), 4.50 (dd, 1H, J=3.40, 9.48 Hz, H-4’), 
4.44 (d, 1H, J=7.64, H-1), 4.40 (d, 1H, J=11.8 Hz, PhCH), 4.38 (d, 1H, J=11.7 Hz, PhCH), 4.30 
(dd, 1H, J=2.32, 12.5 Hz, H-9”), 4.20 (d, 1H, J=11.8 Hz, PhCH), 4.13-4.05 (m, 1H, H-5”), 4.02-
3.95 (m, 2H, H-9”, H-4), 3.83 (s, 3H, OCH3), 3.77 (dd, 1H, J=1.24, 11.3 Hz, H-6), 3.72 (dd, 1H, 
J=2.68, 10.7 Hz, H-6”), 3.68 (t, 1H, J=7.32 Hz, H-6’), 3.63 (dd, 1H, J=5.4, 11.1 Hz, H-6), 3.54 (t, 
1H, J=9.00 Hz, H-3), 3.48-3.43 (m, 3H, H-2’, H-3, H-2’), 3.35-3.28 (m, 2H, H-5, H-6’), 2.50 (dd, 
1H, J=4.68, 12.6 Hz, H-3), 2.09 (s, 3H, Ac), 2.01 (s, 3H, Ac), 2.00 (s, 3H, Ac), 1.97 (s, 3H, Ac), 
1.86 (s, 3H, Ac) 1.87-1.83 (m, 1H, H-3), 1.77 (s, 3H, Ac); 13C NMR (100 MHz, CDCl3): δ, 170.9, 
170.7, 170.5, 170.1, 168.0, 139.6, 139.4, 138.8, 138.8, 138.3, 137.7, 129.3, 128.5, 128.4, 128.3, 
128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 127.2, 102.5 (C-1), 102.2 (C-1’), 
97.4 (C-2”), 83.0 (C-3), 82.0 (C-2’), 79.7 (C-3’), 75.2 (C-4), 75.1 (C-5), 75.0 (PhCH), 74.0 
(PhCH), 73.3 (C-4’), 72.3 (PhCH), 71.5 (PhCH), 71.0 (C-6”), 70.5 (PhCH), 69.7 (PhCH), 68.9 (C-
6), 68.8 (C-5’), 68.5 (C-8’’), 67.8 (C-6’), 67.2 (C-7”), 62.2 (C-9’’), 53.2 (OCH3), 52.7 (C-2’), 49.4 
(C-5’’), 37.7 (C-3’’), 23.4, 21.4, 21.0, 20.9, 20.6; LRMS calc. for C76H87NO24NH4 [M+NH4]+: 
1415.6, found 1415.7. 
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(2R,3S,4R,5R,6S)-6-(((2R,3S,4S,5R,6S)-3-acetoxy-5-(benzyloxy)-2-((benzyloxy)methyl)-6-
(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-
yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-2-(acetoxymethyl)-5-(((2,2,2-
trichloroethoxy)carbonyl)amino)tetrahydro-2H-pyran-3,4-diyl diacetate (47). A solution of 
25 (1.3 eq., 1.04 g, 1.67 mmol) and 44 (1.0 eq., 1.14 g, 1.24 mmol) in CH2Cl2 (12.5 mL) was 
stirred over freshly activated 4 Å molecular sieves for 60 min. The solution was cooled to -5 °C 
and TfOH (0.3 mL of solution of 1 drop in 1.0 mL CH2Cl2) was added. The reaction stirred for 15 
min, was quenched with triethylamine, filtered through a plug of Celite with additional CH2Cl2, 
and concentrated in vacuo.  The crude residue was purified by flash column chromatography 
(hexanes→1:2 hexanes/EtOAc) to yield 47 (1.58 g, 92%) as a white solid: mp: 52-54 °C; Rf 0.40 
(1:1 hexanes/EtOAc); IR (thin film, cm-1): 3397, 3054, 2987, 1752, 1712; 1H NMR (400 MHz, 
CDCl3): δ 7.42-7.16 (m, 30H, Ar), 5.41 (d, J=3.44 Hz, 1H, H-4’), 5.01 (dd, J=9.60, 9.64 Hz, 1H, 
H-4’), 4.98 (d, J=10.6 Hz, 1H, PhCH), 4.93 (d, J=12.2 Hz, 1H, PhCH), 4.90 (d, J=11.1 Hz, 1H, 
PhCH), 4.87 (d, J=11.9 Hz, 1H, PhCH), 4.74 (d, J=10.5, 1H, H-3”), 4.73 (d, J=11.0 Hz, 1H, PhCH), 
4.70 (d, J=12.2 Hz, 1H, PhCH), 4.69-4.63 (m, 2H, CH2CCl3), 4.67 (d, J=9.68 Hz, 1H, H-1”),  4.58 
(d, J=12.0 Hz, 1H, PhCH), 4.49 (d, J=12.0 Hz, 1H, PhCH), 4.48 (d, J=8.08 hZ, 1H, H-1’), 4.46 (d, 
J=7.76 Hz, 1H, H-1) 4.44 (m, 2H,), 4.37 (d, J=9.96 Hz), 4.27 (d, J=11.92 Hz, 2H, PhCH), 4.20 (d, 
J=3.44 Hz, 2H, H-6”), 4.05 (dd, J=9.28, 9.36 Hz, 1H, H-4), 3.80 (dd, J=3.84, 11.2 Hz, 1H, H-6), 
3.72-3.64 (m, 2H, H-6, H-3’), 3.62-3.51 (m, 5H, H-3, H-2’, H-5’, H-2”, H-5”), 3.47 (dd, J=7.72, 
9.00 Hz, H-2), 3.34 (d, J=6.92 Hz, 2H, H-6’), 3.33-3.29 (m, 1H, H-5), 2.06 (s, 3H, OAc), 2.03 (s, 
3H, OAc), 2.01 (s, 3H, OAc), 1.96 (s, 3H, OAc); 13C NMR (100 MHz, CDCl3): δ 170.9, 170.7, 
170.0, 169.4, 154.0 139.1, 138.7, 138.3, 138.1, 137.6, 128.9, 128.6, 128.5, 128.5, 128.3, 128.2, 
128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.5, 127.0, 102.6 (C-1), 102.1 (C-1’), 101.1 (C-1”), 
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99.7 (Troc-CCl3), 82.8 (C-5”), 81.8 (C-2), 81.1 (C-2’), 76.0 (C-3’), 75.5 (C-4), 75.2 (PhCH), 75.1 
(C-5), 75.0 (PhCH, Troc-CH2), 74.4 (PhCH), 73.7 (PhCH), 73.6 (C-5’), 72.7 (C-3), 72.0 (PhCH), 
71.9 (C-3”), 71.1 (PhCH), 69.6 (C-4’), 68.7 (C-4”), 68.1 (C-6), 68.0 (C-6’), 62.0 (C-6’), 56.2 (C-
2”), 20.9 (OAc), 20.9 (OAc), 20.8 (OAc), 20.7 (OAc); LRMS calc. for C75H85Cl3N3O21 
[M+2ACN+H]+: 1468.5, found 1468.3. 
  
(2S,3R,4S,5S,6R)-2-(((2R,3S,4S,5R,6S)-3-acetoxy-5-(benzyloxy)-2-((benzyloxy)methyl)-6-
(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-
yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (48). A solution of 28 (1.4 eq., 0.922 g, 1.87 mmol) and 44 (1.0 eq., 1.264 g, 1.34 
mmol) in CH2Cl2 (10 mL, 0.1 M) was stirred over freshly activated 4 Å molecular sieves for 60 
min. The solution was cooled to -5 °C and TfOH (0.300 mL of solution of 1 drop in 1.00 mL 
CH2Cl2) was added. The reaction stirred for 15 min, was quenched with triethylamine, filtered 
through a plug of Celite with additional CH2Cl2, and concentrated in vacuo.  The crude residue 
was purified by flash column chromatography (hexanes→1:2 hexanes/EtOAc) to yield 48 (1.72 g, 
95%) as a white foam: mp: 44-47°C; Rf 0.39 (1:1 EtOAc/hexanes); IR (thin film, cm-1): 2870, 
1751; 1H NMR (400 MHz, CDCl3): δ 7.38-7.19 (m, 30H, Ph), 5.40 (d, 1H, J=3.52 Hz, H-4’), 5.34 
(dd, 1H, J=0.83, 3.45 Hz, H-4”), 5.14 (dd, 1H, J=7.88, 10.5 Hz, H-2”), 4.98 (d, 1H, J=10.6 Hz, 
PhCH), 4.96-4.92 (m, 2H, PhCH, H-3”), 4.90 (d, 1H, J=10.9 Hz, PhCH), 4.80 (d, 1H, J=7.88 Hz, 
H-1”), 4.74 (d, 1H, J=10.6 Hz, PhCH), 4.73 (d, 2H, J=10.9 Hz, PhCH), 4.65 (d, 1H, J=12.1 Hz, 
PhCH), 4.62 (d, 1H, J=10.3 Hz, PhCH), 4.62 (d, 1H, J=12.0 Hz, PhCH), 4.59 (d, 1H, J=10.7 Hz, 
PhCH), 4.47 (d, 1H, J=7.52 Hz, H-1), 4.47 (d, 1H, J=7.80 Hz, H-1), 4.43 (d, 1H, J=11.9 Hz, PhCH), 
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4.42 (d, 1H, J=12.2 Hz, PhCH), 4.29 (d, 1H, J=11.8 Hz, PhCH), 4.15 (dd, 1H, J=1.92, 6.48 Hz, H-
6”), 4.02 (dd, 1H, J=9.16, 9.36 Hz, H-4), 3.83 (dt, 1H, J=0.71, 6.68 Hz, H-5”), 3.76 (dd, 1H, 
J=4.08, 11.08 Hz, H-6), 3.71-3.67 (m, 2H, H-3’,H-6), 3.56-3.45 (m, 4H, H-3, H-2’, H-5’, H-2), 
3.35 (d, 2H, J=6.20 Hz, H-6’), 3.33-3.29 (m, 1H, H-5), 2.17 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.00 (s, 
3H, Ac), 1.97 (s, 3H, Ac), 1.86 (s, 3H, Ac); 13C NMR (100 MHz, CDCl3): δ 170.6, 170.5, 170.3, 
169.9, 169.2, 139.2, 138.7, 138.4, 138.3, 138.2, 137.7, 128.6, 128.5, 128.3, 128.4, 128.2, 128.1, 
128.0, 127.9, 127.8, 127.7, 127.5, 102.6 (C-1’), 102.2 (C-1), 101.0 (C-1”), 82.8 (C-3), 81.9 (C-2), 
80.4 (C-2’), 77.7 (C-3’), 76.1 (C-4), 75.4 (PhCH), 75.3 (PhCH), 75.2 (C-5), 75.1 (PhCH), 73.7 
(PhCH), 73.4 (C-5’), 72.8 (PhCH), 71.1 (PhCH), 71.0 (C-3”), 70.8 (C-5”), 69.6 (C-4’), 69.4 (C-
2”), 69.3 (C-6), 67.2 (C-6’), 67.1 (C-4”), 61.2 (C-6”), 20.9 (Ac), 20.8 (Ac), 20.7 (Ac); LRMS calc. 
for C70H82NO21 [M+NH4]+: 1272.5, found 1272.9. 
  
(2S,3R,4S,5R,6R)-2-(((2R,3S,4S,5R,6S)-3-acetoxy-5-(benzyloxy)-2-((benzyloxy)methyl)-6-
(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-
yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-6-(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (49). A solution of 31 (1.7 eq., 1.00 g, 2.03 mmol) and 44 (1.0 eq., 1.10 g, 1.19 mmol) in 
CH2Cl2 (10.0 mL, 0.1 M) was stirred over freshly activated 4 Å molecular sieves for 60 min. The 
solution was cooled to -5 °C and TfOH (0.300 mL of solution of 1 drop in 1.00 mL CH2Cl2) was 
added. The reaction stirred for 30 min, was quenched with triethylamine, filtered through a plug 
of Celite with additional CH2Cl2, and concentrated in vacuo.  The crude residue was purified by 
flash column chromatography (hexanes→1:2 hexanes/EtOAc) to yield 49 (1.11 g, 75%) as a white 
foam: mp: 44-47 °C; Rf 0.50 (1:1 EtOAc/hexanes); IR (thin film, cm-1): 3400, 2923, 1754; 1H 
O
AcO
O
OBn
O
OBn
O
BnO
OBn
OBn
BnO
OAcO
AcO
OAc
OAc
49
  216 
NMR (400 MHz, CDCl3): δ 7.39-7.17 (m, 30 H, Ph), 5.41 (d, 1H, J=3.52 Hz, H-4’), 5.16 (t, 1H, 
J=9.32 Hz, H-3”), 5.09 (dd, 1H, J=9.40, 9.60 Hz, H-4”), 5.01-4.98 (m, 2H, H-2”, PhCH), 4.95 (d, 
1H, J=11.8 Hz, PhCH), 4.91 (d, 1H, J=10.9 Hz, PhCH), 4.81 (d, 1H, J=7.80 Hz, H-1”), 4.74 (d, 
1H, J=10.9 Hz, PhCH), 4.73 (d, 1H, J=10.9 Hz, PhCH), 4.71 (d, 1H, J=11.2 Hz, PhCH), 4.66 (d, 
1H, J=12.1 Hz, PhCH), 4.62 (d, 1H, J=12.1 Hz, PhCH), 4.60 (d, 1H, J=10.7 Hz, PhCH), 4.48 (d, 
1H, J=7.56 Hz, H-1), 4.46 (d, 1H, J=7.72 Hz, H-1’), 4.44, (d, 1H, J=11.1 Hz, PhCH), 4.41 (d, 1H, 
J=11.6 Hz, PhCH), 4.27 (d, 1H, J=11.8 Hz, PhCH), 4.24 (dd, 1H, J=2.88, 12.5 Hz, H-6”), 4.18 
(dd, 1H, J=4.40, 12.1 Hz, H-6”), 4.02 (dd, 1H, J=9.24, 9.32 Hz, H-4), 3.77 (dd, 1H, J=4.16, 11.1 
Hz, H-6), 3.70-3.62 (m, 3H, H-6, H-3’, H-5”), 3.57-3.45 (m, 4H, H-3, H-5’, H-2’, H-2), 3.35 (d, 
2H, J=6.28 Hz, H-6’), 3.35-3.31 (m, 1H, H-5), 2.07 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.03 (s, 3H, 
OAc), 2.00 (s, 3H, OAc), 1.84 (s, 3H, OAc); 13C NMR (100 MHz, CDCl3): δ 170.8, 170.4, 169.8, 
169.5, 169.1, 139.2, 138.6, 138.4, 138.2, 138.2, 137.6, 128.6, 128.5, 128.4, 128.2, 128.1, 128.0, 
127.9, 127.8, 127.7, 127.5, 102.6 (C-1), 102.1 (C-1’), 100.7 (C-1”), 82.8 (C-3), 81.9 (C-2), 80.0 
(C-2’), 78.3 (C-3’), 76.2 (C-4), 75.5 (PhCH), 75.4 (PhCH), 75.3 (PhCH), 75.2 (C-5), 73.7 (PhCH), 
73.4 (PhCH), 73.0 (C-3”), 72.7 (C-5’), 71.8 (C-5”), 71.8 (C-2”), 71.1 (PhCH), 69.7 (C-4’), 68.5 
(C-4”), 68.2 (C-6, C-6’), 61.8 (C-6”), 20.8  (Ac), 20.7 (Ac), 20.6 (Ac); LRMS calc. for C70H82NO21 
[M+NH4]+: 1272.5, found 1272.8. 
 
(2R,3S,4S,5R,6S)-5-(benzyloxy)-2-((benzyloxy)methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-
tris(benzyloxy)-2-((benzyloxy)methyl)tetrahydro-2H-pyran-3-yl)oxy)-4-(((2R,3S,4S,5R,6R)-
3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-
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pyran-3-yl acetate (50). A solution of 34 (1.3 eq., 1.04 g, 1.65 mmol) and 44 (1.0 eq., 1.01 g, 1.09 
mmol) in CH2Cl2 (10 mL, 0.1 M) was stirred over freshly activated 4 Å molecular sieves for 60 
min. The solution was cooled to -5 °C and NIS (2.1 eq, 0.514 g, 2.28 mmol) and AgOTf (1.6 eq, 
0.449 g, 1.75 mmol) were added. The reaction stirred for 15 min, was quenched with triethylamine, 
filtered through a plug of Celite with additional CH2Cl2, and concentrated in vacuo.  The crude 
residue was purified by flash column chromatography (hexanes→1:2 hexanes/EtOAc) to yield 50 
(1.471 g, 93%) as a white foam: mp: 35-38 °C;  Rf 0.71 (1:1 EtOAc/hexanes); IR (thin film, cm-
1): 3063, 3030, 2923, 2855, 1741, 1453; 1H NMR (400 MHz, CDCl3): δ 7.53-6.99 (m, 50H, Ph), 
5.46 (d, 1H, J= 3.08 Hz, H-4’), 5.32 (d, 1H, J=1.08 Hz, H-1”), 4.96 (d, 1H, J=10.3 Hz, PhCH), 
4.94 (d, 1H, J=11.6 Hz, PhCH), 4.92 (d, 1H, J=10.3 Hz, PhCH), 4.91 (d, 1H, J=10.9 Hz, PhCH), 
4.84 (d, 1H, J=12.5 Hz, PhCH), 4.73 (d, 2H, J=10.8 Hz, PhCH), 4.69 (d, 1H, J=12.7 Hz, PhCH), 
4.66 (d, 1H, J=12.3 Hz, PhCH), 4.59 (d, 1H, J=10.2 Hz, PhCH), 4.58 (d, 1H, J=12.5 Hz, PhCH), 
4.55 (d, 1H, J=10.2 Hz, PhCH), 4.49 (d, 1H, J=12.2 HZ, PhCH), 4.49 (d, 1H, J=10.4 Hz, PhCH), 
4.49 (m, 2H, PhCH), 4.48 (d, 1H, J=6.44 Hz, H-1), 4.46 (d, 1H, J=7.60 Hz, H-1’), 4.42 (d, 1H, 
J=12.1 Hz, PhCH), 4.32 (d, 1H, J=12.4 Hz, PhCH), 4.28 (d, 1H, J=12.1 Hz, PhCH), 4.26 (d, 1H, 
J=12.2 Hz, PhCH), 4.04-3.96 (m, 3H, H-5”, H-4, H-4”), 3.83 (dd, 1H, J=2.32, 2.92 Hz, H-3”), 
3.81 (dd, 1H, J=3.28, 3.48 Hz, H-3’), 3.73 (dd, 1H, J=4.08, 11.0 H, H-6), 3.66-3.52 (m, 5H, H-6, 
H-6”, H-2”, H-3), 3.49 (d, 1H, J=7.6 Hz, H-2), 3.43 (dd, 1H, J=5.8, 6.84 HZ, H-5’), 3.39-3.31 (m, 
4H, H-2’, H-5, H-6’), 2.00 (s, 3H, OAc); 13C NMR (100 MHz, CDCl3): δ 170.2, 139.1, 138.8, 
138.7, 138.6, 138.5, 138.1, 137.8, 137.6, 129.0, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 
128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 103.0 (C-1), 102.7 (C-1’), 94.0 (C-1”), 83.2 (C-3), 82.2 
(C-2), 79.5 (C-3”), 78.9 (C-2’), 77.6 (PhCH), 76.4 (C-4), 76.2 (PhCH), 75.8 (PhCH), 75.5 (C-5), 
75.4 (PhCH), 75.4 (PhCH), 75.2 (C-4”), 74.6 (C-2”), 74.2 (C-3’), 73.7 (PhCH), 73.4 (PhCH), 73.2 
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(PhCH), 72.1 (PhCH), 71.9 (PhCH), 71.8 (C-5”), 71.7 (C-5’), 71.4 (PhCH), 69.4 (C-6”), 68.5 (C-
6), 67.3 (C-6’), 66.1 (C-4’), 21.2 (Ac); LRMS calc. for C90H94O17 [M+2Na]2+: 746.3, found 746.4. 
 
(2R,3S,4S,5R,6S)-3,4-bis((2,5,8,11-tetraoxatridecan-13-yl)oxy)-5-(benzyloxy)-2-((benzyloxy) 
methyl)-6-(((2R,3R,4S,5R,6R)-4,5,6-tris(benzyloxy)-2-((benzyloxy) methyl)tetrahydro-2H-
pyran-3-yl)oxy)tetrahydro-2H-pyran (42). To a solution of lactose acceptor 44 (1.0 eq., 213 mg, 
0.241 mmol) and 36 (2.6 eq, 225 mg, 0.620 mmol) in DMF (2.5 mL) at 0 °C was added NaH (60%, 
16 eq., 0.160 g, 4.0 mmol). The reaction warmed to ambient temperature and stirred for 48 h. The 
reaction was quenched with water and extracted with EtOAc (3 x 15 mL). The organic extracts 
were combined and washed with water (2 x 10 mL) and brine (1 x 10 mL), dried (MgSO4), filtered, 
and concentrated in vacuo. The crude oil was purified by flash column chromatography 
(hexanes→EtOAc) to yield 42 (257 mg, 84%) as a clear oil: Rf 0.28 (EtOAc), IR (thin film, cm-1): 
3030, 2872, 1752, 1454; 1H NMR (400 MHz, CDCl3): δ 7.41-7.21 (m, 30H, Ar), 4.99 (dd, 1H, 
J=8.68, 10.4 Hz, PhCH), 4.94 (d,1H, J=12.0 Hz, PhCH), 4.90 (dd, 1H, J=2.96, 10.8 Hz, PhCH), 
4.84 (d, 1H, J=11.24 Hz, PhCH), 4.75-4.70 (m, 3H, PhCH), 4.65 (d,1H, J=12.0 Hz, PhCH), 4.54 
(dd, J=7.12, 12.2 Hz, 1H, PhCH), 4.50-4.37 (m, 4H), 3.99-3.91 (m, 1H), 3.85-3.32 (m, 31H); 13C 
NMR (100 MHz, CDCl3): δ 139.4, 139.1, 138.8, 138.1, 137.7, 128.5, 128.5, 128.5, 128.4, 128.3, 
128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 102.8, 102.6, 83.1, 82.0, 81.5, 78.2, 75.4, 
75.3, 75.2, 75.1, 74.5, 73.6, 73.5, 73.2, 73.0, 72.0, 71.1, 70.7, 70.6, 70.5, 68.8, 68.5, 67.9, 59.1. 
LRMS calc. for C63H80NO15 [M+NH4]+: 1090.6, found 1090.5. 
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2R,3R,4R,5S,6R)-5-(((2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-
(((2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-
pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol (1). To a solution of 45 
(1.0 eq., 1.120 g, 0.835 mmol) in MeOH (50 mL) was added a concentrated solution of NaOMe 
(0.5 mL). The reaction stirred at ambient temperature for 4 h and was quenched with 
Dowex50Wx8 resin and filtered. Pd(OH)2/C (20%, 3.0 eq., 1.87 g, 2.7 mmol) was added to the 
resulting solution. The mixture was sparged with Ar then H2 gas and the reaction stirred under an 
atmosphere of hydrogen for 24 h, was filtered through a plug of Celite, and concentrated in vacuo. 
The resulting residue was purified by P-2 Gel size exclution chromatography (H2O) to yield 1 (325 
mg, 80%) as a white solid: [α]23D -16.6° (c 10 mg/mL, H2O); 1H NMR (600 MHz, D2O): δ 5.23 
(d, J=3.66 Hz, H-1α), 5.18 (d, J=3.72, H-1”), 4.67 (d, J=7.92 Hz, H-1β), 4.52 (d, J=6.75 Hz, H-
1’), 4.18 (q, J=6.46 Hz, H-5”), 4.02 (br) 3.89-3.58 (m), 3.29 (t, J=8.4), 1.21 (d, J=6.6 Hz, H-6”); 
13C NMR (150 MHz, D2O): δ 102.7 (C-1’), 100.9 (C-1”), 95.7 (C-1α), 91.8 (C-1β), 80.3, 78.4, 
78.3, 75.3, 74.8, 74.4, 73.8, 71.7, 71.4, 71.1, 70.4, 70.1, 69.4, 68.6, 68.4, 67.1, 60.9, 60.0, 59.9, 
15.3 (C-6”); HRMS calc. for C18H32O15Na [M+Na]+: 511.1639, found 511.2829. 
  
(2S,4S,5R,6R)-5-acetamido-2-(((2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-
(((2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-
yl)oxy)tetrahydro-2H-pyran-4-yl)oxy)-4-hydroxy-6-((1R,2R)-1,2,3-
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trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid (2). To a solution of trisaccharide 46 
(0.0671 g, 0.062 mmol) in MeOH (5 mL) was added a concentrated solution of NaOMe (0.1 mL). 
The reaction stirred at ambient temperature for 36 h and then water (2 mL) was added. Stirring at 
ambient temperature for an additional 48 h was followed by neturalization with Dowex50Wx8 
resin, filtration with MeOH, and concentration. The crude material was resuspended in MeOH (50 
mL) and Pearlman's catalyst (0.130 g, 4 eq, 0.25 mmol) was added. The reaction vessel was purged 
with Ar then H2. The reaction stirred under H2 for 24 h, was purged with Ar, filtered through a 
plug of Celite, concentrated, and purified by P-2 Gel (H2O elutent) to yield 2 (0.0304 g, 78%) as 
a white solid: [α]23D +10.8° (c 10 mg/mL, H2O); 1H NMR (400 MHz, D2O): δ 5.23 (d, 0.35H, 
J=3.80 Hz, H-1α), 4.67 (d, 0.65H, J=7.96 Hz, H-1β), 4.54 (d, 1H, J=7.84 Hz, H-1’), 4.12 (dd, 1H, 
J=3.08, 9.88 Hz), 4.00-3.56 (m, 18H), 3.29 (t, J=8.16 Hz), 2.77 (dd, 1H, J=4.72, 12.6 Hz, H-3”eq), 
2.04 (s, 3H, Ac), 1.81 (t, 1H, J=12.0 Hz, H-3”ax); 13C NMR (150 MHz, D2O): δ 175.2, 170.1 
(CO2H), 102.9, 102.6, 98.5 (C-2”), 95.7, 91.8, 78.4, 78.3, 78.1, 75.9, 75.4, 75.3, 75.2, 75.1, 74.9, 
74.8, 74.3, 73.8, 73.7, 73.2, 72.9, 72.5, 71.5, 71.4, 71.1, 70.9, 70.6, 70.4, 70.2, 70.1, 69.7, 69.3, 
68.5, 68.1, 68.1, 67.6, 67.5, 67.2, 66.8, 63.1, 63.0, 62.7, 61.0, 60.9, 60.8, 60.1, 59.9, 53.5, 52.0, 
51.9, 51.6, 51.5, 39.4, 38.9, 38.8, 35.8, 22.0; HRMS calc. for C38H39NO19Na [M+Na]+: 656.2014, 
found 656.3000. 
 
N-((2S,3R,4R,5S,6R)-2-(((2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-
(((2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy) 
tetrahydro-2H-pyran-4-yl)oxy)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-
yl)acetamide (3). Activated Zn/PbO couple was added to a solution of 47 (0.729 g, 0.525 mmol) 
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in THF:Ac2O (10:1, 5.25 mL). The reaction was allowed to stir at ambient temperature under 
Argon atmosphere for 48 h. The reaction mixture was filtered and concentrated in vacuo to a clear 
residue. The crude product was resuspended in MeOH (15 mL) and NaOMe (0.5 mL) was added. 
After stirring at ambient temperature for 3 h, the reaction was quenched with Dowex50w8 resin, 
filtered, and concentrated in vacuo to a white crystalline solid. The solid was then dissolved in 
MeOH (20 mL) and Pd(OH)2 (2.0 eq. 0.800 g, 1.0 mmol) was added. The reaction mixture was 
purged with Ar then H2. The reaction stirred at ambient temperature for 48 h, was purged with Ar, 
filtered through a plug of Celite, concentrated, and purified by P-2 Gel (H2O elutent) to yield 3 
(0.234 g, 82%) as a white solid: [α]23D +5.3° (c 10 mg/mL, H2O) ;1H NMR (600 MHz, D2O): δ 
5.23 (d, J=.372 Hz, 0.65H, H-1α), 4.72 (d, J=8.58 Hz, 0.37H, H-1β), 4.71 (d, J=8.34 Hz, 1H, H-
1”), 4.68 (d, J=7.98 Hz, 1H, H-1’), 4.45 (d, J=7.98 Hz, 1H), 4.10 (d, J=2.38 Hz, 1H), 3.97-3.39 
(m), 3.28 (t, J=8.40 Hz, 0.7H), 2.07 (s, 3H, NHAc); 13C NMR (150 MHz, D2O): δ 174.7, 102.9, 
102.2, 95.7, 91.8, 81.9, 78.3, 76.3, 75.5, 74.8, 74.4, 74.3, 73.8, 73.7, 73.5, 72.4, 71.1, 70.1, 69.9, 
69.67 61.0, 60.9, 60.7, 60.0, 55.7, 22.3; HRMS calc. for C18H32NO16Na [M+Na]+: 568.1854, found 
568.3058. 
  
(2R,3R,4R,5S,6R)-5-(((2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-
(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy) 
tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol (4). To a 
solution of 48 (1.0 eq., 0.472 g, 0.376 mmol) in MeOH (10 mL) was added a concentrated solution 
of NaOMe (0.1 mL). The reaction stirred at ambient temperature for 3 h. The mixture was 
quenched with Dowex50w8, filtered, and concentrated in vacuo. The resulting white solid was 
O
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dissolved in MeOH (20 mL) and Pd(OH)2 (3.0 eq., 0.790 g, 1.13 mmol) was added. The reaction 
was sparged with Ar then H2. The reaction stirred under H2 for 24 h and was purged with Ar, 
filtered through a plug of Celite and concentrated in vacuo. The crude solid was purified by P-2 
Gel (H2O elutent) to yield 4 (0.171 g, 90%) as a white solid: [α]23D +23.5° (c 10 mg/mL, H2O); 1H 
NMR (600 MHz, D2O): δ 5.23 (br, 0.37H, H-1α), 4.67 (d, J=7.44 Hz, 0.9H, H-1β), 4.62 (d, J=6.96 
Hz, 1H, H-1”), 4.51 (d, J=7.02 Hz, 1H, H-1’), 4.20 (br, 1H, H-4’), 3.97-3.60 (m), 3.29 (t, J=7.74 
Hz, 0.5H); 13C NMR (150 MHz, D2O): δ 105.3, 102.5, 95.8, 91.8, 81.9, 78.2, 78.1, 75.0, 74.9, 
74.8, 74.3, 73.8, 72.5, 71.4, 71.1, 71.0, 70.2, 70.1, 68.6, 68.4, 60.9, 60.1, 59.9; HRMS calc. for 
C18H32O16Na [M+Na]+: 527.1588, found 527.2698 
  
(2R,3R,4R,5S,6R)-5-(((2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-
(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy) 
tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol (5). To a 
solution of 49 (1.0 eq., 0.553 g, 0.441 mmol) in MeOH (10 mL) was added a concentrated solution 
of NaOMe (0.1 mL). The reaction stirred at ambient temperature for 3 h then quenched with 
Amberlyst Resin, filtered, and concentrated in vacuo. The resulting white solid was dissolved in 
MeOH (20 mL) and Pd(OH)2 (3.0 eq., 0.93 g, 1.32 mmol) was added. The reaction was sparged 
with Ar then H2. The reaction stirred under H2 for 24 h and was sparged with Ar, filtered through 
a plug of Celite, and concentrated. The crude solid was purified by P-2 Gel (H2O elutent) to yield 
5 (0.207 g, 93%) as a white solid: [α]23D +37.2° (c 1 mg/mL, H2O); 1H NMR (400 MHz, D2O): δ 
5.23 (d, 0.39H, J=3.76 Hz, H-1α), 4.69 (d, 1H, J=7.80 Hz, H-1”), 4.68 (d, 0.61H, J=7.96 Hz, H-
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1β), 4.52 (d, 1H, J=7.80 Hz, H-1’), 4.20 (d, 1H, J=3.12 Hz, H-4’), 3.99-3.28 (m);  13C NMR (100 
MHz, D2O): δ 103.7, 102.4, 95.7, 91.7, 81.9, 78.1, 78.0, 75.7, 75.4, 74.9, 74.7, 74.3, 73.7, 73.2, 
71.3, 71.1, 70.8, 70.6, 70.5, 70.0, 69.3, 68.2, 60.9, 60.6, 60.4, 60.0, 59.9, 48.8; LRMS calc. for 
C18H32O16Na [M+Na]+: 527.2, found 527.4. 
  
(2R,3R,4R,5S,6R)-5-(((2S,3R,4S,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-
(((2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4-triol 
(6). To a solution of 49 (1.0 eq., 1.471 g, 1.02 mmol) in MeOH (25 mL) was added a concentrated 
solution of NaOMe (0.1 mL). The reaction stirred at ambient temperature for 3 h and was then 
quenched with Amberlyst Resin, filtered, and concentrated in vacuo. The resulting white solid was 
dissolved in MeOH (30 mL) and Pd(OH)2 (2.0 eq., 1.40 g, 2.03 mmol) was added. The reaction 
was sparged with Ar then H2. The reaction stirred under H2 for 24 h and was sparged with Ar, 
filtered through a plug of Celite, and concentrated. The crude solid was purified by P-2 Gel (H2O 
elutent) to yield 6 (0.231 g, 45%) as a white solid: [α]23D +1.48° (c 0.5 mg/mL, H2O); 1H NMR 
(400 MHz, D2O): δ 5.23 (d, 0.4H, J=3.76 Hz, H-1α), 5.05 (d, 1H, J=1.28 Hz, H-1”), 4.69 (d, 0.6H, 
J=7.96 Hz, H-1β), 4.51 (d, 1H, J=7.80 Hz, H-1’), 4.19 (d, 1H, J=3.12 Hz, H-4’), 4.01-3.57 (m), 
3.35 (s, 1H), 3.29 (t, 1H, J=8.72 Hz); 13C NMR (150 MHz, D2O): δ 102.8, 101.3, 96.2, 95.7, 81.1, 
78.7, 78.5, 76.2, 76.1, 75.1, 75.0, 74.7, 74.4, 74.3, 73.8, 72.8, 72.7, 70.6, 70.3, 70.2, 69.5, 66.7, 
66.6, 64.2, 61.0, 60.9, 60.1, 60.0; LRMS calc. for C18H32O16K [M+K]+: 543.1, found 543.4 
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(2R,3R,4R,5S,6R)-5-(((2S,3R,4R,5S,6R)-4,5-bis((2,5,8,11-tetraoxatridecan-13-yl)oxy)-3-
hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(hydroxymethyl)tetrahydro-
2H-pyran-2,3,4-triol (7). Hydrogen gas was bubbled through a suspension of 42 (1.0 eq., 0.585 
g, 0.552 mmol) and Pd(OH)2/C (20%, 2.0 eq., 0.780 g, 1.11 mmol) in MeOH/AcOH/acetone 
(1:1:1, 40 mL). The reaction stirred under atmosphere of hydrogen for 24 h, was filtered through 
a plug of Celite, and concentrated in vacuo.  The crude material was purified by P-2 Gel (H2O 
elutent) to yield 7 (0.226 g, 79%) as an opaque solid: [α]D23 +41.4 (c 1 mg/mL, H2O);  1H NMR 
(400 MHz, D2O): δ 5.21 (d, J=2.68 Hz, 0.55H, H-1α), 4.65 (d, J=7.72 Hz, 1H), 4.47 (d, J=7.64 Hz, 
1H, H-1’), 4.42 (d, 0.45H, J=7.68 Hz, H-1β), 4.17 (d, 1H, J=1.64 Hz), 4.96-3.47 (m), 3.37 (s, 3H, 
OCH3), 3.15 (t, J=5.28 Hz, 1H); 13C NMR (100 MHz, D2O): δ 102.6, 102.5, 95.6, 91.8, 90.8, 75.2, 
75.1, 71.3, 71.2, 70.9, 70.0, 69.9, 69.8, 69.5, 69.4, 69.3, 68.1, 61.0, 57.9; LRMS calc. for 
C21H40O15Na [M+Na]+: 555.2, found 555.5. 
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Table 4. 9 Comparison of 1H NMR spectroscopic data of 3’-fucosyllactose (1) 
 
Reference59 
δ 1H [ppm; mult; J (Hz)] 
 
Synthetic 
δ 1H [ppm; mult; J (Hz)] 
600 MHz 
Deviation 
(reference-synthetic) 
Δδ (ppm) 
5.23; d; 3.96 5.23; d; 3.66 0 
5.18; d; 3.96 5.18; d; 3.72 0 
4.68; d; 8.25 4.67; d; 7.92 0.01 
4.52; t 4.52; d; 6.75 0 
- 4.18; q; 6.46 - 
- 4.02; br - 
1.26 1.21; d; 6.6 0.05 
 
 
Table 4. 10 Comparison of 13C NMR spectroscopic data of 3’-fucosyllactose (1) 
 
Reference59 
δ 13C (ppm) 
 
Synthetic 
δ 13C (ppm) 
150 MHz 
Deviation 
(reference - synthetic) 
Δδ (ppm) 
105.33 102.68 2.65 
103.74 100.90 2.84 
98.6 95.74 2.86 
94.64 91.80 2.85 
83.16 80.31 2.85 
81.31 78.41 2.90 
81.19 78.28 2.91 
78.09 75.25 2.84 
77.61 74.76 2.85 
77.23 74.36 2.87 
76.64 73.78 2.86 
74.59 71.74 2.85 
74.29 71.42 2.87 
73.98 71.11 2.87 
73.24 70.38 2.86 
72.92 70.06 2.86 
72.24 69.37 2.87 
71.46 68.59 2.87 
71.27 68.40 2.87 
69.99 67.14 2.85 
63.77 60.91 2.86 
62.93 60.04 2.89 
62.8 59.91 2.89 
18.17 15.29 2.88 
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Table 4. 11 Comparison of 1H NMR spectroscopic data of 3’-sialyllactose (2) 
 
Reference60 
δ 1H [ppm; mult; J (Hz)] 
250 MHz 
Synthetic 
δ 13C (ppm) 
600 MHz 
Deviation 
(reference - synthetic) 
Δδ (ppm) 
5.21; d; 3.7 5.22; br 0.01 
4.65; d; 7.9 4.67; d; 7.62 -0.02 
4.51; d; 7.8 4.53; d; 7.44 -0.02 
4.10; d; br 4.13; m -0.03 
3.95-3.54; overlapped 3.96-3.59; m -0.01 
3.30; m 3.31; m -0.01 
2.74; dd; 4.4, 12.1 2.77; m -0.03 
2.04; s 2.04; s 0 
1.83; t; 12.1 1.84; t; 12.06 -0.01 
 
Table 4. 12 Comparison of 13C NMR spectroscopic data of 3’-sialyllactose (2) 
 
Reference60 
δ 13C (ppm) 
 
Synthetic 
δ 13C (ppm) 
150 MHz 
Deviation 
(reference - synthetic) 
Δδ (ppm) 
175.32 175.16 0.16 
173.2 170.05 3.15 
102.9 102.88 0.02 
- 102.58 - 
99.66 98.54 1.12 
96.09 95.74 0.35 
- 91.79 - 
78.42 78.40 0.02 
- 78.28 - 
- 78.14 - 
75.75 75.88 -0.13 
75.39 75.44 -0.05 
- 75.32 - 
- 75.25 - 
- 75.08 - 
- 74.86 - 
74.63 74.77 -0.14 
74.11 74.31 -0.20 
- 73.78 - 
- 73.65 - 
73.28 73.17 0.11 
- 72.94 - 
- 72.49 - 
71.75 71.48 0.27 
71.45 71.37 0.08 
- 71.12 - 
- 70.93 - 
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- 70.59 - 
70.39 70.41 -0.02 
- 70.21 - 
- 70.06 - 
69.69 69.66 0.03 
- 69.34 - 
68.33 68.52 -0.19 
- 68.09 - 
- 68.06 - 
67.84 67.61 0.23 
- 67.49 - 
- 67.20 - 
- 66.75 - 
- 63.11 - 
63.02 63.06 -0.04 
- 62.66 - 
61.3 61.00 0.30 
- 60.96 - 
- 60.76 - 
60.37 60.05 0.32 
- 59.91 - 
- 53.49 - 
- 52.04 - 
- 51.99 - 
- 51.63 - 
- 51.58 - 
39.63 39.37 0.26 
- 38.94 - 
- 38.82 - 
- 35.79 - 
22.41 22.02 0.39 
 
Table 4. 13 Comparison of 1H NMR spectroscopic data of lacto-N-triose (3) 
 
Reference61 
δ 1H [ppm; mult; J (Hz)] 
250 MHz 
Synthetic 
δ 13C (ppm) 
600 MHz 
Deviation 
(reference - synthetic) 
Δδ (ppm) 
5.07; d; 3.6 5.23; d; 3.72 -0.16 
4.56; d; 8.2 4.72; d; 8.58 -0.16 
4.54; d; 8.0 4.71; d; 8.34 -0.17 
- 4.68; d; 7.98 - 
4.31; d; 7.8 4.45; d; 7.98 -0.14 
- 4.1; d; 2.38 - 
- 3.97-3.39; m - 
- 3.28; t; 8.4 - 
1.90; s 2.07; s -0.17 
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Table 4. 14 Comparison of 1H NMR spectroscopic data of epi-Isoglobotriaose (4) 
 
Reference62 
δ 1H [ppm; J (Hz)] 
250 MHz 
Synthetic 
δ 13C (ppm) 
600 MHz 
Deviation 
(reference - synthetic) 
Δδ (ppm) 
5.224; 3.4 5.227; br -0.003 
4.667; 7.5 4.668; d; 7.44 -0.001 
4.612; 8.0 4.617; d; 6.96 -0.005 
4.511; 7.4 4.513; d; 7.02 -0.002 
4.199; 2.8 4.297; br -0.098 
- 3.60-3.97; m - 
- 3.288; t; 7.74 - 
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Figure A3. 1 Fractionation of HMOs from Donor 42. Fractions were characterized by LCMS. 
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Figure A3. 2 Biofilm to biomass ratio for S. agalactiae strain CNCTC 10/84 after 24 h of growth in media alone 
or in the presence of ca. 5 mg/mL fractionated HMOs from Donor 42 (A) THB medium alone. Data represented 
as the mean biofilm/biomass ratio ± SEM of 3 separate experiments, each with 3 technical replicates. * p < 0.05, ** p 
< 0.01, *** p < 0.001, and **** p < 0.0001 by one-way ANOVA, F = 6.969 with posthoc Dunnett’s multiple 
comparison test comparing each HMO sample against the control sample without HMOs. (B) THB medium 
supplemented with 1% glucose. Data are expressed as the mean biofilm/biomass ratio ± SEM of 3 separate 
experiments, each with 3 technical replicates. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 by oneway 
ANOVA, F = 7.233 with posthoc Dunnet’s multiple comparison, compared to media alone. 
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Figure A3. 3 1H NMR spectra (400 MHz, CDCl3) of compound 9 
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Figure A3. 4 13C NMR spectra (100 MHz, CDCl3) of compound 9 
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Figure A3. 5 1H NMR spectra (400 MHz, MeOD) of compound 10 
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Figure A3. 6 13C NMR spectra (100 MHz, MeOD) of compound 10 
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Figure A3. 7 1H NMR spectra (400 MHz, CDCl3) of compound 11 
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Figure A3. 8 13C NMR spectra (100 MHz, CDCl3) of compound 11 
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Figure A3. 9 1H NMR spectra (400 MHz, CDCl3) of compound 13 
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Figure A3. 10 13C NMR spectra (100 MHz, CDCl3) of compound 13 
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Figure A3. 11 1H NMR spectra (400 MHz, CDCl3) of compound 14 
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Figure A3. 12 13C NMR spectra (100 MHz, CDCl3) of compound 14  
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Figure A3. 13 1H NMR spectra (400 MHz, CDCl3) of compound 15 
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Figure A3. 14 13C NMR spectra (100 MHz, CDCl3) of compound 15  
O
OB
n
OB
n
OB
n
SP
h
15
  251 
 
 
Figure A3. 15 1H NMR spectra (400 MHz, CDCl3) of compound 16 
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Figure A3. 16 13C NMR spectra (100 MHz, CDCl3) of compound 16 
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Figure A3. 17 1H NMR spectra (400 MHz, MeOD) of compound 18  
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Figure A3. 21 1H NMR spectra (400 MHz, CDCl3) of compound 20  
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Figure A3. 22 13C NMR spectra (100 MHz, CDCl3) of compound 20 
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Figure A3. 23 13C NMR spectra (100 MHz, CDCl3) of compound 21 
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Figure A3. 25 1H NMR spectra (400 MHz, CDCl3) of compound 23  
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Figure A3. 29 1H NMR spectra (400 MHz, CDCl3) of compound 25  
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Figure A3. 30 13C NMR spectra (100 MHz, CDCl3) of compound 25  
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Figure A3. 31 1H NMR spectra (400 MHz, CDCl3) of compound 27 
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Figure A3. 32 13C NMR spectra (100 MHz, CDCl3) of compound 27 
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Figure A3. 33 1H NMR spectra (400 MHz, CDCl3) of compound 28  
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Figure A3. 34 13C NMR spectra (100 MHz, CDCl3) of compound 28  
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Figure A3. 35 1H NMR spectra (400 MHz, CDCl3) of compound 30  
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Figure A3. 36 13C NMR spectra (100 MHz, CDCl3) of compound 30  
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Figure A3. 37 1H NMR spectra (400 MHz, CDCl3) of compound 31  
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Figure A3. 38 13C NMR spectra (100 MHz, CDCl3) of compound 31  
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Figure A3. 41 1H NMR spectra (400 MHz, CDCl3) of compound 34  
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Figure A3. 42 13C NMR spectra (100 MHz, CDCl3) of compound 34  
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Figure A3. 43 1H NMR spectra (400 MHz, CDCl3) of compound 36  
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Figure A3. 45 1H NMR spectra (600 MHz, CDCl3) of compound 37  
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Figure A3. 46 13C NMR spectra (150 MHz, CDCl3) of compound 37 
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Figure A3. 47 1H NMR spectra (600 MHz, CDCl3) of compound 38 
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Figure A3. 48 13C NMR spectra (150 MHz, CDCl3) of compound 38  
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Figure A3. 49 1H NMR spectra (600 MHz, CDCl3) of compound 39  
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Figure A3. 50 13C NMR spectra (150 MHz, CDCl3) of compound 39  
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Figure A3. 51 1H NMR spectra (600 MHz, CDCl3) of compound 40  
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Figure A3. 52 13C NMR spectra (150 MHz, CDCl3) of compound 40  
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Figure A3. 53 1H NMR spectra (600 MHz, CDCl3) of compound 41  
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Figure A3. 54 13C NMR spectra (150 MHz, CDCl3) of compound 41  
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Figure A3. 55 1H NMR spectra (400 MHz, CDCl3) of compound 42  
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Figure A3. 56 13C NMR spectra (100 MHz, CDCl3) of compound 42  
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Figure A3. 57 1H NMR spectra (400 MHz, CDCl3) of compound 43  
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  Figure A3. 58 13C NMR spectra (100 MHz, CDCl3) of compound 43 
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Figure A3. 59 1H NMR spectra (400 MHz, CDCl3) of compound 44  
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Figure A3. 60 31C NMR spectra (100 MHz, CDCl3) of compound 44  
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Figure A3. 61 1H NMR spectra (400 MHz, CDCl3) of compound 45  
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Figure A3. 62 13C NMR spectra (100 MHz, CDCl3) of compound 45  
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Figure A3. 63 1H NMR spectra (400 MHz, CDCl3) of compound 46  
O
Ac
O
OA
c
OA
c
M
eO
2C
O
Ac
O
Ac
HN
O
Ac
O
OB
n
O
OB
n
O
Bn
O
OB
n
OB
n
Bn
O
46
  300 
 
 
Figure A3. 64 13C NMR spectra (100 MHz, CDCl3) of compound 46  
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Figure A3. 65 1H NMR spectra (400 MHz, CDCl3) of compound 47  
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Figure A3. 66 13C NMR spectra (100 MHz, CDCl3) of compound 47  
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Figure A3. 67 1H NMR spectra (400 MHz, CDCl3) of compound 48  
O
Ac
O O
OB
n
O
OB
n
O
Bn
O
OB
n
OB
n
Bn
O
O
Ac
O
Ac
O
OA
c
OA
c
48
  304 
 
 
Figure A3. 68 13C NMR spectra (100 MHz, CDCl3) of compound 48  
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Figure A3. 69 1H NMR spectra (400 MHz, CDCl3) of compound 49  
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Figure A3. 70 13C NMR spectra (100 MHz, CDCl3) of compound 49  
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Figure A3. 71 1H NMR spectra (400 MHz, CDCl3) of compound 50  
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Figure A3. 72 13C NMR spectra (100 MHz, CDCl3) of compound 50  
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Figure A3. 73 1H NMR spectra (400 MHz, CDCl3) of compound 1  
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Figure A3. 74 1H NMR spectra (400 MHz, CDCl3) of compound 1  
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Figure A3. 75 1H NMR spectra (400 MHz, CDCl3) of compound 2  
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Figure A3. 76 13C NMR spectra (100 MHz, CDCl3) of compound 2  
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Figure A3. 77 1H NMR spectra (400 MHz, CDCl3) of compound 3  
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Figure A3. 78 13C NMR spectra (100 MHz, CDCl3) of compound 3  
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Figure A3. 79 1H NMR spectra (400 MHz, CDCl3) of compound 4  
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Figure A3. 81 1H NMR spectra (400 MHz, CDCl3) of compound 5  
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Figure A3. 82 13C NMR spectra (100 MHz, CDCl3) of compound 5  
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Figure A3. 83 1H NMR spectra (400 MHz, CDCl3) of compound 6  
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Figure A3. 84 13C NMR spectra (100 MHz, CDCl3) of compound 6  
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Figure A3. 85 1H NMR spectra (400 MHz, CDCl3) of compound 7
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Figure A3. 86 13C NMR spectra (100 MHz, CDCl3) of compound 7
O
HO O
OH
O
OH
O
HO
OH
OH
HO
O
4
7
CHAPTER V 
 323 
Conclusions 
In this dissertation, data revealing the antimicrobial and anti-biofilm activities of HMOs 
against GBS was presented. Furthermore, a potential relationship between fucosylated HMOs and 
antimicrobial activity was reported. These results call for additional studies to broaden the 
understanding of this activity. 
First, these findings necessitate the elucidation of a mechanism of action for both the 
antimicrobial and anti-bioiflm activity of HMOs. While we are only able to hypothesize 
mechanisms at this stage, our hypotheses can serve as a starting point for future investigations. As 
mentioned previously, alterations in carbohydrate catabolism, enzyme inhibition that leads to gene 
regulation, or excess polysaccharide-induced biofilm modifications are plausible mechanisms. 
These hypotheses can be tested by monitoring the carbohydrate catabolism and metabolism 
through metabolomics and media characterization and genetic analysis. Analyzing the media for a 
difference in metabolites being released or any HMOs remaining after a period of growth will 
inform if the bacteria uses HMOs as a carbon source and if their catabolism or metabolism changes 
compared to a control. Another avenue that could be used to probe the mechanism is RNA 
sequencing and comparison of gene regulation between GBS grown in the presence or absence of 
HMOs. This will provide insight into the mechanisms that GBS employs to survive in the presence 
of HMOs. Musser and coworkers performed similar transcriptome sequencing studies for GBS 
(strain NEM316, serotype III) grown in media or human amniotic fluid.1 While many genes were 
up or downregulated, their study revealed that genes for carbohydrate intake and metabolism are 
controlled by the growth media. We would expect to see changes in similar types of genes because 
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our study would include carbohydrates as part of one growth condition. For the genetic sequencing, 
it would be of particular interest to use the strain Bode and co-workers used in making their mutant 
library, as this could reveal if that particular gene (gbs0738/gbs0408) was up or down regulated 
when GBS is grown in the presence of HMOs.  
As a continuation of the individual entity screens, it would be fitting to test other 
oligosaccharides present in fraction 7 of the fractionated HMOs from donor 42. We only explored 
trisaccharides that were present in the mixture along with related congeners. However, other 
longer-chain HMOs such as LNT, LNnT, and their fucosylated derivatives have masses 
corresponding to those observed in mass spectrometry characterization of the fraction. To support 
the viability of this approach, Bode and coworkers have tested several HMOs, including LNT, 
LNnT, LNnH, LNFPI, and LNFPV, and found that LNT and LNFP-I have antimicrobial activity. 
While previous studies have only measured the antimicrobial activity of HMOs, further studies 
should be done to look at the anti-biofilm activity of these compounds. The anti-biofilm activity 
seen by 3’-PEGylated lactose warrants further investigations into PEGylated derivatives of varying 
lengths and other ether polymers for their anti-biofilm activity. Additionally, because two 
negatively charges polymers, colominic acid and dextran sulfate, exhibited antimicrobial activity, 
designing a PEG derivative with sulfates or other charged moieties would be of interest. It is 
interesting to note that singly sialylated derivatives such as 3’-SL and 6’-SL had no effect on the 
growth but were able to inhibit biofilm formation. Perhaps the multiple negative charges are 
important for the antimicrobial activity seen by colominic acid and dextran sulfate. 
We have tested whole HMO extracts, fractionated HMOs, and individual entities for their 
activity against GBS. As we saw a decrease in inhibitory activity for individual compounds 
  325 
compared to pools of HMOs isolated from human milk, and we postulated this was due to the 
synergistic activity of HMOs, further work testing combination of individual entities could provide 
a framework for which compounds participate in synergistic activity. 
Additionally, while HMOs act in vitro to affect the growth and biofilm production of GBS, 
it is important to study how HMOs act in vivo or in concert with elements of the innate immune 
system. HMOs have been shown to prevent the binding of other pathogens to host epithelial cells, 
such LNT in E. histolytica infections, LNnT and LSTc for S. pneumoniae, and fucosylated species 
for C. jejuni.2-4 Similar studies to assay the ability of HMOs to prevent GBS binding to host 
epithelial cells would provide knowledge about the in vivo activity of HMOs to inhibit GBS 
pathogenesis. 
A final area of inquiry is in antibiotic resistance. Over use and misuse of antibiotics has led 
to the development of antibiotic-resistant bacteria.5 In fact, the CDC estimates that over 30% 
antibiotics prescribed are unnecessary, as many antibiotics are prescribed for viral infections.6, 7 
Furthermore, antibiotics are the most frequently prescribed medication to children.8 While 
campaigns by the CDC and AAP have resulted in a decrease in pediatric antibiotic use, further 
improvement can be made in approaches for the use of broad- versus narrow-spectrum antibiotics. 
9-14 While broad spectrum antibiotics are central to treating bacterial infections, their use promotes 
resistance evolution across species, and is a primary cause of microbiome dysbiosis.15-17 In 
contrast, narrow-spectrum antibiotics are highly valuable and advantageous over broad-spectrum 
antibiotics due to their lower susceptibility to resistance development, decreased collateral damage 
to the host microbiome, and decreased development of antibiotic-associated colitis.18 Given the 
growing threats to health posed by antibiotic resistance, the use of narrow spectrum antibiotics are 
  326 
an urgent priority.19, 20 As reported by Bode and coworkers and our lab, it appears as though HMOs 
possess narrow-spectrum activity against GBS, though we found minimal antimicrobial activity 
was seen against Acinetobacter baumannii.21 We have begun a program assessing the ability of 
HMOs to act synergistically with several common antibiotics to lower their MIC related to GBS 
growth. The first inquiry along these lines was measuring the effect of HMOs with polymyxin B, 
an antimicrobial peptide, and we observed that when HMOs from donor 43 were dosed with 
polymyxin B, complete growth inhibition of the colony occurred. Next, we dosed HMOs and 
antibiotics, and found that HMOs are able to significantly reduce the MIC of several antibiotics by 
4-fold or higher. While most MIC-reduction activity was seen with penicillins and gentamycin, 
HMOs were able to reduce the MICs of both erythromycin and clindamycin in at least one strain. 
This is encouraging as GBS has begun to develop resistance to erythromycin and clindamycin. 
While it appears that HMOs may serve as a line of defense to rescue some antibiotics, it would 
also be beneficial to determine if GBS can develop resistance to HMOs themselves. It is unlikely 
that this resistance would develop as infants colonized with GBS have long received HMOs 
through breastfeeding and clinical isolates of GBS are still susceptible to the antimicrobial and 
anti-biofilm activity of HMOs, suggesting that if GBS were going to develop resistance it already 
would have. 
To complement their antimicrobial and anti-biofilm properties, HMOs are themselves 
nontoxic at any concentration and are well-known to aid in proper neonate microbiome 
development. As such, the antimicrobial and anti-biofilm properties of HMOs position them to 
become tools to combat infectious diseases.  
In summary, while we have established the antimicrobial and anti-biofilm activity of 
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HMOs against GBS, much work to detail the mechanisms by which this activity occurs remain. 
The outlook for developing the use of human milk oligosaccharides as a defense against Group B 
strep remains positive.  
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